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Abstract 
Epidemiology of HIV-1 and hepatitis virus co-infection: distribution and 
pathogenesis in an urban clinic population 
Kristen Melissa Johnson 
 
 
 
 
Given similar routes of exposure, hepatitis B virus (HBV) and hepatitis C virus (HCV) 
co-infection is common among HIV-positive populations. The long-term impact of these 
is becoming an important public health concern, given the high rates of co-exposure 
coupled with increased AIDS-related survival and widespread accessibility of 
antiretroviral therapy.  Using a population drawn from an urban HIV clinic, we 
investigated prevalence rates of co-exposure, and identified factors associated with co-
exposure, sexual transmission of HCV, and HCV viral clearance using a cross-sectional 
study design on data collected from 2002-11.  We also conducted survival analyses using 
Cox proportional hazards regressions to model the risk of progression to four outcomes 
(clinical AIDS, all-cause mortality, HIV virologic failure, and decline in CD4 count) 
based on HBV and HCV status.    
 
Among 2,880 HIV-positive subjects, relatively high seroprevalences of HBV (44%), 
HCV (34%), and HBV/HCV (19%) was observed.  Injection drug users (IDUs) had the 
greatest odds of each co-exposure. Additionally, race, sex, socioeconomic status, older 
age, and more recent HIV diagnosis were associated with co-exposure.  Sexual 
transmission of HCV was associated with Black race, younger age, and a more recent 
HIV diagnosis  Among subjects with a history of HCV exposure, 13% had evidence of 
HCV viral clearance; being HBV surface antigen-positive was highly predictive of 
x 
 
 
clearance.  In the survival analysis, HBV status negatively affected HIV disease 
progression, particularly time to clinical AIDS and HIV virologic failure. Additionally, 
HCV status may be related to faster progression to clinical AIDS and all-cause mortality. 
 
Taken together, our findings highlight the burden of viral hepatitis co-infections among 
HIV-positive individuals, and the need to reduce this burden through routine testing, 
HBV vaccination, and appropriate therapy. Further research, particularly with a 
prospective study design, is warranted to fully understand the factors associated with 
viral hepatitis co-infection among HIV-positive populations.  Identification of those more 
likely to develop chronic HCV infections can inform therapy decisions.  Further, given 
the relatively high rates of HBV and HCV co-infection and the current debate on their 
impact on HIV disease progression, additional research is needed to further elucidate 
these relationships.   
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1 BACKGROUND 
1.1 HIV-1 
HIV/AIDS continues to be a significant public health concern in the United States (US).  
In 2009, there were an estimated 1.2 million American living with HIV/AIDS, 20% of 
which were undiagnosed.1  In the US, HIV is primarily transmitted through exposure to 
contaminated blood and semen, putting those who engage in male-to-male sexual contact 
and injection drug use at the greatest risk for infection.  Indeed, approximately three-
quarters of infections are attributable to one or both of these modes of transmission.1 
However, HIV infections acquired through heterosexual contact have increased over the 
past decade, and it is now considered to be a major source of infection.  HIV infection 
disproportionately affects Blacks and Hispanics, with a 2-fold increase in prevalence in 
these groups compared to Whites.  Although the incidence of new HIV diagnoses has 
remained stable over the past few years,2 people are living longer with a HIV diagnosis 
due to widespread accessibility of highly active antiretroviral therapy (HAART) and 
identification of early diagnoses through routine testing.3-5  In 2009, 90% of infected 
individuals survived longer than 36 months following a HIV diagnosis and 84% 
following an AIDS diagnosis.6 With HIV-infected individuals living longer, the negative 
health outcomes due to chronic conditions, such as liver disease from viral hepatitis, are 
now a substantial public health concern.7  
 
HIV is a retrovirus in the lentivirus genus.  In the first part of its lifecycle, HIV binds to 
and enters target cells (CD4 T cells and macrophages).  The viral envelope is then 
removed, leaving the core particle.  Reverse transcriptase then translates viral RNA into 
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viral DNA, which is incorporated into the host cell’s DNA (i.e., integration).  Viral RNA 
is then produced in the cell, making HIV infected cells persistent reservoirs for virus.  
The viral particles leave the cell, matures, and the process repeats itself.8,9 
 
The host’s immune response to HIV consists of both specific and non-specific humoral 
and cell-mediated responses.  In the humoral response, HIV-specific antibodies are 
produced and secreted into the bloodstream, which triggers additional non-specific cells 
to attack the antigen (e.g., phagocytes, natural killer cells).  In the cell-mediated response, 
CD4 (T-helper) and CD8 (T-killer) cells are generated, which specifically bind to foreign 
antigens and kill them.8 
 
There are two phases of HIV infection.  Primary or acute infection, lasting approximately 
six months, is marked by massive loss of CD4 cells and high viral replication.10 Chronic 
infection is marked by a persistent state of immune activation.  This phase can last 
approximately 10 years, after which the immune system becomes so compromised due to 
loss of CD4 cells that opportunistic infections take hold (i.e., the onset of AIDS).  This 
chronic immune activation causes increased cell death and proliferation (i.e., turnover) of 
CD4 cells.  However, cell death is more rapid than proliferation, so over time all CD4 
cells are lost, ultimately rendering the immune system compromised. Chronic immune 
activation also disrupts the lymphatic system, leading to increased expression of pro-
inflammatory cytokines, which can adversely affect the survival of CD4 cells.  Chronic 
inflammation causes long-term co-morbidities, such as cancer and cardiovascular disease.  
Viral replication is also maintained during chronic immune activation by direct HIV 
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infection of CD4 cells.11 The chronic activation phase can be lessened by use of ARTs, 
which controls viral replication and decreases expression of CD4 cell activation makers, 
leading to the recovery of CD4 cells. 
 
1.2 Hepatitis B virus 
Similar to HIV, hepatitis B virus (HBV) is transmitted through percutaneous exposure 
(e.g., needle stick, blood transfusion), sexual contact, and perinatal exposure.12  In the 
US, transmission of HBV primarily occurs through unprotected sex.13  Although a 
vaccine has been available to prevent HBV for over two decades, there were an estimated 
43,000 new HBV infections in the US in 2007, with the highest incidence observed in 
sexually active young adults and a higher incidence in Blacks and Hispanics compared to 
Whites.14   
 
Within 2-10 weeks following exposure, hepatitis B surface antigen (HBsAg), a protein on 
the surface of HBV, appears in the serum.12  It indicates that the exposed individual is 
infectious.  If the acute infection is self-limited, HBsAg becomes undetectable by six 
months; persistence of HBsAg more than six months following exposure implies 
progression to chronic infection.  If HBsAg is cleared from the serum, hepatitis B surface 
antibody (anti-HBs) can be detected.  This antibody persists for life and provides long-
term immunity against re-infection. It is also produced following successful vaccination 
against HBV.  In addition to HBsAg, hepatitis B e antigen (HBeAg) is detected in the 
serum early during an acute infection.  Its presence indicates greater infectivity, increased 
levels of viral replication, and, during chronic infection, active liver disease.  Therefore, 
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among those chronically infected, seroconversion to hepatitis B e antigen antibody (anti-
HBe) is associated with a reduction of circulating HBV DNA and remission of liver 
damage.  Another important serological marker is hepatitis B core antibody (anti-HBc), 
which appears at the onset of symptoms in acute infection and persists for life.  Among 
adults, approximately 2-5% of acute infections will develop into chronic infections (viral 
persistence), which can result in serious liver disease, including cirrhosis, liver failure, 
and hepatocellular carcinoma.12  Among those infected at birth, 90% progress onto 
chronic infection.12  It is estimated that 1.2-2 million Americans with a chronic HBV 
infection.15-17 
 
HBV, a small DNA virus, is non-cytopathic, meaning HBV itself does not cause death of 
infected hepatocytes (liver cells).12 Rather, the host immune response, specifically CD8 
cytotoxic T lymphocytes (CTLs), plays a key role in the pathogenesis of liver damage.  
CTLs attempt to eliminate HBV infection by killing infected cells and producing 
cytokines (e.g., interferon-γ) that reduce viral replication. Therefore, the severity of 
HBV-associated liver disease is related to the intensity of the host immunologic response. 
 
During an acute HBV infection phase, HBV DNA is rapidly cleared from the liver first 
through cytokine-mediated mechanisms released by the innate immune response and 
subsequently by HBV-specific CD8 cells.18  As noted above, HBV-specific antibodies 
are produced as part of the humoral immune response.  Chronic infections are marked by 
increased levels of HBV replication and increased liver damage, due to persistent liver 
inflammation and integration of viral DNA into the host cell. 
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Currently available therapy for chronic HBV infections includes long term treatment with 
antiviral medication and pegylated interferon.19  Eight distinct HBV genotypes have been 
identified (A through H); response to interferon therapy can vary by genotype.12  
Although successful therapy can reduce fibrosis and ultimately reduce the number of 
liver transplants, therapy regimens may be complex and potentially harmful liver-related 
side effects of the drugs cannot be discounted.19,20  
 
1.3 Hepatitis C virus 
An estimated 2.7-3.9 million persons in the US (1.2-1.8% of the population) have a 
chronic hepatitis C virus (HCV) infection.21  Prevalence is greatest among those aged 40-
49 years, among males compared to females, and among Blacks and Hispanics compared 
to Whites.12  HCV transmission occurs primarily through percutaneous exposure, placing 
injecting drug users (IDUs) at the greatest risk for acquiring the infection.22  HCV is more 
efficiently transmitted through contaminated blood than HIV, and approximately 75-90% 
of IDUs have been HCV-infected,23-27 with estimates varying across race, geographic 
regions, and length of IDU history.28  This may be attributable to differences in injecting 
practices, available prevention outreach (e.g., syringe exchange), and the relative 
mobility of networks of IDUs.  Currently, the optimal therapy for chronic HCV infection 
is long-term combination of peg interferon and ribavirin, with duration and dosage 
affected by the HCV genotype.29    
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Similar to HBV, HCV is not cytopathic; the host immune response and subsequent 
chronic inflammation during the chronic phase are responsible for related liver damage.12 
HCV exposure is diagnosed by being positive for HCV-specific antibodies (anti-HCV) 
that are produced as part of the humoral immune response.  An acute infection is marked 
by a strong cell-mediated response (i.e., HCV-specific CD4 and CD8 cells), elevated 
liver enzymes, and HCV viral decline. Presence of HCV RNA in blood is indicative of 
chronic infection, where pathogenesis of liver damage is largely immune mediated.  
Further, chronic immune activation leads to immune dysfunction and cytokine 
production.  CD8 cells predominate the adaptive response, suggesting that CTLs are the 
main cause of hepatocellular injury. 
 
It is estimated that approximately 20-25% of HCV infections will spontaneously clear, 
with the remaining developing into chronic infections.21,30-33 Serologically, HCV 
clearance is identified by being positive for anti-HCV coupled with an inability to detect 
viral RNA in the blood.  Viral clearance, if it occurs, usually occurs during the first six 
months following infection.  Viral persistence after an acute infection leads to chronic 
infection, which in turn, can lead to serious liver disease, such as liver fibrosis, cirrhosis, 
and end stage liver disease.34,35 Being female has been associated with greater rates of 
HCV clearance.  A recent meta-analysis consisting of 31 longitudinal studies on HCV 
clearance found the relative risk (RR) of HCV clearance was 2.33 (95% confidence 
interval (CI), 1.89-3.16) in women compared to men.32  HCV clearance has also been 
found to be higher among those infected at a younger age,36,37 which is in contrast to 
what is seen with HBV; younger age at infection with HBV is associated with greater 
development of chronic infections.12   For example, a large study of HIV-negative 
 18 
 
 
hemophiliacs found HCV clearance was significantly reduced for those who were 
infected at an age of 16 years or greater compared to those infected at less than two years 
of age (odds ratio (OR)=3.4, 95% CI, 0.18-0.65).37  Black race has also been associated 
with decreased HCV clearance.30,31,33,36,37 Using data from the National Health and 
Nutrition Examination Survey (NHANES), Alter et al. found the rate of chronic 
infections was higher among Blacks compared to Whites (86 vs. 68%, respectively).36  
Further, a large study of IDUs found that being non-Black was significantly associated 
with HCV clearance (OR=5.2; 95% CI, 2.6-10.2).31  This has also been observed in a 
HIV-negative hemophiliac cohort, with an odds ratio for clearance of 0.46 among Blacks 
compared to Whites (95% CI, 0.23-0.91).37  Being positive for HBsAg, indicating a 
chronic hepatitis B virus (HBV) infection, has also been associated with HCV clearance 
rates 2-3 fold greater compared to those who have no serologic evidence of a chronic 
HBV infection.31,37  
 
Although HCV is primarily transmitted through injection drug use, there have been an 
increasing number of reports of sexual HCV transmission,38-40 especially among HIV-
positive men who have sex with men (MSM) in the US and Europe.  Exposure to infected 
body fluids through traumatic sexual practices has been identified as the likely mode of 
HCV transmission in this population.  In New York City, for example, among a group of 
74 HIV-positive MSM, high-risk behaviors, specifically unprotected receptive anal 
intercourse (OR=23.0; 95% CI, 2.2-243.8) and sexual encounters while high on 
methamphetamine (OR=28.6; 95% CI, 1.8-443.0), were recently found to be associated 
with HCV acquisition.40  Additionally, a study in of HIV-positive MSM in Europe also 
found that recreational drug use and high-risk, mucosally traumatic sexual practices, such 
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as fisting and use of sex toys, were associated with sexual transmission of HCV.38 This 
type of high-risk behavior among MSM has increased since HAART became widely 
available41,42 reportedly due to the believe that HAART reduces HIV infectivity coupled 
with decreased concern about acquiring HIV.43  A recent review found the odds of 
acquiring HCV sexually was 4-5 times greater among HIV-positive MSM compared to 
HIV-negative men.44  
 
There are several HCV genotypes and their distributions vary considerably worldwide.  
In the US, the majority of HCV infections are type 1 genotype (approximately 75%), 
followed by types 2 and 3 (approximately 15% and 7%, respectively).45-48  However, a 
recent study among IDUs and HIV-positive subjects in San Francisco found more non-
genotype 1 among IDUs less than 30 years old compared to older IDUs, indicating a 
possible temporal change in the genotype distribution among subgroups in the US.49  
Genotype 1 has been associated with reduced response to antiviral therapy and higher 
HCV viral loads, leading to a smaller likelihood of reaching a sustained virologic 
response compared to genotypes 2 and 3.50-53 Additionally, treatment duration is longer 
for those with genotype 1 compared to genotypes 2 and 3 (12 vs. 6 months).48  Black race 
has been identified as a strong predictor of having genotype 1, which can cause 
disproportionate viral persistence in this group compared to other races.47,48 Given that 
HCV genotype is related to the likelihood of response to therapy, the distribution of 
genotypes in a population an important tool in estimating the long term impact of 
therapeutic regimens.  
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1.4 HIV and viral hepatitis co-infections 
1.4.1 Hepatitis B and HIV co-infection 
Due to similar routes of exposure, HBV co-infection among those that are HIV-positive 
is common.  Approximately one-half of HIV-positive subjects have evidence of a past 
HBV infection, with the highest prevalence reported among MSM and IDUs compared to 
other transmission groups.  Further, an estimated 3-9% of HIV-positive individuals are 
chronically infected with HBV.54-56   Since the development and widespread availability 
of highly active antiretroviral therapy (HAART) in the 1990’s, hepatitis-related liver 
disease has emerged as an important cause of morbidity and mortality among those that 
are HIV-positive, and is now a substantial public health concern.7,57-61   
 
Co-infection with HIV substantially alters the natural history of HBV infection.  HIV-
induced impairment of the cell-mediated immunity leads to reduced HBV-specific CTL 
response, less HBV viral clearance, longer duration of HBeAg positivity (indicating 
ongoing viral replication and elevated viral loads), and more rapid progression to 
clinically significant liver disease, such as hepatocellular carcinoma and cirrhosis, and 
liver-related death.7,13,62-64  Even though HBV infection may lead to enhanced 
transcription and up-regulation of HIV,65 the impact of this interaction on clinical disease 
is less clear and disparate findings have been reported in the literature.  Findings from 
previous studies have suggested that HBV co-infection had no impact on HIV disease 
progression.54-56,66-69 For example, a large, multi-center European study of HIV/HBV co-
infected subjects found the incidence of new AIDS diagnoses was similar among HIV-
positive patients that were HBsAg-positive compared to HBsAg-negative (incidence rate 
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ratio (IRR)=0.9, 95% CI, 0.7-1.2).54  Conversely, other previous research also suggests 
that HBV co-infection does have a negative effect on HIV disease progression.70-72  For 
example, a recent study by Chun at al. reported that co-infection had a negative impact on 
HIV-related outcomes, specifically clinical AIDS or death.72 Here, the authors report an 
almost 2-fold increase in the hazard for AIDS or death among those that had a chronic 
hepatitis B infection compared to those who were mono-infected with HIV.  Many of 
these previous HIV/HBV co-infection studies were conducted during the pre-HAART 
era66,67 or have been limited by small sample size,70 an inability to account for baseline 
CD4 cell counts,70,71 were conducted in homogenous risk groups,68,70 or were unable to 
distinguish between those with evidence of a previous HBV exposure and those never 
exposed to HBV.54,56 
 
Currently, treatment of HBV in HIV infected individuals is recommended when there is 
active HBV replication and evidence of elevated liver enzymes, as these indicate the 
potential for liver damage.13,73 There are numerous agents available against HBV in HIV 
infected individuals, including interferon alfa, peginterferon alfa, lamivudine, adefovir, 
entecavir, telbivudine, emtricitabine, and tenofovir.73 Due to concerns of hepatoxicity and 
adverse events, factors such as prognostic markers of liver disease progression, severity 
of liver disease, likelihood of response to treatment, including HBV genotype, and 
interactions with HIV antiretroviral therapy (ART) needs to be considered when deciding 
on initiation of HBV treatment.12,73   
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1.4.2 Hepatitis C and HIV co-infection 
Similar to HBV, HCV co-infection is common among those that are HIV-positive, given 
their shared routes of exposure, such as percutaneous exposure (e.g., needle stick, blood 
transfusion), sexual contact, and perinatal exposure.12  It has been estimated that 25-30% 
of HIV infected individuals are co-infected with HCV.74  This is especially true among 
IDUs, with an estimated co-infection prevalence of 72-95%. However, several outbreaks 
of sexual transmission of HCV have been recently reported, especially among HIV-
positive MSM.38-40  Further, the prevalence of HIV among those with a chronic HCV 
infection is approximately 16%.75  This is especially true among IDUs, with an estimated 
co-infection prevalence of 33%.13  Since the development of HAART in the 1990’s, 
HCV-related liver disease has emerged as an important cause of morbidity and mortality 
among those that are HIV-positive due to decreasing rates of AIDS and AIDS-related 
mortality.57-61  
 
Rates of HCV clearance are lower among those that are HIV-positive compared to HIV-
negative, and are associated with more rapid progression to HCV-related liver disease, 
including fibrosis and cirrhosis, and increased mortality.31  In the absence of HIV 
infection, it is estimated that approximately 20-25% of HCV infections will 
spontaneously clear, with the remaining developing into chronic infections.21,30-33 
However, this percentage is reduced in HIV-positive populations (13-23%).53,76-81 The 
natural history of HCV clearance in HIV-positive populations is not fully described.  
Many of the studies that have specifically examined this are limited by small sample sizes 
(less than 250 co-infected subjects), homogenous populations with respect to race and/or 
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risk factor, geographic location (most studies have been in Europe), and/or a cross-
sectional study design.53,76,78,79,81-84 Similar to what has been described in HIV-negative 
populations, HCV clearance was 40-80% more likely among females compared to 
males.53,76 Further, a 3- to 10-fold increase in the likelihood of clearance among those 
who were HBsAg-positive compared to those who were negative has been reported.53,76,79  
However, there is disagreement on the impact of the route of transmission on HCV 
clearance in a co-infected population.53,76,79  For example, a multi-site European and US 
study reported that heterosexual risk was positively associated with viral clearance when 
compared to other transmission routes (OR=2.8, 95% CI, 1.6-5.1).79  While two 
European studies reported that IDU and MSM were each significantly associated with 
increased HCV viral clearance when compared to heterosexual risk (OR=5.2, OR=1.5 to 
10.2, respectively).53,76 A fuller understanding of this factor has been somewhat limited 
by studies conducted in homogeneous populations with respect to mode of transmission.    
 
The timing of HAART initiation with respect to HCV therapy can be challenging, and 
requires a balance between decreasing liver disease progression and preventing 
hepatoxicity and related increases in liver fibrosis.29,85 As seen with HBV, co-infection 
with HIV can accelerate the progression of HCV disease HIV infection leads to persistent 
HCV viremia, increased HCV VL levels, an increased rate of liver fibrosis progression, 
and more rapid progression to HCV-related liver disease, including fibrosis, and cirrhosis 
and increased liver-related mortality.13,35,85-89  These effects may be caused by a decline 
in HCV-specific CD4 and CD8 cell response, activation of hepatic stellate cells that 
promote further pro-inflammatory cytokines, or direct binding of HIV to liver cells.90 The 
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resulting reduced levels of HCV clearance is associated with accelerated rates of liver 
fibrosis due to HIV-induced CD4 cell depletion and chronic immune activation.18 Several 
pathways have been proposed for the possible effects of HCV on HIV disease 
progression, including increased immune activation and cytokine production and 
increased CD4 death, leading to severe immunodeficiency.85 However, the clinical effect 
is less clear.  For example, a large longitudinal study within the Swiss HIV Cohort found 
an increased risk for AIDS or death among those co-infected with HCV (hazard ratio 
(HR)=1.7; 95% CI, 1.3-2.3).57  Decreased survival was also reported within another large 
longitudinal study recently conducted (RR=1.5; 95% CI, 1.2-1.9).91 However, other large 
longitudinal studies did not find similar results.  For example, a study conducted within a 
US HIV clinic found no association between HCV serostatus and risk for an AIDS 
defining illness (HR=1.03; 95% CI, 0.86-1.23), death (HR=1.05; 95% CI, 0.85-1.30), or 
CD4 decline to < 200 cells/µL (HR=1.28; 95% CI, 0.98-1.68).92  A large study conducted 
within the EuroSIDA study group also reported no association between HCV serostatus 
and AIDS or death (incidence rate ratio (IRR)=1.06; 95% CI, 0.89-1.28).93  Differences 
may be due to differences between underlying populations, such as size, risk profile, and 
geographic location, and the ability to control for behavior confounders such as alcohol 
use. 
 
Current treatment guidelines for HIV/HCV co-infected patients include long-term (≥ 48 
weeks) treatment with peginterferon and ribavirin.13 As with HBV treatment, the risks of 
hepatoxicity and adverse events must be considered, along with HCV genotype, HCV 
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viral load, patient motivation, and potential drug interactions with HIV ART when 
considering initiation of HCV therapy.13,73   
 
1.5 Philadelphia as urban catchment area 
Differences with respect to the magnitude of HIV infection and transmission factors vary 
across urban and non-urban areas.  According to the CDC, metropolitan areas with more 
than 500,000 residents had the highest rate of people living with HIV (24.3 per 100,000 
population compared to 12.1 per 100,000 in areas with 50,000-<500,000 residents and 
8.0 per 100,000 in non-metropolitan areas.94 The proportion of HIV positive individuals 
reporting MSM as a primary risk factor was highest in the metropolitan areas with the 
greatest populations.  Transmission via heterosexual risk was more common in non-urban 
areas.  
 
This study was conducted within a large HIV clinic in Philadelphia, PA, a city 
disproportionately burdened by viral hepatitis- and HIV-associated morbidity and 
mortality.  Philadelphia is ranked fifth in US cities for rates of new HIV diagnoses (102 
per 100,000 population) and people living with HIV/AIDS (1,384 per 100,000 
population).95  Further, the rate of newly diagnosed HIV infections in Philadelphia is five 
times the national rate and twice the rate of New York City.95 Given the similar routes of 
exposure to HIV, there is substantial HBV and HCV infections in the city as well.96  
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1.6 Conclusion 
The overall goal of the related studies was to further understand the epidemiology of HIV 
and viral hepatitis co-infections, specifically in an urban setting with relatively high 
endemic rates of HIV and hepatitis infections.  Findings from this study will help 
estimate the prevalence of hepatitis and HIV co-infections.  Further understanding of 
modes of transmission, factors associated with HCV clearance, and the impact of 
hepatitis viral infection on HIV disease progression can inform both therapeutic decisions 
as well as development of prevention campaigns and policies related to routine testing in 
subpopulations.  
 
 
 
 
  
 27 
 
 
1.7 List of references 
 
 
 
 
1. Centers for Disease Control and Prevention. HIV surveillance--United States, 
1981-2008. MMWR Morb Mortal Wkly Rep. Jun 3 2011;60(21):689-693. 
2. Prejean J, Song R, Hernandez A, et al. Estimated HIV incidence in the United 
States, 2006-2009. PLoS One. 2011;6(8):e17502. 
3. Schwarcz SK, Hsu LC, Vittinghoff E, Katz MH. Impact of protease inhibitors and 
other antiretroviral treatments on acquired immunodeficiency syndrome survival 
in San Francisco, California, 1987-1996. Am J Epidemiol. Jul 15 
2000;152(2):178-185. 
4. Murphy EL, Collier AC, Kalish LA, et al. Highly active antiretroviral therapy 
decreases mortality and morbidity in patients with advanced HIV disease. Ann 
Intern Med. Jul 3 2001;135(1):17-26. 
5. Chou R, Huffman LH, Fu R, Smits AK, Korthuis PT. Screening for HIV: a 
review of the evidence for the U.S. Preventive Services Task Force. Ann Intern 
Med. Jul 5 2005;143(1):55-73. 
6. Centers for Disease Control and Prevention. HIV Surveillance Report 2010 2012. 
7. Dore GJ, Cooper DA. The impact of HIV therapy on co-infection with hepatitis B 
and hepatitis C viruses. Curr Opin Infect Dis. Dec 2001;14(6):749-755. 
8. Fan HY, Conner RF, Villarreal LP. AIDS: Science and society. Boston, MA: 
Jones and Bartlett Publishers; 2004. 
9. Levy JA. HIV pathogenesis: 25 years of progress and persistent challenges. AIDS. 
Jan 14 2009;23(2):147-160. 
10. Fernandez S, Lim A, French M. Immune activation and the pathogenesis of HIV 
disease: implications for therapy. J HIV Ther. Nov 2009;14(3):52-56. 
11. Hunt PW. Role of immune activation in HIV pathogenesis. Curr HIV/AIDS Rep. 
Feb 2007;4(1):42-47. 
12. Feldman R, Friedman, L., Brandt, L.,, ed Sleisenger and Fordtran's 
Gastrointestinal and Liver Disease: Pathophysiology, diagnosis, managment. 9th 
ed. Philadelphia, PA: Saunders Elsevier; 2010. 
13. Sulkowski MS. Viral hepatitis and HIV coinfection. J Hepatol. Feb 
2008;48(2):353-367. 
 28 
 
 
14. Centers for Disease Control and Prevention. Viral hepatitis surveillance, United 
States 2009: National Center for HIV/AIDS, viral hepatitis, STD & TB 
prevention;2009. 
15. Centers for Disease Control and Prevention. Incidence of acute hepatitis B--
United States, 1990-2002. MMWR Morb Mortal Wkly Rep. Jan 2 2004;52(51-
52):1252-1254. 
16. Gish RG, Gadano AC. Chronic hepatitis B: current epidemiology in the Americas 
and implications for management. J Viral Hepat. Dec 2006;13(12):787-798. 
17. Cohen C, Evans AA, London WT, Block J, Conti M, Block T. Underestimation of 
chronic hepatitis B virus infection in the United States of America. J Viral Hepat. 
Jan 2008;15(1):12-13. 
18. Joshi D, O'Grady J, Dieterich D, Gazzard B, Agarwal K. Increasing burden of 
liver disease in patients with HIV infection. Lancet. Apr 2 2011;377(9772):1198-
1209. 
19. Dienstag JL. Hepatitis B virus infection. N Engl J Med. Oct 2 2008;359(14):1486-
1500. 
20. Ganem D, Prince AM. Hepatitis B virus infection--natural history and clinical 
consequences. N Engl J Med. Mar 11 2004;350(11):1118-1129. 
21. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. 
The prevalence of hepatitis C virus infection in the United States, 1999 through 
2002. Ann Intern Med. May 16 2006;144(10):705-714. 
22. Williams IT, Bell BP, Kuhnert W, Alter MJ. Incidence and transmission patterns 
of acute hepatitis C in the United States, 1982-2006. Arch Intern Med. Feb 14 
2011;171(3):242-248. 
23. Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in 
short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, 
human immunodeficiency, and human T-lymphotropic viruses. Am J Public 
Health. May 1996;86(5):655-661. 
24. Villano SA, Vlahov D, Nelson KE, Lyles CM, Cohn S, Thomas DL. Incidence 
and risk factors for hepatitis C among injection drug users in Baltimore, 
Maryland. J Clin Microbiol. Dec 1997;35(12):3274-3277. 
25. Centers for Disease Control and Prevention. Recommendations for prevention and 
control of hepatitis C virus (HCV) infection and HCV-related chronic disease. 
Centers for Disease Control and Prevention. MMWR Recomm Rep. Oct 16 
1998;47(RR-19):1-39. 
 29 
 
 
26. Hagan H, McGough JP, Thiede H, Weiss NS, Hopkins S, Alexander ER. Syringe 
exchange and risk of infection with hepatitis B and C viruses. Am J Epidemiol. 
Feb 1 1999;149(3):203-213. 
27. Diaz T, Des Jarlais DC, Vlahov D, et al. Factors associated with prevalent 
hepatitis C: differences among young adult injection drug users in lower and 
upper Manhattan, New York City. Am J Public Health. Jan 2001;91(1):23-30. 
28. Amon JJ, Garfein RS, Ahdieh-Grant L, et al. Prevalence of hepatitis C virus 
infection among injection drug users in the United States, 1994-2004. Clin Infect 
Dis. Jun 15 2008;46(12):1852-1858. 
29. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and 
treatment of hepatitis C: an update. Hepatology. Apr 2009;49(4):1335-1374. 
30. Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia 
and the importance of long-term follow-up after acute hepatitis C infection. 
Hepatology. Mar 1999;29(3):908-914. 
31. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus 
infection: host, viral, and environmental factors. JAMA. Jul 26 2000;284(4):450-
456. 
32. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute 
hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat. 
Jan 2006;13(1):34-41. 
33. Shah DP, Grimes CZ, Brown E, Hwang LY. Demographics, socio-behavioral 
factors, and drug use patterns: what matters in spontaneous HCV clearance? J 
Med Virol. Feb 2012;84(2):235-241. 
34. Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis. Aug 
2005;9(3):383-398, vi. 
35. Fierer DS, Uriel AJ, Carriero DC, et al. Liver fibrosis during an outbreak of acute 
hepatitis C virus infection in HIV-infected men: a prospective cohort study. J 
Infect Dis. Sep 1 2008;198(5):683-686. 
36. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C 
virus infection in the United States, 1988 through 1994. N Engl J Med. Aug 19 
1999;341(8):556-562. 
37. Zhang M, Rosenberg PS, Brown DL, et al. Correlates of spontaneous clearance of 
hepatitis C virus among people with hemophilia. Blood. Feb 1 2006;107(3):892-
897. 
 30 
 
 
38. Danta M, Brown D, Bhagani S, et al. Recent epidemic of acute hepatitis C virus 
in HIV-positive men who have sex with men linked to high-risk sexual 
behaviours. AIDS. May 11 2007;21(8):983-991. 
39. van de Laar T, Pybus O, Bruisten S, et al. Evidence of a large, international 
network of HCV transmission in HIV-positive men who have sex with men. 
Gastroenterology. May 2009;136(5):1609-1617. 
40. Centers for Disease Control and Prevention. Sexual transmission of hepatitis C 
virus among HIV-infected men who have sex with men--New York City, 2005-
2010. MMWR Morb Mortal Wkly Rep. Jul 22 2011;60(28):945-950. 
41. Macdonald N, Dougan S, McGarrigle CA, et al. Recent trends in diagnoses of 
HIV and other sexually transmitted infections in England and Wales among men 
who have sex with men. Sex Transm Infect. Dec 2004;80(6):492-497. 
42. Dodds JP, Mercey DE, Parry JV, Johnson AM. Increasing risk behaviour and high 
levels of undiagnosed HIV infection in a community sample of homosexual men. 
Sex Transm Infect. Jun 2004;80(3):236-240. 
43. Crepaz N, Hart TA, Marks G. Highly active antiretroviral therapy and sexual risk 
behavior: a meta-analytic review. JAMA. Jul 14 2004;292(2):224-236. 
44. Tohme RA, Holmberg SD. Is sexual contact a major mode of hepatitis C virus 
transmission? Hepatology. Oct 2010;52(4):1497-1505. 
45. Mahaney K, Tedeschi V, Maertens G, et al. Genotypic analysis of hepatitis C 
virus in American patients. Hepatology. Dec 1994;20(6):1405-1411. 
46. Hyams KC, Riddle J, Rubertone M, et al. Prevalence and incidence of hepatitis C 
virus infection in the US military: a seroepidemiologic survey of 21,000 troops. 
Am J Epidemiol. Apr 15 2001;153(8):764-770. 
47. Blatt LM, Mutchnick MG, Tong MJ, et al. Assessment of hepatitis C virus RNA 
and genotype from 6807 patients with chronic hepatitis C in the United States. J 
Viral Hepat. May 2000;7(3):196-202. 
48. Nainan OV, Alter MJ, Kruszon-Moran D, et al. Hepatitis C virus genotypes and 
viral concentrations in participants of a general population survey in the United 
States. Gastroenterology. Aug 2006;131(2):478-484. 
49. Dias PT, Hahn JA, Delwart E, et al. Temporal changes in HCV genotype 
distribution in three different high risk populations in San Francisco, California. 
BMC Infect Dis. 2011;11:208. 
50. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin 
for chronic hepatitis C virus infection. N Engl J Med. Sep 26 2002;347(13):975-
982. 
 31 
 
 
51. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus 
ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of 
chronic hepatitis C: a randomised trial. Lancet. Sep 22 2001;358(9286):958-965. 
52. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the 
treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med. 
May 27 2004;350(22):2265-2271. 
53. Soriano V, Mocroft A, Rockstroh J, et al. Spontaneous viral clearance, viral load, 
and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients 
with anti-HCV antibodies in Europe. J Infect Dis. Nov 1 2008;198(9):1337-1344. 
54. Konopnicki D, Mocroft A, de Wit S, et al. Hepatitis B and HIV: prevalence, 
AIDS progression, response to highly active antiretroviral therapy and increased 
mortality in the EuroSIDA cohort. AIDS. Mar 24 2005;19(6):593-601. 
55. Omland LH, Weis N, Skinhoj P, et al. Impact of hepatitis B virus co-infection on 
response to highly active antiretroviral treatment and outcome in HIV-infected 
individuals: a nationwide cohort study. HIV Med. May 2008;9(5):300-306. 
56. Law WP, Duncombe CJ, Mahanontharit A, et al. Impact of viral hepatitis co-
infection on response to antiretroviral therapy and HIV disease progression in the 
HIV-NAT cohort. AIDS. May 21 2004;18(8):1169-1177. 
57. Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and 
immune recovery during antiretroviral therapy in patients with HIV-1 and 
hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet. Nov 25 
2000;356(9244):1800-1805. 
58. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver 
disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 
Feb 1 2001;32(3):492-497. 
59. Lewden C, Salmon D, Morlat P, et al. Causes of death among human 
immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral 
therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J 
Epidemiol. Feb 2005;34(1):121-130. 
60. Bhaskaran K, Hamouda O, Sannes M, et al. Changes in the risk of death after 
HIV seroconversion compared with mortality in the general population. JAMA. 
Jul 2 2008;300(1):51-59. 
61. Smith C, Sabin CA, Lundgren JD, et al. Factors associated with specific causes of 
death amongst HIV-positive individuals in the D:A:D Study. AIDS. Jun 19 
2010;24(10):1537-1548. 
62. McMahon BJ. Natural history of chronic hepatitis B. Clin Liver Dis. Aug 
2010;14(3):381-396. 
 32 
 
 
63. Gilson RJ, Hawkins AE, Beecham MR, et al. Interactions between HIV and 
hepatitis B virus in homosexual men: effects on the natural history of infection. 
AIDS. Apr 1997;11(5):597-606. 
64. Cheruvu S, Marks K, Talal AH. Understanding the pathogenesis and management 
of hepatitis B/HIV and hepatitis B/hepatitis C virus coinfection. Clin Liver Dis. 
Nov 2007;11(4):917-943, ix-x. 
65. Benhamou Y. Hepatitis B in the HIV-coinfected patient. J Acquir Immune Defic 
Syndr. Jul 1 2007;45 Suppl 2:S57-65; discussion S66-57. 
66. Solomon RE, VanRaden M, Kaslow RA, et al. Association of hepatitis B surface 
antigen and core antibody with acquisition and manifestations of human 
immunodeficiency virus type 1 (HIV-1) infection. Am J Public Health. Dec 
1990;80(12):1475-1478. 
67. Sinicco A, Raiteri R, Sciandra M, et al. Coinfection and superinfection of 
hepatitis B virus in patients infected with human immunodeficiency virus: no 
evidence of faster progression to AIDS. Scand J Infect Dis. 1997;29(2):111-115. 
68. Hoffmann CJ, Seaberg EC, Young S, et al. Hepatitis B and long-term HIV 
outcomes in coinfected HAART recipients. AIDS. Sep 10 2009;23(14):1881-
1889. 
69. Lincoln D, Petoumenos K, Dore GJ. HIV/HBV and HIV/HCV coinfection, and 
outcomes following highly active antiretroviral therapy. HIV Med. Jul 
2003;4(3):241-249. 
70. Eskild A, Magnus P, Petersen G, et al. Hepatitis B antibodies in HIV-infected 
homosexual men are associated with more rapid progression to AIDS. AIDS. Jun 
1992;6(6):571-574. 
71. Ockenga J, Tillmann HL, Trautwein C, Stoll M, Manns MP, Schmidt RE. 
Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value. J 
Hepatol. Jul 1997;27(1):18-24. 
72. Chun HM, Roediger MP, Hullsiek KH, et al. Hepatitis B Virus Coinfection 
Negatively Impacts HIV Outcomes in HIV Seroconverters. J Infect Dis. Jan 
2012;205(2):185-193. 
73. Soriano V, Vispo E, Labarga P, Medrano J, Barreiro P. Viral hepatitis and HIV 
co-infection. Antiviral Res. Jan 2010;85(1):303-315. 
74. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 
2006;44(1 Suppl):S6-9. 
75. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C Virus prevalence 
among patients infected with Human Immunodeficiency Virus: a cross-sectional 
 33 
 
 
analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis. Mar 15 
2002;34(6):831-837. 
76. Clausen LN, Weis N, Schonning K, et al. Correlates of spontaneous clearance of 
hepatitis C virus in a Danish human immunodeficiency virus type 1 cohort. Scand 
J Infect Dis. Oct 2011;43(10):798-803. 
77. Clausen LN, Weis N, Astvad K, et al. Interleukin-28B polymorphisms are 
associated with hepatitis C virus clearance and viral load in a HIV-1-infected 
cohort. J Viral Hepat. Apr 2011;18(4):e66-74. 
78. Melendez-Morales L, Konkle BA, Preiss L, et al. Chronic hepatitis B and other 
correlates of spontaneous clearance of hepatitis C virus among HIV-infected 
people with hemophilia. AIDS. Jul 31 2007;21(12):1631-1636. 
79. Shores NJ, Maida I, Soriano V, Nunez M. Sexual transmission is associated with 
spontaneous HCV clearance in HIV-infected patients. J Hepatol. Sep 
2008;49(3):323-328. 
80. Wolff FH, Fuchs SC, Barcellos NN, et al. Co-infection by hepatitis C virus in 
HIV-infected patients in southern Brazil: genotype distribution and clinical 
correlates. PLoS One. 2010;5(5):e10494. 
81. Thomson EC, Fleming VM, Main J, et al. Predicting spontaneous clearance of 
acute hepatitis C virus in a large cohort of HIV-1-infected men. Gut. Jun 
2011;60(6):837-845. 
82. Martin-Carbonero L, Barreiro P, Jimenez-Galan G, et al. Clearance of hepatitis C 
virus in HIV-infected patients with multiple chronic viral hepatitis. J Viral Hepat. 
Jun 2007;14(6):392-395. 
83. Lunge VR, da Rocha DB, Beria JU, Tietzmann DC, Stein AT, Simon D. IL28B 
Polymorphism Associated with Spontaneous Clearance of Hepatitis C Infection in 
a Southern Brazilian HIV Type 1 Population. AIDS Res Hum Retroviruses. Jul 26 
2011. 
84. van den Berg CH, Grady BP, Schinkel J, et al. Female sex and IL28B, a 
synergism for spontaneous viral clearance in hepatitis C virus (HCV) 
seroconverters from a community-based cohort. PLoS One. 2011;6(11):e27555. 
85. Operskalski EA, Kovacs A. HIV/HCV co-infection: pathogenesis, clinical 
complications, treatment, and new therapeutic technologies. Curr HIV/AIDS Rep. 
Mar 2011;8(1):12-22. 
86. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human 
immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc 
Group. Hepatology. Oct 1999;30(4):1054-1058. 
 34 
 
 
87. Darby SC, Ewart DW, Giangrande PL, et al. Mortality from liver cancer and liver 
disease in haemophilic men and boys in UK given blood products contaminated 
with hepatitis C. UK Haemophilia Centre Directors' Organisation. Lancet. Nov 15 
1997;350(9089):1425-1431. 
88. Pol S, Lamorthe B, Thi NT, et al. Retrospective analysis of the impact of HIV 
infection and alcohol use on chronic hepatitis C in a large cohort of drug users. J 
Hepatol. Jun 1998;28(6):945-950. 
89. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus 
infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect 
Dis. Aug 15 2001;33(4):562-569. 
90. Andreoni M, Giacometti A, Maida I, Meraviglia P, Ripamonti D, Sarmati L. HIV-
HCV co-infection: epidemiology, pathogenesis and therapeutic implications. Eur 
Rev Med Pharmacol Sci. Nov 2012;16(11):1473-1483. 
91. Branch AD, Van Natta ML, Vachon ML, Dieterich DT, Meinert CL, Jabs DA. 
Mortality in hepatitis C virus-infected patients with a diagnosis of AIDS in the era 
of combination antiretroviral therapy. Clin Infect Dis. Jul 2012;55(1):137-144. 
92. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Hepatitis C 
and progression of HIV disease. JAMA. Jul 10 2002;288(2):199-206. 
93. Rockstroh JK, Mocroft A, Soriano V, et al. Influence of hepatitis C virus infection 
on HIV-1 disease progression and response to highly active antiretroviral therapy. 
J Infect Dis. Sep 15 2005;192(6):992-1002. 
94. Centers for Disease Control and Prevention. HIV surveillance in urban and 
nonurban areas2012. 
95. Hall HI, Espinoza L, Benbow N, Hu YW. Epidemiology of HIV infection in large 
urban areas in the United States. PLoS One. 2010;5(9):e12756. 
96. Philadelphia Department of Public Health. 2009 Annual Report2009. 
 
  
 35 
 
 
2 SEROPREVALENCE OF VIRAL HEPATITIS INFECTIONS AMONG HIV-
POSITIVE INDIVIDUALS ATTENDING AN URBAN HIV CLINIC 
 
2.1 Abstract 
Co-infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) is common in 
HIV-1-positive individuals due to shared routes of exposure.  Since the widespread 
implementation of highly active antiretroviral therapy (HAART), negative health 
outcomes from viral hepatitis co-infections, such as liver disease and liver-related 
mortality, are becoming significant public health concern.  We assessed the 
seroprevalence (i.e., evidence of previous exposure) of HBV, HCV, and HBV/HCV 
among a population of HIV-positive subjects attending a large, urban HIV clinic from 
2002-11.  We also identified factors associated with each co-exposure and of sexual 
transmission of HCV using a sample of subjects.  We found a relatively high 
seroprevalence of HBV (44%), HCV (34%), and HBV/HCV (19%).  Male injection drug 
users (IDUs) had the greatest odds of HBV, HCV, and HBV/HCV co-exposure (odds 
ratio (OR)=1.77; 95% confidence interval (CI), 1.28-2.45, OR=7.86; 95% CI, 5.50-11.23, 
and OR=6.25; 95% CI, 4.51-8.67, respectively). Additionally, MSM risk, heterosexual 
risk, race, socioeconomic status, older age, and more recent HIV diagnosis were 
significantly associated with co-exposure.  Forty-three percent of HCV-positive subjects 
reported non-IDU sexual risk as their HIV risk factor.  We found presumptive sexual 
transmission of HCV was associated with Black compared to White race (OR=3.85; 95% 
CI, 2.48-5.96), especially among females (OR=11.60; 95% CI, 4.83-27.84), younger age 
(OR=1.39 per 10 year decrease; 95% CI, 1.12-1.69), and a more recent HIV diagnosis 
(OR=1.04 per 1 year increase; 95% CI, 1.02-1.07).  Our findings highlight the burden of 
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viral hepatitis co-infections among HIV-positive individuals, and the need to reduce this 
burden through routine testing, HBV vaccination, and appropriate therapy.  Further 
research, particularly with a prospective study design, is further warranted to fully 
understand the factors associated with viral hepatitis co-infection among HIV-positive 
populations. 
2.2 Introduction 
HIV/AIDS continues to be a significant health concern in the United States (US), with an 
estimated 1.2 million American living with HIV/AIDS in 2008.  Co-infection with 
hepatitis B virus (HBV) and hepatitis C virus (HCV) is common among HIV-positive 
individuals, given their shared routes of exposure, such as percutaneous exposure (e.g., 
needle stick, blood transfusion), sexual contact, and perinatal exposure.1  Approximately 
one-half of HIV-positive subjects have evidence of a past HBV infection, with the 
highest prevalence reported among men who have sex with men (MSM) and injection 
drug users (IDUs) compared to other transmission groups, and recent estimates of the 
prevalence of chronic HBV range from 3-9%.2-4 It has been estimated that 25-30% of 
HIV infected individuals are co-infected with HCV.5  This is especially true among 
IDUs, with an estimated co-infection prevalence of 72-95%. However, several outbreaks 
of sexual transmission of HCV have been recently reported, especially among HIV-
positive MSM.6-8   
 
Since the development and widespread availability of highly active antiretroviral therapy 
(HAART) in the 1990’s, hepatitis-related liver disease has emerged as an important cause 
of morbidity and mortality among those that are HIV-positive, and is now a substantial 
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public health concern.9-14  Being co-infected with HIV and both HBV and/or HCV has 
been shown to negatively impact the natural history of HBV and HCV disease 
progression, which can result in more rapid progression to clinically significant liver 
disease, such as hepatocellular carcinoma and cirrhosis, and death.1 Is it likely that HBV 
and HCV co-infection is related to negative AIDS-related health outcomes as well, but 
the current research has found inconsistent results.2-4,15-22 
 
Currently, treatment of HBV in HIV infected individuals is recommended when there is 
active HBV replication and evidence of elevated liver enzymes, as these indicate the 
potential for liver damage.22,23 There are numerous agents available against HBV in HIV 
infected individuals, including interferon alfa, peginterferon alfa, lamivudine, adefovir, 
entecavir, telbivudine, emtricitabine, and tenofovir.23 Due to concerns of hepatoxicity and 
adverse events, factors such as prognostic markers of liver disease progression, severity 
of liver disease, likelihood of response to treatment, including HBV genotype, and 
interactions with HIV antiretroviral therapy (ART) needs to be considered when deciding 
on initiation of HBV treatment.1,23   
 
Current treatment guidelines for HIV/HCV co-infected patients include long-term (≥ 48 
weeks) treatment with peginterferon and ribavirin.22 As with HBV treatment, the risks of 
hepatoxicity and adverse events must be considered, along with HCV genotype, HCV 
viral load, patient motivation, and potential drug interactions with HIV ART when 
considering initiation of HCV therapy.22,23   
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The objectives of this analysis were to measure the seroprevalence of HBV, HCV, and 
HBV/HCV infections (i.e., evidence of a previous exposure) in a HIV-positive population 
attending an urban HIV clinic using a cross-sectional study design.  Additionally, we 
assessed factors associated with each co-exposure.  Given the recent interest in sexual 
transmission of HCV, we also conducted a small cross-sectional sub-analysis to 
specifically investigate factors associated with sexual transmission of HCV. 
 
2.3 Methods 
Study population 
This study used the Drexel University’s College of Medicine’s Partnership 
Comprehensive Care Practice, which provides routine primary and specialty HIV medical 
care to HIV-positive individuals in Philadelphia, to draw its study population.  This 
practice is the largest and most comprehensive HIV primary care practice in Philadelphia, 
serving 1,900 patients in 2010.  All subjects who had at least two visits at the clinic 
between the years 2002 and 2011 were eligible for inclusion in the study (n=2,880). At 
each clinic visit, patients had comprehensive laboratory work (e.g., CD4 cell count, HIV 
RNA viral load (VL), hepatitis testing), in accordance with clinical standards of care and 
practical guidelines at the time.   
 
Hepatitis B definitions 
Only those tested for HBV during the study period were included in HBV-related 
estimates (n=2,185).  Being HBV exposed was defined as having any positive lab result 
from at least one of the following HBV-related tests at any time from 2002-11: core 
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antibody (IgM anti-HBc, IgG anti-HBc, or anti-HBc), surface antigen (HBsAg), e antigen 
(HBeAg), or HBV DNA.  These tests were chosen as they would more accurately capture 
individuals with a true hepatitis infection compared to relying on those with a positive 
antibody test only.  Given the cost of hepatitis B antibody test, a provider in a clinic 
setting may bypass an antibody test and only test for one of the above tests to assess 
infectivity or infection status for individuals who self-report being hepatitis B-positive.   
Infections were further classified as resolved, defined as having concurrent (within 30 
days) HBV core antibody and surface antibody reactivity,17,21 or chronic, defined as 
having two consecutive reactive HBsAg or HBV DNA tests.21  Seventy-five percent of 
subjects with a history of HBV exposure could be classified as having either a resolved or 
chronic infection. 
 
Hepatitis C definitions 
Only subjects with an available anti-HCV test result were eligible for inclusion in the 
HCV prevalence estimates (N=2,232).  Subjects were classified as being HCV-positive or 
negative based on anti-HCV test results prior to the study period or at any time from 
2002-11.  All anti-HCV-positive subjects were further classified as having a resolved 
infection (defined as having undetectable (< 50 copies) HCV RNA viral load using a 
quantitative assay) or having a persistent infection (defined as having detectable HCV 
VL).24,25 A total of 552 ant-HCV-positive subjects could not be classified due to missing 
HCV RNA information.   
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Additional definitions 
The following factors were described and investigated as potential factors associated with 
viral hepatitis co-exposures: sex; race; primary HIV risk factor; insurance status; year of 
HIV diagnosis; age; and CD4 cell count, HIV RNA VL, AIDS diagnosis, prior exposure 
to HBV, HBsAg positivity, and anti-HCV positivity at entry into cohort (“baseline”).  
 
HAART was first defined as any of the following combinations:  ≥ 2 protease inhibitors 
(PI) and ≥ 1 nucleoside reverse transcriptase inhibitor (NRTI), without a non-nucleoside 
reverse transcriptase inhibitor (NNRTI) (PI-containing HAART); ≥ 2 NNRTI and ≥ 1 
NRTI, without PI (NNRTI-containing HAART); ≥ 1 NNRTI and ≥ 2 NNRTI, without PI 
(NNRTI-containing HAART); ≥ 1 PI and ≥1 NNRTI and ≥ 1 NRTI (PI- and NNRTI-
containing HAART); and a fusion inhibitor, entry inhibitor, or integrase inhibitor, not 
meeting a definition above (other HAART). Those not meeting one of the above 
definitions were considered not to be on HAART.  Baseline HIV therapy was defined as 
medication taken within the first three months of entry into the cohort.  To improve 
statistical efficiency, we explored creating a binary HIV treatment variable in which all 
HAART categories were collapsed into one.  Additionally, given that lamivudine is 
effective at both HIV and HBV,26 categories were created for HAART with and without 
lamivudine.27  
 
If available, the CD4 cell count taken on the baseline date was used for the baseline value 
(n=2,653; 94%).  If this was not available, then subsequent values were used.  If the 
difference between the first two values following the baseline date was ≤ 10% and both 
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were within six months of baseline, then the mean of these values was used as the 
baseline value (n=31; 1%).  If the difference was greater than 10%, then the first value 
following baseline was used, as long as it was within six months of the baseline date 
(n=136; 5%).  Sixty subjects did not meet any of the criteria above and therefore had a 
missing baseline CD4 cell count value.  
 
A similar approach was used to define baseline HIV RNA VL as is described above for 
baseline CD4, resulting in 91% with a VL taken on the baseline date. One hundred ten 
subjects did not meet any of the criteria above and therefore had a missing baseline HIV 
VL.  HIV VL values were transformed to the log scale. 
 
Analysis 
The seroprevalence of each viral hepatitis infection (i.e., HBV/HIV, HCV/HIV, and 
HBV/HCV/HIV) was generated and presented.  Potential factors associated with each co-
exposure were summarized using descriptive statistics.  For continuous variables, means 
were presented with standard deviations and were compared with Wilcoxon tests. For 
categorical variables, differences in proportions were compared with χ tests.  A two-
sided alpha level of 0.05 was used to determine statistical significance. 
 
Logistic regression models were used to model the odds of each viral hepatitis co-
exposure.  For each analysis, the referent group was patients HIV-positive patients 
without evidence of a past exposure to the hepatitis virus(es) under examination. Crude 
logistic regression models were first presented for all potential factors associated with co-
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exposure, including: demographics (sex, race, HIV risk group, age, year of HIV diagnosis 
and type of insurance); HIV ART; HIV VL; CD4 count; and past/present viral hepatitis 
(HBV, HCV) infection.  Insurance status (private, public, uninsured, or unknown) was 
used as a proxy for socioeconomic status.28,29   
 
To assess factors that may be associated with viral hepatitis infection in a HIV-positive 
population, the statistical significance of each potential factor was first assessed using a 
χ test for categorical variables or a Wilcoxon test for continuous variables.30  Exact 
methods (e.g., Fisher’s exact test) were used with small cell counts.  Next, potential 
associated factors were assessed univariately in a logistic regression model to determine 
if they were statistically associated with the outcome of interest (i.e., viral hepatitis 
exposure).  Logistic regression assumes a linear relationship between the independent 
variable and the log odds of the outcome (i.e., the relationship is linear on the log scale).30 
All continuous variables met this assumption for each of the analyses (see Appendix A).  
A backward selection approach was used to build the final logistic regression model. The 
first step of this process involved building an initial regression model that contained all 
potential factors that reached statistical significance at an alpha level of 0.05.  Next, 
variables were removed from the model one at a time based on the corresponding p-value 
and the model was re-run; those with the highest p-values were removed first.  This 
process continued iteratively until only variables reaching statistical significance at an 
alpha level of 0.05 were included in the model.  This backward selection approach was 
modified to allow investigators to include variables that did not reach statistical 
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significance (i.e., “force in”), but were thought to be a potential predictor due to prior 
knowledge or a large (≥ 2.0) effect estimate. 
 
Sexual transmission of HCV sub-analysis 
We also conducted a sub-analysis on 787 anti-HCV-positive subjects reporting sexual 
(heterosexual or MSM; n=336) or IDU (n=451) risk behavior as their primary HIV risk 
factor to identify factors relating to probable sexual transmission of HCV.  Given the role 
that sexually transmitted infections (STIs) have in sexual transmission of HCV,31 we 
sought to include a history of various STIs as possible transmission factors. Therefore, 
we analyzed subjects with a STI test taken during the study period, but prior to the first 
positive anti-HCV test.  Due to small sample sizes with respect to available test results, 
we were not able to assess gonorrhea, chlamydia, trichomonas, or herpes simplex virus; 
only a history of syphilis was assessed.  Factors associated with sexual transmission of 
HCV were identified using multivariate logistic regression, modeling the odds of sexual 
transmission of HCV.  The same approach described above was used for this sub-
analysis.  Regression analyses were also stratified by sex and type of sexual risk (i.e., 
MSM, heterosexual). 
 
All analyses were conducted in SAS 9.2. The Drexel College of Medicine Institutional 
Review Board (IRB) approved this study.  
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2.4 Results  
Study population 
Our study population consisted mostly of males (63.2%) and those of Black race (68.9%) 
(Table 2-1).  Over 43% reported heterosexual risk as a primary HIV risk factor.  Most 
subjects were diagnosed with HIV after 1990.  The mean age of subjects was a little more 
than 40 years.  Less than one-quarter had previously been diagnosed with clinical AIDS 
and the population’s mean CD4 count was 415 cells/µL.  The majority of subjects were 
on HAART at time of entry into the cohort or within three months (58.8%).   
 
Seroprevalence of co-infections 
Hepatitis B 
Among the 2,880 subjects in our study population, 2,185 (76%) had an available HBV 
test during the study period.  Among them, the seroprevalence of HBV was 44.2%.  
Evidence of past HBV exposure was highest among males (48.2%; p<0.0001), Blacks 
(45.2%; p=0.2886), those reporting IDU risk behaviors (54.0%; p<0.0001), those with 
public insurance (47.9%; p=0.0002), those who were HCV-positive (56.6%; p<0.0001), 
and those who had clinical AIDS (49.2%; p=0.0104) (Table 2-2).  Seroprevalence was 
also significantly higher for those with an earlier HIV diagnosis and older age.  
Additionally, seroprevalence rates were similar for CD4 cell count, HIV RNA VL, and 
HAART therapy.  
 
The prevalence of chronic HBV infection in this HIV-positive population was 2.8%.  
Prevalence of chronic infection was statistically higher among males compared to 
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females (3.6 vs. 1.6%; p=0.0139) (Table 2-3).  With respect to risk factor, prevalence was 
highest among MSM (4.2%), followed by IDU risk (3.0%) and heterosexual risk (1.8%) 
(p=0.0336). Although not significant, prevalence of chronic HBV was highest among 
Blacks, those with a HIV diagnosis prior to 2000, those aged 30-39 years, those who 
were HCV-negative, and those on HAART with lamivudine.  Of all HBV-positive 
subjects, 9% developed a chronic infection.   
 
Hepatitis C 
Among the 2,880 subjects in our study population, 2,232 (78%) had an available anti-
HCV test during the study period.  The prevalence of anti-HCV was 34.1% in this study 
population.  Evidence of a previous HCV exposure was markedly higher in IDUs 
(75.8%) compared to other risk groups (p<0.0001) (Table 2-2).  Seroprevalence was also 
higher among males (36.3%; p=0.2556), those with public or unknown insurance type 
(37.3% and 38.9%, respectively; p<0.0001), those who were HBsAg-negative (44.7%; 
p=0.0371), and those that did not have clinical AIDS (36.7%; p=0.0228).  Unlike what 
was observed with HBV, seroprevalence of HCV was highest among Whites (47.3%) 
compared to other races (p<0.0001).  Similar to what was observed for HBV, 
seroprevalence was also significantly higher for those with an earlier HIV diagnosis and 
older age, and rates were similar for CD4 cell count, HIV RNA VL, and HAART 
therapy.   
 
Prevalence of chronic HCV in this HIV-positive population was 12.3%.  Prevalence was 
similar among men compared to women (13.0 vs. 11.6%; p=0.4228) (Table 2-4).  
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Prevalence was also greatest among Whites (21.8%; p<0.0001), those reporting IDU risk 
behaviors (48.2%; p<0.0001), those with public insurance (13.9%; p=0.0362), those 
diagnosed with HIV prior to 1990 (23.2%; p=0.0001), and those aged ≥ 50 years (21.0%; 
p<0.0001).  Among HCV-positive individuals, 87% of them went on to have a chronic 
infection.  
 
Hepatitis B and hepatitis C 
Among the 2,880 subjects in our study population, 2,013 (73.0%) were tested for both 
HBV and HCV during the study period.  The seroprevalence of HBV/HCV/HIV was 
19.0% in this study population.  Similar to what was observed with HBV/HIV and 
HCV/HIV co-exposure, the seroprevalence of HBV/HCV among HIV-positive 
individuals was greater among IDUs (43.7%; p<0.0001) and those with public insurance 
(21.8%; p<0.0001) (Table 2-2).  It was also greatest among females (26.3%; p=0.0219) 
and lowest among Blacks (16.6%; p<0.0001).  Similar to what was observed for HBV, 
seroprevalence was also significantly higher for those with an earlier HIV diagnosis and 
older age, and rates were similar for CD4 cell count, HIV RNA VL, and HAART 
therapy. 
 
Factors associated with co-exposure 
Hepatitis B 
Univariate logistic regression analysis identified the following factors as being potential 
factors associated with a past/present HBV infection in this HIV-positive clinic 
population: male sex (OR=1.63; 95% CI, 1.36-1.96); males reporting IDU or MSM risk 
 47 
 
 
behaviors compared to heterosexual sex (OR=2.20; 95% CI, 1.73-2.81, and OR=1.38; 
95% CI, 1.14-1.68, respectively), having public compared to private insurance (OR=1.34; 
95% CI, 1.06-1.69); having an earlier HIV diagnosis (OR=1.05, 95% CI, 1.04-1.06, for 
every 1 year earlier); older age (OR=1.49; 95% CI, 1.36-1.63, per 10 year increase); 
having AIDS (OR=1.29; 95% CI, 1.06-1.58); being HCV-positive (OR=2.06; 95% CI, 
1.71-2.49); and being on certain types of HAART (Table 2-5).   The following factors 
remained significantly associated with a past/present HBV infection on multivariate 
analysis: IDU or MSM risk compared to heterosexual risk among males (OR=1.77; 95% 
CI, 1.28-2.45, and OR=1.72; 95% CI, 1.36-2.19, respectively); having earlier HIV 
diagnosis (OR=1.03 per 1 year earlier; 95% CI, 1.01-1.04); older age (OR=1.30 per 10 
year increase; 95% CI, 1.16-1.45); being anti-HCV-positive (OR=1.57; 95% CI, 1.23-
2.02); and being on PI- and NNRTI-containing HAART compared to NNRTI-containing 
HAART (OR=1.92; 95% CI, 1.14-3.23) (Table 2-5).  The increased risk associated with 
IDU risk compared to heterosexual among males was not seen among females. 
 
Hepatitis C 
Crude logistic regression analysis identified the following factors associated with HCV 
co-exposure: White race compared to Black race (OR=1.97; 95% CI, 1,57-2.48), IDU 
risk compared to heterosexual risk in both males and females (OR=8.11; 95% CI, 6.16-
10.67 and OR=4.98; 95% CI, 3.64-6.80, respectively), public insurance compared to 
private insurance (OR=1.65; 95% CI, 1.29-2.13), less recent HIV diagnosis (OR=1.05 per 
1 year decrease in year; 95% CI, 1.04-1.06), older age (OR=1.75 per 10 year increase; 
95% CI, 1.59-1.92), not having clinical AIDS (OR=1.27; 95% CI, 1.03-1.56), having past 
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exposure to HBV (OR=2.06; 95% CI, 1.71-2.49), being HBsAg-negative (OR=1.54; 95% 
CI, 1.02-2.33), and being on certain types of HAART therapy (Table 2-6).  On 
multivariate analysis, the following factors remained significantly associated with HCV 
exposure among HIV-positive individuals: White race compared to Black race (OR=1.92; 
95% CI, 1.37-2.69); IDU risk compared to heterosexual risk among males and females 
(OR=7.86; 95% CI, 5.50-11.23 and OR=6.10; 95% CI, 3.95-9.42, respectively); public 
insurance compared to private insurance (OR=1.55; 95% CI, 1.10-2.17); less recent HIV 
diagnosis (OR=1.02 per 1 year decrease; 95% CI, 1.00-1.04); older age (OR=1.61 per 10 
year increase; 95% CI, 1.41-1.86); having past exposure to HBV (OR=1.65; 95% CI, 
1.28-2.12); and being on PI-containing HAART or NRTI HAART compared to PI- and 
NNRTI-containing HAART (OR=1.95; 95% CI, 1.05-3.61, and OR=4.15; 95% CI, 1.84-
9.36, respectively) (Table 2-6).   
 
Hepatitis B and hepatitis C 
Crude logistic regression identified the following variables as being potentially associated 
with HBV/HCV/HIV co-exposure: male sex (OR=1.33; 95% CI, 1.04-1.69); White and 
Hispanic race compared to Black race (OR=1.71; 95% CI, 1.29-2.27 and OR=1.77; 95% 
CI, 1.27-2.46, respectively); IDU risk compared to heterosexual risk among men and 
women (OR=8.11; 95% CI, 6.16-10.67, and OR=4.98, 95% CI, 3.64-6.80, respectively); 
public insurance compared to private insurance (OR=1.75, 95% CI, 1.26-2.43); less 
recent HIV diagnosis (OR=1.05 per 1 year decrease; 95% CI, 1.03-1.08); older age 
(OR=1.70 per 10 year increase; 95% CI, 1.51-1.91); and certain types of HAART therapy 
(Table 2-7).  The following variables remained significantly associated with HBV/HCV 
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co-exposure among HIV-positive individuals on multivariate analysis: IDU risk 
compared to heterosexual risk among both males and females (OR=6.70; 95% CI, 4.86-
9.23, and OR=4.34; 95% CI, 2.88-6.55, respectively); older age (OR=1.54 per 10 year 
increase; 95% CI, 1.34-1.77); and being on PI-containing HAART or NRTI HAART 
compared to PI-and NNRTI-containing HAART (Table 2-7). 
 
Sexual transmission of HCV 
In a sub-analysis, we identified 336 HCV-positive individuals who reported sexual risk as 
their primary HIV risk factor (35% were MSM and 65% were heterosexual) and this was 
used as a proxy for probable sexual acquisition of HCV.  Among those with a history of 
being tested for syphilis (n=360), 31 (9%) were positive.  Among those who reported 
sexual risk, significantly more were Black (75.5 vs. 53.9%, p<0.0001), had private 
insurance (11.0 vs. 5.7%, p=0.0415), were diagnosed with HIV since the year 2000 (42% 
vs. 32.2%; p=0.0351), and had a history of syphilis (12.1 vs. 5.1%; p=0.0174) compared 
to those who reported any IDU risk (Table 2-8).   
 
Crude logistic regression found the following factors to be possibly associated with 
sexual transmission of HCV:  Black compared to White race (OR=2.58; 95% CI, 1.78-
3.74); later year of HIV diagnosis (OR=1.04; 95% CI, 1.01-1.06, per 1 year increase); 
and a history of syphilis infection (OR=2.58; 95% CI, 1.15-5.77) (Table 2-9).  On 
multivariate analysis, only Black race (OR=3.85; 95% CI, 2.48-5.96), more recent HIV 
diagnosis (OR=1.04, 95% CI, 1.02-1.07; per 1 year increase), and decreased age 
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(OR=2.27, 95% CI, 1.12-1.69; per 10 year decrease) were significantly associated with 
sexual transmission of HCV (Table 2-9). 
 
A sex- and risk-stratified multiple logistic regression model found that Black females had 
the greatest odds for sexual acquisition of HCV (OR=11.60; 95% 4.83-27.84) (Table 2-
10).  Black males reporting heterosexual risk also had increased odds of sexual 
acquisition of HCV (OR=3.30; 95% CI, 1.56-6.96).  Among males reporting MSM 
behavior, the factors most related to sexual transmission of HCV were White compared 
to Hispanic race (OR=3.03; 95% CI 1.27-7.14) and younger age (OR=1.80; 95% CI, 
1.35-2.44).   
 
2.5 Discussion 
In this HIV-positive population, the seroprevalence of HBV, HCV, and HBV/HCV was 
44%, 34%, and 19%, respectively.   We found that 9% of HBV infections and 87% of 
HCV exposures develop into chronic infections.  We found similar factors associated 
with each viral hepatitis co-exposure, including IDU risk behavior and older age.  We 
also identified MSM behavior, and earlier HIV diagnosis to be associated with a history 
of HBV exposure, and lower socioeconomic status, earlier HIV diagnosis, and being 
White to be associated with being anti-HCV-positive  In a sub-analysis, we found that 
Black race, a more recent HIV diagnosis, and younger age were associated with sexually 
transmitted HCV.    
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Hepatitis B 
Although sexual transmission is usually associated with HBV infection, we were not 
surprised to also find a high prevalence among IDU in our population, as percutaneous 
exposure is an highly effective mode of HBV transmission.5  When adjusted for sex, year 
of HIV diagnosis, age, anti-HCV positivity, and HAART, males with IDU and MSM risk 
had an increased risk of HBV exposure of similar magnitude (approximately 70% greater 
odds of infection compared to heterosexual contact).  Nine percent of our IDU population 
also reported MSM behavior, which could also have contributed to our increased rates in 
the IDU population.  Increased risk of HBV exposure among those anti-HCV-positive is 
likely attributable to the shared risk factors of these viruses.  Additionally, over 75% of 
subjects with evidence of prior HBV/HCV infection reported IDU or MSM risk behavior, 
which could elevate rate of co-exposure in our study population.  We also found that 
being on a PI- and NNRTI-containing HAART regimen was associated with increased 
HBV co-exposure compared to a NNRTI-HAART regimen.  This does not seem to be 
attributable to a higher proportion of IDU or MSMs in this population (63 vs. 66%).  This 
group also has similar proportion of subjects on a lamivudine-containing HAART 
regimen (42 vs. 41%).  The NNRTI-HAART group was somewhat less healthy upon 
entry into the cohort (mean CD4 count 440 vs. 364 cells/µl), however we did not find 
CD4 count to be associated with HBV exposure.  Our finding was more likely due to 
unmeasured confounders in our population, such as drug adherence specifically to 
regimens containing agents effective against HBV or factors associated with overall 
health. 
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The prevalence of chronic hepatitis B in our population was consistent to what has 
recently been reported in a HIV-positive population with access to healthcare (2.7%).21  
However, together, these estimates are substantially lower than what has previously been 
reported in the literature.  In the pre-HAART and -vaccine era, the prevalence of chronic 
HBV ranged from 7-9%.20,26 Even as recent as a decade ago, the reported prevalence of 
chronic HBV was quite high (6-9%).2-4,27,32 Our estimates could be lower for a number of 
reasons.  First, it may reflect a true shift in the epidemiology of HBV/HIV co-infection 
due to increased vaccinations in the HIV-positive population.  However, recent data from 
the National Health Interview Survey showed that HBV coverage among high-risk 
individuals in 2010 remained steady at about 42% compared to 2008.33  However, our 
clinic-based population may not be representative of the general HIV-positive population.   
HBV vaccination rates have been reported to be greater in clinic settings compared to 
other healthcare settings or no health care.34 Current guidelines recommend all adults 
seeking healthcare at a high-risk setting (such as a HIV clinic) receive the HBV 
vaccine.35  Given that this HIV clinic is not the only place for our subjects to receive 
healthcare and not all of the subjects had extensive hepatitis B serology testing 
performed, our data may not hold complete information on hepatitis B vaccine coverage 
in our population.  However, we did identify at least 40% of subjects had either received 
hepatitis B vaccine in the clinic during the study period or had serological evidence of a 
hepatitis immunity due to vaccine.  This fairly high level of vaccine coverage likely 
caused our smaller prevalence estimates than what has previously been reported.  Studies 
that have reported high vaccine coverage (22%) also reported lower HBV prevalence,21 
while studies with low vaccination rates (5%) reported much higher HBV prevalence.27  
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Additionally, we required two positive HBsAg measurements to define a chronic 
infection while other studies with higher prevalence rates only required one,2 leading to 
the potential for misclassification of chronicity.  
 
Similar to what has previously been reported, we found the prevalence of chronic HBV to 
be highest among men and those reporting MSM or IDU risk factors, and lowest among 
Hispanics.27 Due to our low levels of HBV exposure in general in this population, we 
may have been limited in our ability to reach statistical significance when comparing 
categories of potential factors associated with chronic HBV.  We also found that 9% of 
all those with a previous exposure to went on to develop a chronic infection, which is 
consistent to what has been previously reported in the literature.21 
 
Hepatitis C 
The seroprevalence of HCV (i.e., anti-HCV-positive) was 34% in this HIV-positive 
population attending a large, urban HIV clinic.  This is consistent with findings from 
previous research; studies with a low proportion of IDUs have found HCV 
seroprevalence to be 15-16%,13,36 while a large study comprised of 36% IDUs reported 
HCV seroprevalence to be 37%.9  HCV exposure was significantly associated with White 
race, IDU risk behaviors, and lower socioeconomic status, as indicated by being on 
public compared to private insurance.  Given the primary mode of HCV transmission in 
the US is through injection drug use, it is not surprising that we found that subjects 
reporting IDU behavior had significantly higher seroprevalence of HCV (76%) compared 
to other risk groups, which is similar to what other studies have found (73-92%).9,36,37  
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We also found that subjects < 30 years old at time of HIV diagnosis had the lowest 
seroprevalence of HCV (25%).  This finding could be attributable to a variety of reasons.  
First, this age group may exhibit less risky behavior once they learn of their HIV 
diagnosis, thereby reducing their risk of acquiring HCV.  Unfortunately, this is not 
measureable in this population and research indicates that HCV infection usually 
precedes HIV infection.38  Second, it is possible that individuals in this group had a 
smaller duration of time in the clinic, which may lead to decreased opportunity for HCV 
testing.  However, those aged < 30 years had only slightly less follow-up time on average 
than those ≥ 30 years (5.8 vs. 6.4 years).  Further, they had an average of 1.6 anti-HCV 
tests compared to an average of 1.7 for those ≥ 30 years.  Therefore, these differences 
likely did not affect HCV seroprevalence in this age group. The most likely explanation 
for this difference is that 44% of this group reported heterosexual contact and an 
additional 37% reported MSM behavior as their primary HIV risk group, which are 
groups known to have less HCV exposure than IDU groups.  Similar to HBV, we found 
that certain types of HAART regimens were associated with higher risk of HCV co-
exposure.  Further investigation of the data revealed these groups were similar with 
respect to risk factor and baseline CD4 cell count, indicating unmeasured confounders 
may be the reason for this difference. 
 
Similar to what has previously been reported, we found the prevalence of chronic HCV to 
be highest among Whites, men, those reporting IDU risk factors, those of lower 
socioeconomic status, older age, those with an earlier HIV diagnosis, and HBV 
positivity.24,39,40 Given the small proportion of subjects that cleared their HCV infection, 
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we may have been limited in our ability to reach statistical significance when comparing 
categories of factors potentially associated with chronic HCV.  We also found that 87% 
of all anti-HCV-positive individuals went on to develop a chronic infection, which is 
consistent to what has been previously reported in the literature.25,40-42 
 
Hepatitis B and hepatitis C 
The seroprevalence of HBV/HCV was greatest among IDUs (44%).  Given the shared 
routes of transmission and prevalence estimates for HBV and HCV co-exposure 
generated from this analysis, these results were expected.  Similar to what was observed 
separately for HBV and HCV, HBV/HCV co-exposure was significantly associated with 
race, risk group, increased age, and certain types of HAART.   
 
Sexual transmission of HCV 
We had a unique opportunity to conduct a sub-analysis on a large group of HIV-positive 
individuals who reported only sexual risk as their risk factor for HIV, and therefore 
presumably for HCV as well.  Sexual transmission of HCV has been recently been 
discussed in the literature as an important factor for HCV transmission, especially among 
both HIV-positive7,8,43,44 and –negative45 MSM and women who report heterosexual sex 
with an IDU partner.46  A recent study from the Swiss HIV Cohort reported the incidence 
of HCV in MSM increased 16-fold from 0.23 per 100 person-years in 1998 to 4.09 per 
100 person-years in 2011.47  Increased prevalence of high-risk sexual behavior in these 
groups has coincided with widespread access to HAART48,49 and the perception that 
HAART-inducted virologic control reduces HIV infectivity.50   This phenomenon can 
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help explain why our HCV co-infection prevalence was slightly greater among those 
reporting sexual exposure (17-23%) than what has been reported previously (4-
14%).9,36,37   
 
In our sub-analysis, we found that Black race had an almost 4-fold increased odds of 
sexual transmission of HCV compared to Whites.  A stratified analysis found that Black 
females were primarily driving this observation, however, increased odds of sexual 
transmission of HCV among Blacks was also identified among males reporting 
heterosexual sex and to a lesser degree males reporting MSM behavior.  This may also be 
attributable to under-reporting of true IDU risk; 25% our clinic population reported IDU 
risk compared to 35% city-wide in Philadelphia.51  Additionally, a more recent HIV 
diagnosis and younger age were found to be significantly associated with sexual 
transmission of HCV.  We found those reporting sexual risk factors were more likely to 
have a history of a syphilis infection (12 vs. 5%; p=0.0174), although this did not remain 
statistically significant on multivariate analysis.  This could be due to our small sample 
size (only 360 subjects were tested for syphilis); limited testing for other ulcerative STIs 
(e.g., herpes simplex virus) did not allow us to assess these important potential factors.  
These finings are consistent with findings from the Swiss HIV Cohort study, which found 
that those with MSM transmission of HCV had a higher prevalence of a concurrent 
syphilis infection (5 vs. 2%).31 Unlike a recent study, we did not find an association 
between HCV transmission and high HIV RNA viral loads on multivariate analysis.52 In 
addition to limited STI data, we were unable to assess specific sexual or drug use risk 
factors that have previously been associated with sexual transmission of HCV in similar 
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populations.  Recent epidemiologic studies with access to behavior data identified unsafe 
sexual practices,31,43 especially those that caused mucosal damage in the rectum (e.g., 
fisting),53,54 were in the setting of group sex, or during use of non-injection recreational 
drugs7,8,43,54 (i.e., amphetamines) to be highly associated with an increased risk of HCV 
transmission. These studies suggest that having HIV is a marker for more traumatic 
sexual practices that put individuals at increased risk for HCV, rather than HIV affecting 
the infectiousness of HCV.7  
 
Limitations 
Our study is limited in several ways.  First, we relied on analysis of data previously 
collected during routine clinical care at a large HIV clinic.  Although this yielded over 10 
years of clinical data, our assessment of factors associated with viral hepatitis exposure 
was limited to available data.  We could not collect information on recreational drug use, 
given that dis-inhibition may lead to more risky sexual behavior;7 specific sexual 
practices; complete hepatitis B vaccination rates; comprehensive history of STIs, 
specifically those cause genital ulcers, such as herpes simplex virus; and alcohol use, 
given that those with high levels of alcohol use may be tested for hepatitis more often due 
to elevated liver enzymes.27  
 
Additionally, our study population was drawn from HIV-positive subjects attending an 
urban HIV clinic in the Northeast and may not be generalizable to other HIV-positive 
populations.  We had slightly higher proportion of IDUs in our study population (25 vs. 
22% nationally reported HIV risk profile) and a much larger proportion of subjects 
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reporting heterosexual risk as the lone HIV risk factor (44 vs. 26% nationally).55  The 
larger proportion of heterosexual, normally considered “low risk” for HBV and HCV 
may have lowered our seroprevalence estimates.  Misclassification of HIV risk, with 
those subjects with true MSM or IDU risk reporting heterosexual risk only may have lead 
to an increased association with heterosexual risk.  Further, as this study was conducted 
in a clinic population, it is possible that subjects included in our study may differ with 
respect to health-seeking behaviors, risky sexual and drug use behavior, vaccination 
coverage and adherence to antiretroviral therapy than the general HIV population.34,56,57 
which may cause an underestimation of the true seroprevalence rates.  Our study was 
further limited by its cross-sectional design, which may not accurately reflect the rate of 
chronic infections due to loss of detectable antibody among those who recover from their 
infection.58  We also could not substantially consider re-infection with any of the viral 
hepatitis infections.  However, our relatively large and heterogeneous population, with 
respect to sex, race, and risk factor, help balance these limitations. 
 
Public health and clinical impact 
Our findings highlight the burden of HBV and HCV co-infection among HIV-positive 
individuals.   Understanding the risk factors associated with viral hepatitis exposure in 
HIV-positive populations is becoming an important issue, as hepatitis-related morbidity 
has increased markedly in this population.9-14 Existing mechanisms, such as condom use 
education and distribution, pre-exposure prophylaxis, and treatment of serodiscordant 
partners, can be further implemented to reduce infection rates.  In efforts to reduce the 
morbidity and mortality associated with co-infection, clinical and public health policies 
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should be focused on increased HBV vaccination in this population, including use of a 
modified schedule, which has recently been shown to be effective in mounting an 
immune response to the vaccine.59,60 Additionally, routine screening for HBV and HCV 
in HIV-positive populations and vice versa, regardless of risk profile should be 
considered, along with routine HBsAg tests for all patients with a serologic history of 
HBV exposure and RNA tests for all anti-HCV-positive patients.  Additionally, 
immediate HBV, HCV, and HIV therapy should be considered when infections are 
identified, as chronic infections may be asymptomatic, in order to preserve the immune 
function of affected individuals and reduce negative health outcomes associated with 
hepatitis infections. Although there must be considerations for hepatoxicity due to 
hepatitis therapy among HIV-positive individuals, it has been demonstrated that the 
benefits of hepatitis therapy in co-infected patients outweigh the risks under certain 
circumstances.61  
 
Conclusion 
In conclusion, we reported the seroprevalence rates of HBV, HCV, and HBV/HCV 
infection in a population of HIV-positive subjects attending an urban HIV clinic.  We 
found relatively high rates of HCV exposure, but lower rates of HBV exposure than what 
has previously been reported; this is likely due to higher rates of HBV vaccination in this 
population.  These findings highlight the burden of disease of hepatitis and HIV co-
infection, and procedures should be implemented on a clinical and public health level to 
reduce the amount of co-infection in these populations.  Further exploration of specific 
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behaviors that may increase risk of co-infection should be conducted, especially those 
investigating sexual transmission of HCV.   
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2.6 Tables and Figures 
 
 
 
Table 2-1. Baseline population characteristics of HIV-positive subjects at entry into 
cohort (N=2,880) 
Characteristic 
Baseline population (N=2,880) 
N (%) 
Male sex 1821 (63.2) 
Race   
 Black 1984 (68.9) 
White 484 (16.8) 
Hispanic 392 (13.6) 
HIV risk group   
 Heterosexual 1253 (43.5) 
Any IDU 715 (24.8) 
MSM 878 (30.5) 
Insurance type   
 Private 309 (10.7) 
Public 1488 (51.7) 
Uninsured 62 (2.2) 
Unknown 865 (30.0) 
Year of HIV diagnosis   
 < 1990 191 (8.6) 
1990-1999 984 (44.0) 
≥ 2000 1060 (47.4) 
Age (years) (mean (SD)) 40.1 (10.2) 
Age group (years)   
 <30 884 (30.7) 
30-<40 752 (26.1) 
40-<50 369 (12.8) 
≥50 140 (4.9) 
AIDS 602 (20.9) 
CD4 count (cells/µL) (mean (SD)) 415 (284) 
CD4 count (cells/µL)   
 < 200  675 (23.4) 
200 - < 350 625 (21.7) 
≥ 350 1520 (52.8) 
HIV RNA (log10 copies/mL) (mean (SD)) 3.4 (1.3) 
HIV therapy   
 PI- and NNRTI-containing HAART 121 (4.7) 
PI-containing HAART 863 (33.6) 
NNRTI-containing HAART 588 (22.9) 
NRTI alone HAART 121 (4.7) 
Not on HAART 879 (34.2) 
On HAART  1693 (65.8) 
On lamivudine-containing HAART 727 (28.3) 
On tenofovir-containing HAART 507 (19.7) 
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Table 2-2.  Seroprevalence of HBV, HCV, and HBV/HCV among a HIV-positive population (N=2,880) 
Characteristic 
HBV HCV  HBV/HCV 
N 
Seroprevalence 
(%) p-value* N 
Seroprevalence 
(%) p-value* N 
Seroprevalence 
(%) p-value* 
No. tested 2,185  2,232  2,013  
Overall 966 44.2 791 34.1 383 19.0 
Sex    
 Male 687   48.2 <0.0001 525 36.3 0.2556 268 20.5 0.0219 Female 270 36.3 260 33.9 112 26.3 
Race    
 Black 708 45.2 
0.2886 
496 31.3 
<0.0001 
241 16.6 
<0.0001 White 148 41.8 178 47.3 85 25.5 
Hispanic 104 41.1 114 43.9 57 26.0 
HIV risk group    
 Heterosexual 350 37.2 
<0.0001 
218 23.2 
<0.0001 
95 11.0 
<0.0001 Any IDU 287 54.0 451 75.8 219 43.7 
MSM 323 46.6 118 17.4 66 10.5 
Insurance type    
 Private 103 38.3 
0.0002 
59 22.0 
<0.0001 
28 11.0 
<0.0001 Public 595 47.9 475 37.3 254 21.8 Uninsured 17 35.2 10 21.7 4 9.5 
Unknown 197 38.5 202 38.9 75 17.0 
Year of HIV diagnosis    
 < 1990 103 62.1 
<0.0001 
86 48.9 
<0.0001 
51 31.3 
<0.0001 1990-1999 422 49.7 321 36.6 168 20.8 
≥ 2000 342 39.6 234 26.9 116 14.5 
Age group (years)    
 <30 68 20.4 
<0.0001 
188 25.3 
<0.0001 
8 2.7 
<0.0001  30-<40 295 44.5 246 37.0 94 15.4  40-<50 411 51.0 141 43.0 184 24.5 
 ≥50 192 51.3 56 44.8 97 27.9 
Anti-HCV-positive    
 Yes 383 56.6 <0.0001    No 515 38.6 
Prior HBV exposure    
 Yes  383 42.7 <0.001   No 294 26.5 
HBsAg-positive    
 Yes  41 34.5 0.0371  No 308 44.7 
  
63 
 
8AIDS     
 Yes 258 49.2 0.0104 169 31.4 0.0228 83 16.5 0.0911 No 708 42.6 622 36.7 300 19.9 
CD4 count (cells/µL)    
 < 200  203 42.7 
0.2921 
181 36.6 
0.4328 
82 18.7 
0.8794 200 - < 350 236 47.4 189 37.1 93 20.0 
≥ 350 517 44.0 408 34.3 206 19.1 
HIV RNA (copies/mL)     
 < 50 197 43.4 
0.4996 
166 35.5 
0.1114 
78 18.4 
0.3099 50 - < 1000 216 46.6 189 39.4 93 21.4 
≥ 1000 516 43.3 411 34.0 197 18.0 
HIV therapy    
 PI- and NNRTI-
containing HAART 
52 55.3 
0.0769 
28 28.6 
0.0088 
11 12.4 
0.1783 
PI-containing 
HAART 
304 47.5 256 39.1 125 21.1 
NNRTI-containing 
HAART 
190 41.3 162 33.2 78 17.9 
NRTI alone 
HAART 
40 43.5 44 47.8 21 25.0 
Not on HAART 303 44.2 238 34.0 121 19.1 
On HAART    
 Yes 586 45.6 0.5709 494 36.6 0.2951 235 19.5 0.8168 No 303 44.2 234 34.2 121 19.1 
On HAART with 
lamivudine 
   
 HAART without 
lamivudine 
337 44.2 
0.7628 
 139 19.5 
0.9753 HAART with 
lamivudine 
249 47.5 96 19.6 
Not on HAART 303 44.2 121 19.1 
On HAART with 
tenofovir 
   
 HAART without 
tenofovir 
421 46.3 
0.6005 
 167 19.3 
0.9339  HAART with 
tenofovir 
165 43.8 68 20.1 
 Not on HAART 30 44.3 121 19.2 
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Table 2-3. Prevalence of chronic HBV infection among 1,802 HIV-positive subjects 
Characteristic 
Population (n=1802)  
N (%) p-value 
Overall 51 (2.8)  
Sex    
 Male 41 (3.6) 0.0139  Female 10 (1.6) 
Race    
 Black 39 (3.0) 
0.8419 White 7 (2.5) 
Hispanic 4 (2.0) 
HIV risk group    
 Heterosexual 25 (1.8) 
0.0336 Any IDU 12 (3.0) 
MSM 24 (4.2) 
Insurance type    
 Private 6 (2.6) 
0.8020 Public 27 (2.7) Uninsured 0  
Unknown 14 (3.3) 
Year of HIV diagnosis    
 < 1990 4 (3.5) 
0.5165 1990-1999 22 (3.1) 
≥ 2000 17 (2.3) 
Age group (years)    
 <30 7 (2.3) 
0.6530 30-<40 19 (3.4) 40-<50 19 (3.0) 
≥50 6 (2.0) 
AIDS    
 Yes 40 (2.9) 0.7239 No 11  (2.6) 
Anti-HCV-positive    
 Yes 32 (2.7) 0.5927 No 16 (3.2) 
CD4 count (cells/µL)    
 < 200  10 (2.5) 
0.8066 200 - < 350 13 (3.2) 
≥ 350 26 (2.7) 
HIV RNA (copies/mL)    
 <50 9 (2.4) 
0.6776 50-<1000 13 (3.4) 
≥1000 29 (3.0) 
HIV therapy    
 PI- and NNRTI-containing HAART   3 (4.2) 
0.9023 
PI-containing HAART 14 (2.7) 
NNRTI-containing HAART 10 (2.6) 
NRTI alone HAART 2 (2.5) 
Not on HAART 17 (3.0) 
On HAART     
 Yes 17 (3.0) 0.6964 No 29 (2.7) 
On HAART with lamivudine    
 HAART without lamivudine 13 (2.1) 
0.2787 HAART with lamivudine 16  (3.7) 
Not on HAART 17 (3.0) 
On HAART with tenofovir    
 HAART without tenofovir 21 (2.3) 
0.9288 HAART with tenofovir 8 (2.6) 
Not on HAART 17 (3.0) 
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Table 2-4.  Prevalence of chronic HCV among 1,680 HIV-positive subjects 
Characteristic 
Population (N=1,680) 
p-value * N (%) 
Overall 207 (12.3)  
Sex    
 Male 128 (13.0) 0.4228  Female 61 (11.6) 
Race    
 Black 114 (10.1) 
<0.0001 White 50 (21.8) 
Hispanic 25 (16.0) 
HIV risk group    
 Heterosexual 44 (6.2) 
<0.0001 Any IDU 117 (48.2) 
MSM 28 (5.1) 
Insurance type    
 Private 16 (7.4) 
0.0362 Public 119 (13.9) Uninsured 2 (5.3) 
Unknown 43 (13.2) 
Year of HIV diagnosis    
 < 1990 25 (23.2) 
0.0001 1990-1999 90 (14.8) 
≥ 2000 64 (9.7) 
Age group at HIV diagnosis (years)    
 <30 9 (3.2) 
<0.0001 30-<40 35 (7.3) 40-<50 97 (18.1) 
≥50 48 (21.0) 
Past HBV exposure    
 No 73 (8.2) <0.0001  Yes 116 (18.4) 
AIDS    
 Yes 143 (12.7) 0.5562  No 46 (11.6) 
CD4 count  (cells/µL)    
 < 200  36 (10.9) 
0.5011 200 - < 350 40 (11.8) 
≥ 350 111 (13.3) 
HIV RNA (copies/mL)     
 < 50 40 (12.5) 
0.0949  50-<1000 50 (15.6) 
 ≥1000 92 (11.0) 
HIV therapy    
 PI- and NNRTI-containing HAART 9 (12.2) 
0.0539 
PI-containing HAART 75 (16.6) 
NNRTI-containing HAART 35 (10.5) 
NRTI alone HAART 4 (8.5) 
Not on HAART 55 (11.4) 
On HAART     
 No 55 (11.4) 0.2481  Yes 123 (13.6) 
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Table 2-5.  Logistic regression modeling the odds of having HBV exposure among HIV-positive subjects (n=2,185) 
 
   Characteristic 
Model 1 (Crude) Model 2 (Adjusted) 
p-value OR CI p-value OR CI 
Male sex <0.0001 1.63 1.36-1.96    
Race    
 White 0.2382 0.87 0.69-1.10    
Hispanic 0.2233 0.85 0.65-1.11    
Black -- 1.00 --    
HIV risk group (males)       
 Any IDU < 0.0001 2.20 1.73-2.81 0.0006 1.77 1.28-2.45 
MSM  0.0010 1.38 1.14-1.68 <0.0001 1.72 1.36-2.19 
Heterosexual -- 1.00 -- -- 1.00 -- 
HIV risk group (females)       
 Any IDU 0.7701 1.05 0.77-1.43 0.6408 1.10 0.74-1.64 
Heterosexual -- 1.00 -- -- 1.00 -- 
Insurance type    
 Public 0.0144 1.34 1.06-1.69    
Uninsured 0.4588 0.79 0.42-1.48    
Unknown 0.4892 0.91 0.69-1.19    
Private -- 1.00 --    
Year of HIV diagnosis (per 1 year increase) <0.0001 0.95 0.94-0.96 0.0014 0.97 0.96-0.99 
Year of HIV diagnosis (group)   
 < 1990 <0.0001 2.67 1.91-3.73    
1990-1999 <0.0001 1.61 1.35-1.93    
≥ 2000 -- 1.00 --    
Age (per 10 year increase) < 0.0001 1.49 1.36-1.63 <0.0001 1.30 1.16-1.45 
AIDS  0.0105 1.29 1.06-1.58 -- -- -- 
Anti-HCV-positive <0.0001 2.06 1.71-2.49 0.0004 1.57 1.23-2.02 
CD4 count (per 100 cells/µl increase) 0.6088 0.99 0.96-1.02    
HIV RNA (per log10 copies/mL increase) 0.7728 1.00 0.97-1.02    
HIV therapy    
 PI-containing HAART 0.1578 0.73 0.47-1.13 0.0812 0.64 0.38-1.06 
NNRTI-containing HAART 0.0132 0.57 0.36-0.89 0.0143 0.52 0.31-0.88 
NRTI alone HAART 0.1072 0.62 0.35-1.11 0.1209 0.58 0.30-1.15 
Not on HAART 0.0442 0.64 0.42-0.99 0.0656 0.62 0.37-1.03 
PI- and NNRTI-containing HAART -- 1.00 -- -- 1.00 -- 
On HAART  0.5712 1.06 0.88-1.27    
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Table 2-6.  Logistic regression modeling the odds of having HCV exposure among HIV-positive subjects (n=2,232) 
 
Characteristic 
Model 1 (Crude) Model 2 (Adjusted) 
p-value OR CI p-value OR CI 
Male sex 0.2557 1.11 0.93-1.34    
Race   
 White <0 .0001 1.97 1.57-2.48 0.0001 1.93 1.37-2.71 
Hispanic <0.0001 1.71 1.32-2.24 0.2497 1.29 0.84-1.98 
Black -- 1.00 -- -- 1.00 -- 
HIV risk group (males)       
 Any IDU <0.0001 8.11 6.16-10.67 <0.0001 7.86 5.50-11.23 
MSM  0.0044 0.44 0.35-0.56 0.0008 0.58 0.42-0.80 
Heterosexual -- 1.00 -- -- 1.00 -- 
HIV risk group (females)       
 Any IDU <0.0001 4.98 3.64-6.80 <0.0001 6.10 3.95-9.42 
Heterosexual -- 1.00 -- -- 1.00 -- 
Insurance type    
 Public <0.0001 1.65 1.29-2.13 0.0120 1.55 1.10-2.17 
Uninsured 0.4903 0.77 0.37-1.61 0.3991 0.56 0.14-2.17 
Unknown <0.0001 1.77 1.33-2.35 0.1286 1.40 0.91-2.15 
Private -- 1.00 -- -- 1.00 -- 
Year of HIV diagnosis (per 1 year increase) <0.0001 0.95 0.94-0.96 0.0306 0.98 0.96-1.00 
Year of HIV diagnosis (group)   
 < 1990 <0.0001 1.98 1.44-2.72    
1990-1999 0.0569 1.20 1.00-1.44    
≥ 2000 -- 1.00 --    
Age (per 10 year increase) <0.0001 1.75 1.59-1.92 <0.0001 1.61 1.40-1.85 
AIDS  0.0230 0.79 0.64-0.97    
Past HBV exposure <0.0001 2.06 1.71-2.49 0.0001 1.65 1.28-2.12 
HBsAg-positive 0.0381 0.65 0.43-0.98    
CD4 count (per 100 cells/µl increase) 0.8315 1.00 0.97-1.03    
HIV RNA (per log10 copies/mL increase) 0.4238 0.99 0.96-1.02    
HIV therapy    
 PI-containing HAART 0.0467 1.60 1.01-2.56 0.0338 1.95 1.05-3.61 
NNRTI-containing HAART 0.3728 1.24 0.77-2.00 0.0615 1.83 0.97-3.45 
NRTI alone HAART 0.0067 2.29 1.26-4.17 0.0006 4.15 1.84-9.36 
Not on HAART 0.2908 1.29 0.81-2.05 0.0629 1.81 0.97-3.37 
PI- and NNRTI-containing HAART -- 1.00 -- -- 1.00 -- 
On HAART  0.2095 1.13 0.93-1.37    
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Table 2-7.  Logistic regression modeling the odds of having HBV/HCV exposure among HIV-positive subjects (n=2,013) 
 
 
z
 
 
Characteristic 
Model 1 (Crude) Model 2 (Adjusted) 
p-value OR CI p-value OR CI 
Male sex 0.0222 1.33 1.04-1.69    
Race   
 White 0.0002 1.71 1.29-2.27    
Hispanic 0.0008 1.77 1.27-2.46    
Black -- 1.00 --    
HIV risk group (males)       
 Any IDU <0.0001 8.11 6.16-10.67 <0.0001 6.70 4.86-9.23 
MSM  <0.0001 0.44 0.35-0.56 0.8500 1.03 0.73-1.46 
Heterosexual -- 1.00 -- -- 1.00 -- 
HIV risk group (females)       
 Any IDU <0.0001 4.98 3.64-6.80 <0.0001 4.34 2.88-6.55 
Heterosexual -- 1.00 -- -- 1.00 -- 
Insurance type    
 Public 0.0009 1.75 1.26-2.43    
Uninsured 0.4495 0.66 0.23-1.93    
Unknown 0.2030 1.29 0.87-1.90    
Private -- 1.00 --    
Year of HIV diagnosis (per 1 year increase) <0.0001 0.95 0.93-0.97    
Year of HIV diagnosis (group)   
 < 1990 <0.0001 2.44 1.68-3.53    
1990-1999 0.0054 1.40 1.11-1.78    
≥ 2000 -- 1.00 --    
Age (per 10 year increase) <0.0001 1.70 1.51-1.91 <0.0001 1.54 1.34-1.77 
AIDS  0.0916 0.80 0.61-1.04    
CD4 count (per 100 cells/µl increase) 0.6561 1.01 0.97-1.05    
HIV RNA (per log10 copies/mL increase) 0.3775 0.98 0.95-1.02    
HIV therapy    
 PI-containing HAART 0.0584 1.89 0.98-3.67 0.0475 2.03 1.01-4.07 
NNRTI-containing HAART 0.2109 1.54 0.78-3.03 0.1144 1.78 0.87-3.64 
NRTI alone HAART 0.0354 2.36 1.06-5.27 0.0389 2.48 1.05-5.89 
Not on HAART 0.1276 1.67 0.86-3.24 0.0636 1.94 0.96-3.91 
PI- and NNRTI-containing HAART -- 1.00 -- -- 1.00 -- 
On HAART  0.8173 1.03 0.81-1.31    
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Table 2-8. Characterisics and reported HIV risk factor among anti-HCV-positive and HIV-positive individuals (n=787) 
Characteristic 
Any IDU 
transmission (n=451) 
Sexual transmission 
(n=336) 
 
 
p-value * N (%) N (%) 
Male sex 145 (67.6) 216 (64.3) 0.4600 
Race  
 Black 242  (53.9) 253 (75.5) 
<0.0001 Hispanic 81 (18.0) 31 (9.2) 
White 126 (28.1) 51 (15.2) 
Insurance type  
 Private 24 (5.7) 35  (11.0) 
0.0415 Public 271 (64.1) 203 (63.6) Uninsured 7 (1.7) 3 (0.9) 
Unknown 121 (28.6) 78 (24.5) 
Year of HIV diagnosis  
 < 1990 52 (14.8) 34 (11.8) 
0.0351 1990-1999 186 (53.0) 133 (46.2) 
≥ 2000 113 (32.2) 121 (42.0) 
Age at HIV diagnosis (years) (mean (SD)) 44.5 (8.4) 43.4 (8.7) 0.1014 
Age group at HIV diagnosis (years)  
 <30 18 (4.0) 20 (6.0) 
0.2409 30-<40 97 (21.5) 87 (25.9) 40-<50 214 (47.5) 146 (43.5) 
≥50 122 (27.1) 83 (24.7) 
HBV positivity 219 (58.4) 161 (53.9) 0.2363 
HBsAg positivity 21 (10.4) 18 (12.4) 0.5573 
History of syphilis 9 (5.1) 22 (12.1) 0.0174 
AIDS 89 (19.7) 80 (23.8) 0.1684 
CD4 count (cells/µL) (mean (SD)) 421 (281) 419 (282) 0.9409 
CD4 count (cells/µL)  
 < 200  95 (21.6) 85 (25.5) 
0.1901 200 - < 350 116 (26.4) 71 (21.3) 
≥ 350 229 (52.1) 178 (53.3) 
HIV RNA (log10 copies/mL) (mean (SD)) 3.4 (1.3) 3.3 (1.4)  0.6781 
HIV therapy  
 PI- and NNRTI-containing HAART 17 (4.2) 11 (3.5) 
0.8232 PI-containing HAART 140 (34.2) 115 (36.6) 
NNRTI-containing HAART 90 (22.0) 72 (22.9) 
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 NRTI alone HAART 28 (6.8) 16 (5.1)  
Not on HAART 135 (32.9) 100 (31.9) 
On HAART 275 (67.1) 214 (68.2) 0.7585 
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Table 2-9. Logistic regression modeling the odds of sexual transmission of HCV 
 
 
 
 
 
 
 
 
Characteristic 
Model 1 (Crude) 
(n=787) 
Model 2 (Adjusted) 
(n=637) 
p-value OR CI p-value OR CI 
Male sex 0.4601 0.89 0.66-1.21    
Race   
 Black <0.0001 2.58 1.78-3.74 <0.0001 3.85 2.48-5.96 
Hispanic 0.8348 0.95 0.56-1.60 0.9111 0.96 0.51-1.83 
White -- 1.00 -- -- 1.00 -- 
Insurance type    
 Public 0.1830 0.75 0.49-1.15    
Uninsured 0.2377 0.43 0.11-1.75    
Unknown 0.0720 0.65 0.40-1.04    
Private -- 1.00 --    
Year of HIV diagnosis (per 1 year increase) 0.0026 1.04 1.01-1.06 0.0012 1.04 1.02-1.07 
Year of HIV diagnosis (group)   
 < 1990 0.4267 0.82 0.51-1.33    
1990-1999 0.4976 0.90 0.67-1.22    
≥ 2000 -- 1.00 --    
Age (per 10 year increase) 0.0679 0.86 0.72-1.01 0.0017 0.72 0.59-0.89 
History of syphilis infection  0.0210 2.58 1.15-5.77    
AIDS  0.1690 1.27 0.90-1.79    
CD4 count (per 100 cells/µl increase) 0.9408 1.00 0.95-1.05    
HIV RNA (per log10 copies/mL increase) 0.6476 0.99 0.94-1.04    
HIV therapy    
 PI-containing HAART 0.5576 1.27 0.57-2.82    
NNRTI-containing HAART 0.6117 1.24 0.55-2.81    
NRTI alone HAART 0.8029 0.88 0.33-2.34    
Not on HAART 0.7408 1.15 0.51-2.55    
PI- and NNRTI-containing HAART -- 1.00 --    
On HAART  0.7588 1.05 0.77-1.44    
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Table 2-10. Sex- and risk-stratified logistic regression modeling the odds of sexual transmission of HCV 
 
Characteristic 
Males, MSM risk Males, Heterosexual risk Females, Heterosexual risk 
p-value OR CI p-value OR CI p-value OR CI 
Race    
 Black 0.0912 1.58 0.93-2.72 0.0017 3.30 1.56-6.96 <0.0001 11.60 4.83-27.84 
Hispanic 0.0129 0.33 0.14-0.79 0.5746 1.33 0.50-3.56 0.0699 3.07 0.91-10.29 
White -- 1.00 --       
Year of HIV diagnosis 
(per 1 year increase) 
   0.0298 1.06 1.01-1.10 0.0012 1.09 1.04-1.15 
Age (per 10 year 
increase) <0.0001 0.55 0.41-0.74 0.0083 0.70 0.50-0.97 
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3 HEPATITIS C VIRAL CLEARANCE AMONG HIV-POSITIVE 
INDIVIDUALS ATTENDING AN URBAN HIV CLINIC 
3.1 Abstract 
Co-infection with hepatitis C virus (HCV) is common among HIV-positive populations, 
given their shared risk factors, such as injection drug use. In HIV-negative populations, 
approximately 20-25% of acute HCV spontaneously clear while the remaining progress 
to a chronic infection.  We conducted a cross-sectional study to assess the prevalence of 
HCV viral clearance among a population of HIV infected subjects with a history of HCV 
infection attending a large, urban HIV clinic from 2002-11, and used logistic regression 
models to identify factors associated with HCV clearance.  Among 2,322 HIV-positive 
subjects tested for HCV, 35% were anti-HCV-positive.  Among them, 13% had evidence 
of HCV viral clearance.  We identified that being positive for hepatitis B virus surface 
antigen was greatly associated with HCV clearance (OR=16.06; 95% CI, 2.65-97.26), 
and our data suggested heterosexual compared to IDU risk was also associated with 
clearance (OR=2.70), although this did not reach statistical significance (95% CI, 0.81-
9.00).  This effect was stronger in women compared to men (OR=2.63; 95% CI, 0.38-
17.99, and OR=1.57; 95% CI, 0.25-9.77, respectively).  Our findings highlight the burden 
of HCV co-infection among HIV-positive populations, as they are less likely to 
spontaneously clear their HCV infection and therefore are at greater risk for negative 
health outcomes such as serious liver disease and liver-related mortality.  Additional 
studies, especially those of a prospective nature, are warranted to further understand 
factors associated with HCV clearance in HIV-positive populations, especially factors 
that may be modifiable or can inform treatment decisions. 
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3.2 Introduction 
Epidemiology of hepatitis C 
An estimated 2.7-3.9 million persons in the United States (US) (1.2-1.8% of the 
population) have a chronic hepatitis C virus (HCV) infection.1  Prevalence is greatest 
among those aged 40-49 years, among males compared to females, and among Blacks 
compared to Whites.2  HCV transmission occurs primarily through percutaneous 
exposure, placing injecting drug users (IDUs) at the greatest risk for acquiring the 
infection.3  HCV is more efficiently transmitted through contaminated blood than HIV, 
and approximately 75-90% of IDUs have been HCV-infected,4-8 with estimates varying 
across race, geographic regions, and length of IDU history.9  This may be attributable to 
differences in injecting practices, available prevention outreach (e.g., syringe exchange), 
and the relative mobility of networks of IDUs.  
 
HCV viral clearance 
It is estimated that approximately 20-25% of HCV infections will spontaneously clear, 
with the remaining developing into chronic infections.1,10-13 Serologically, HCV 
clearance is identified by being positive for HCV antibody (anti-HCV) coupled with an 
inability to detect viral RNA.  If at all, viral clearance occurs during the first six months 
following infection.  Viral persistence after an acute infection leads to chronic infection, 
which in turn, can lead to serious liver disease, such as liver fibrosis, cirrhosis, and end 
stage liver disease (ESLD).14,15 Being female has been associated with greater rates of 
HCV clearance.   A recent meta-analysis consisting of 31 longitudinal studies on HCV 
clearance found the relative risk of HCV clearance was 2.33 (95% CI, 1.89-3.16) in 
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women compared to men.12  HCV clearance has also been found to be higher among 
those infected at a younger age.16,17 For example, a large study of HIV-negative 
hemophiliacs found HCV clearance was significantly reduced for those who were 
infected at an age of 16 years or greater compared to those infected at less than two years 
of age (odds ratio (OR)=3.4, 95% confidence interval (CI)=0.18-0.65).17  Black race has 
also been associated with decreased HCV clearance.10,11,13,16,17 Using data from the 
National Health and Nutrition Examination Survey (NHANES), Alter et al. found the rate 
of chronic infections was higher among Blacks compared to Whites (86 vs. 68%, 
respectively).16  Further, a large study of IDUs found that being non-Black was 
significantly associated with HCV clearance (OR=5.2; 95% CI, 2.6-10.2).11  This has also 
been observed in a HIV-negative hemophiliac cohort, with an odds ratio for clearance of 
0.46 among Blacks compared to Whites (95% CI, 0.23-0.91).17  Being positive for 
hepatitis B surface antigen (HBsAg), indicating a chronic hepatitis B virus (HBV) 
infection, has also been associated with HCV clearance rates 2-3 fold greater compared to 
those who have no serologic evidence of a chronic HBV infection.11,17  
 
Hepatitis C and HIV  
Given similar routes of transmission, HCV co-infection is common among those that are 
HIV-positive.  It is estimated that 25-30% of HIV infected individuals are co-infected 
with HCV.18  This is especially true among IDUs, with an estimated co-infection 
prevalence of 72-95%.  Since the development of HAART in the 1990’s, HCV-related 
liver disease has emerged as an important cause of morbidity and mortality among those 
that are HIV-positive due to decreasing rates of AIDS and AIDS-related mortality.19-23  
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HCV clearance in HIV-positive populations 
Rates of HCV clearance are lower among those that are HIV-positive, and are associated 
with more rapid progression to HCV-related liver disease, including fibrosis, cirrhosis, 
and ESLD, and increased mortality.11  However the natural history of HCV clearance in 
HIV-positive populations is not fully described.  Many of the studies that have 
specifically examined this are limited by small sample sizes (less than 250 co-infected 
subjects), homogenous populations with respect to race and/or risk factor, geographic 
location (most studies have been in Europe), and/or a cross-sectional study design (Table 
3-1).24-31 Similar to what has been described in HIV-negative populations, HCV 
clearance was 40-80% more likely among females compared to males.26,29 Further, a 3- to 
10-fold increase in the likelihood of clearance among those who were HBsAg-positive 
compared to those who were negative has been reported.26,27,29  However, there is 
disagreement on the impact of the route of transmission on HCV clearance in HIV-
positive population.26,27,29  For example, a multi-site European and US study reported that 
heterosexual risk was positively associated with viral clearance when compared to other 
transmission routes (OR=2.8, 95% CI,1.6-5.1).27  While two European studies reported 
that IDUs and MSM were each significantly associated with increased viral clearance 
when compared to heterosexual risk (OR=5.2 and OR=1.5 to 10.2, respectively).26,29 A 
fuller understanding of this factor has been somewhat limited by studies conducted in 
homogeneous populations with respect to mode of transmission.    
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Given limitations of design and non-agreement of findings from previous studies, the 
objective of this study was to assess the prevalence of HCV clearance among a HIV-
positive urban clinic population, and to describe factors associated with viral clearance. 
 
3.3 Methods  
Study population 
This study used the Drexel University’s College of Medicine’s Partnership 
Comprehensive Care Practice, which provides routine primary and specialty HIV medical 
care to HIV-positive individuals in Philadelphia, to draw its study population.   This 
practice is the largest and most comprehensive HIV primary care practice in Philadelphia, 
serving 1,900 patients in 2010.  All subjects who had at least two visits at the clinic 
between the years 2002 and 2011 were eligible for inclusion in the study (n=2,880).  
Further, subjects were excluded if they did not have anti-HCV testing during the study 
period (n=648), leaving a total study population of 2,232 subjects. At each clinic visit, 
patients had comprehensive laboratory work (e.g., CD4 cell count, HIV RNA viral load 
(VL), hepatitis testing), in accordance with clinical standards of care and practical 
guidelines at the time.   
 
Hepatitis C definitions 
Subjects were classified as being HCV-positive or –negative based on anti-HCV tests 
prior to the study period or at any time from 2002-11.  All anti-HCV-positive subjects 
were further classified as having cleared their HCV infection (defined as having 
undetectable (< 50 copies) HCV RNA viral load using a quantitative assay) or having a 
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persistent HCV infection (defined as having detectable HCV VL).26,27 A total of 552 anti-
HCV-positive subjects could not be classified due to missing HCV RNA information.   
 
The following factors were described and investigated as potential factors associated with 
HCV clearance: sex; race; primary HIV risk factor; insurance status; and age, CD4 cell 
count, HIV RNA VL, AIDS diagnosis, and HBsAg positivity at time of first anti-HCV-
positive test.  Values at the time of the first anti-HCV-positive test were chosen, rather 
than the values at entry into the cohort, as HCV clearance occurs within six months of 
infection, and these values most represent the true values at the time of clearance.  
Utilization of these values also helped describe differences between those that received a 
HCV VL test on the same day or directly after their anti-HCV test compared to those that 
did not get a HCV VL test.   
 
Highly active antiretroviral therapy (HAART) was first defined as any of the following 
combinations:  ≥ 2 protease inhibitors (PI) and ≥ 1 nucleoside reverse transcriptase 
inhibitor (NRTI), without a non-nucleoside reverse transcriptase inhibitor (NNRTI) (PI-
containing HAART); ≥ 2 NNRTI and ≥ 1 NRTI, without PI (NNRTI-containing 
HAART); ≥ 1 NNRTI and ≥ 2 NNRTI, without PI (NNRTI-containing HAART); ≥ 1 PI 
and ≥1 NNRTI and ≥ 1 NRTI (PI- and NNRTI-containing HAART); and a fusion 
inhibitor, entry inhibitor, or integrase inhibitor, not meeting a definition above (other 
HAART). Those not meeting one of the above definitions were considered not to be on 
HAART.  HIV therapy at time of first positive anti-HCV test was defined as medication 
taken at the time of the test or within 3 months prior to the test.  To improve statistical 
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efficiency, we explored creating a binary HIV treatment variable in which all HAART 
categories were collapsed into one.   
 
CD4 cell count at time of first anti-HCV test was defined as follows.  If the CD4 cell 
count taken on the date of the first positive anti-HCV test, it was used for this value 
(n=205; 26%.  If this was not available, then the value immediately prior and 
immediately subsequent the first anti-HCV date were used.  If the difference between the 
two values was ≤ 10% and both were within six months of the first anti-HCV date, then 
the mean of these values was used (n=66; 8%).  If the difference was greater than 10%, 
then the value immediately prior was used, as long as it was within six months of the first 
anti-HCV date (n=243; 31%).  If the first anti-HCV test was prior to the study period, the 
first CD4 value taken was used (n=242; 31%).  Thirty-five subjects did not meet any of 
the criteria above and therefore had a missing value for CD4 count at first anti-HCV test.  
 
A similar approach was used to define HIV RNA VL at time of first anti-HCV test as is 
described above for CD4, resulting in 28% with a VL taken on the date of the first anti-
HCV test. Thirty-five subjects did not meet any of the criteria above and therefore had a 
missing HIV VL. HIV VL values were transformed to the log scale. 
 
HBsAg and AIDS status were defined as status at time of first anti-HCV test or within 
one month of the first positive test. 
 
 
86 
 
 
 
Analysis 
Three HCV groups (cleared infection, persistent infection, and not tested for HCV RNA) 
were summarized using descriptive statistics.  For continuous variables, means were 
presented with standard deviations and were compared with Wilcoxon tests. For 
categorical variables, differences in proportions were compared with χ tests.  A two-
sided alpha level of 0.05 was used to determine statistical significance.   
 
Among the 239 subjects with a classifiable HCV infection (i.e., cleared or persistent), 
logistic regression models were used to model the odds of HCV clearance.  Crude logistic 
regression models were first presented for all potential factors associated with clearance, 
including: demographics (sex, race, HIV risk group, age, year of HIV diagnosis and type 
of insurance); HIV antiretroviral therapy; HIV VL; CD4 count; and HBsAg positivity.  
Insurance status (private, public, uninsured, or unknown) was used as a proxy for 
socioeconomic status.32,33   
 
To assess factors that may be associated with HCV clearance, the statistical significance 
of each potential predictor to HCV clearance was first assessed using a χtest for 
categorical variables or a Wilcoxon test for continuous variables.34  Exact methods (e.g., 
Fisher’s exact test) were used with small cell counts.  Next, potential associated factors 
were assessed univariately in a logistic regression model to determine if they were 
statistically associated with the outcome of interest.  Logistic regression assumes a linear 
relationship between the independent variable and the log odds of the outcome (i.e., the 
relationship is linear on the log scale).34  All continuous variables met this assumption 
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(see Appendix A).  A backward selection approach was used to build the final logistic 
regression model. The first step of this process involved building an initial regression 
model that contained all potential related factors that reached statistical significance at an 
alpha level of 0.05.  Next, variables were removed from the model one at a time based on 
the corresponding p-value and the model was re-run; those with the highest p-values were 
removed first.  This process continued iteratively until only variables reaching statistical 
significance at an alpha level of 0.05 were included in the model.  This backward 
selection approach was modified to allow investigators to include variables that did not 
reach statistical significance (i.e., “force in”), but were thought to be a potential predictor 
due to prior knowledge or a large (≥ 2.0) effect estimate.  A sex-stratified multiple 
logistic regression model was also generated and presented. 
 
All analyses were conducted in SAS 9.2. The Drexel College of Medicine Institutional 
Review Board (IRB) approved this study.  
 
3.4 Results  
The study population consisted of 2322 HIV-positive individuals who were tested for 
anti-HCV from 2002 through 2011.  During the study period, subjects had an average of 
13 visits over an average of 5.9 years.  The majority of subjects were male (65.3%), 
Black (71.4%), reported heterosexual risk (42.4%), and had public insurance (60.4%) 
(Table 3-2).  Further, over 90% were diagnosed with HIV prior to 1990.  The mean age 
entry into the cohort was 40.7 years.  At entry, 14.7% of subjects were HBsAg-positive, 
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24.1% had a diagnosis of clinical AIDS, and 65.5% were on HAART. The mean CD4 
count was 421 cells/µL and the mean HIV VL was log10 copies/mL. 
 
Seroprevalence of HCV 
The seroprevalence of HCV in this HIV-positive population was 35% (n=791).  HCV 
seroprevalence was greatest among males (36.3%; p=0.2556), Whites (47.3%; p<0.0001), 
those ≥ 50 years old at time of HIV diagnosis (44.8%; p<0.0001), and those reporting 
IDU behavior as the primary risk factor for HIV acquisition (75.8%; p<0.0001) (Table 3-
3).  Further, those with public insurance (37.3%), were HBsAg-negative (44.7%), did not 
have AIDS (36.7%), diagnosed with HIV prior to 1990 (48.9%), had CD4 count between 
50 and <350 cells/µL (37.1%), had HIV VL between 50 and 1000 cells/µL (39.4%), and 
on HAART therapy (36.6%) had the highest seroprevalence of HCV. 
 
Of the 791 patients who had a positive anti-HCV result during the study period, 239 
(30%) had available results from HCV RNA VL tests.  Individuals who were tested for 
HCV RNA VL were similar to those not tested for HCV RNA VL (Table 3-4). 
 
Prevalence of HCV clearance 
The prevalence of HCV clearance in this HIV-positive population was 13%.  The 
prevalence of HCV clearance was highest among women (21%; p=0.0120), Whites 
(16%; 0.8171), those aged <30 at time of HIV diagnosis (16%, 0.5240), those reporting 
heterosexual contact as their primary HIV risk factor (19%; p=0.3405), and those with 
public insurance (14%; p=0.4498).  With respect to virologic and immunologic 
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characteristics at entry into cohort, prevalence of HCV clearance was highest among 
those with CD4 count between 200 and 350 cells/µL at time of first anti-HCV (16%; 
p=0.3199), with HIV VL < 50 cells/µL (19%; p=0.4045), without AIDS at time of first 
anti-HCV (15%; p=0.4046), on HAART therapy at time of first anti-HCV (14%; 
p=0.4855), and HBsAg-positive (67%; p=<0.0001).   
 
Those that cleared their HCV infection were statistically more likely to be women (53.1 
vs. 30.6%; p=0.0120) and be HBsAg-positive (33.3 vs. 2.9%) p<0.0001) compared to 
those with a persistent infection (Table 3-5).  There was no statistical difference between 
those that cleared their infection and those with a persistent viral infection for mean age 
at HIV diagnosis (33.9 vs. 35.0 years; p=0.2538), CD4 count (510 vs. 443 cells/µl; 
p=0.2638), or HIV RNA VL at time of first positive anti-HCV test (3.2 vs. 3.0 log10 
copies/mL; p=0.6505).   
 
Crude logistic regression models for the odds of HCV clearance identified the following 
factors to be potential determinants of HCV clearance in this HIV-positive population 
based on univariate analysis: female sex (OR=2.57; 95% CI, 1.21-5.47); heterosexual risk 
compared to IDU risk (OR=1.84; 95% CI, 0.80-4.26), HBsAg positivity (OR=17.00; 95% 
CI, 3.76-76.91), and being on a PI- and NNRTI-containing HAART therapy compared to 
PI-containing HAART (OR=4.17; 95% CI, 0.66-25.0) or not being on HAART 
(OR=4.17;  95% CI, 0.67-25.0) (Table 3-6).  Multivariate analysis suggested that 
heterosexual risk compared to IDU risk (OR=2.70; 95% CI, 0.81-9.00) and HBsAg 
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positivity (OR=16.06, 95% CI, 2.65-97.26) were associated with HCV clearance, 
although only HBsAg positivity reached statistical significance. 
 
The sex-stratified analysis showed that among males, there were similar odds of HCV 
clearance among those reporting heterosexual risk and MSM risk, compared to IDU risk 
(OR=1.57; 95% CI, 0.25-9.77, and OR=1.73; 95% CI, 0.32-9.27, respectively), although 
these estimates did not reach statistical significance (Table 3-7). Among females, 
heterosexual risk was associated with over a 2-fold increased odds of HCV clearance 
(OR=2.63; 95% CI, 0.38-17.99), although this also failed to reach statistical significance.  
The effect of HBsAg positivity was greater among males compared to females 
(OR=19.29; 95% CI, 2.74-135.61, and OR=10.50; 95% CI, 0.46-239.78, respectively), 
although the confidence intervals surrounding the estimates were very wide. 
 
3.5 Discussion 
We found the seroprevalence of HCV to be 35% in this HIV-positive population 
attending a large, urban HIV clinic.  This is in line with findings from previous research; 
studies with a low proportion of IDUs have found HCV prevalence to be 15-16%,23,35 
while a large study comprised of 36% IDUs reported HCV prevalence to be 37%.19    
 
Given the primary mode of HCV transmission in the US is through injection drug use, it 
is not surprising that we found that subjects reporting IDU behavior had significantly 
higher evidence of HCV exposure (76%) compared to other risk groups, which is similar 
to what other studies have found (73-92%).19,35,36 Our seroprevalence was slightly greater 
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among those reporting sexual exposure (17-23%) than what has been reported previously 
(4-14%).19,35,36  The differences in these findings are likely due to the increased incidence 
of sexually acquired HCV that has been reported over the past decade, especially among 
HIV-positive MSM and women who report heterosexual sex with an IDU partner.37-40  A 
recent study from the Swiss HIV Cohort reported the incidence of HCV in MSM 
increased 16-fold from 0.23 per 100 person-years in 1998 to 4.09 per 100 person-years in 
2011.41  Increased prevalence of high-risk sexual behavior in these groups has coincided 
with widespread access to HAART42,43 and the perception that HAART-inducted 
virologic control reduces HIV infectivity.44 Our findings confirm the changes in risk 
factors associated with HCV infections in HIV-positive populations that have recently 
been acknowledged.45 
 
We also found that subjects < 30 years old at time of HIV diagnosis had the lowest 
seroprevalence of HCV (25%).  This finding could be attributable to a variety of reasons.  
First, this age group may exhibit less risky behavior once they learn of their HIV 
diagnosis, thereby reducing their risk of acquiring HCV.  Unfortunately, this is not 
measureable in this population and research indicates that HCV infection usually 
precedes HIV infection.45  Second, it is possible that individuals in this group had a 
smaller duration of time in the clinic, which may lead to decreased opportunity for HCV 
testing.  However, those aged < 30 years had only slightly less follow-up time on average 
than those ≥ 30 years (5.8 vs. 6.4 years).  Further, they had an average of 1.6 anti-HCV 
tests compared to an average of 1.7 for those ≥ 30 years.  Therefore, these differences 
likely did not affect HCV prevalence in this age group. The most likely explanation for 
92 
 
 
 
this difference is that 44% of this group reported heterosexual contact and an additional 
37% reported MSM behavior as their primary HIV risk group, which are groups known 
to have less HCV incidence than IDU groups.   
 
Overall, the prevalence of HCV clearance in this HIV-positive population was 13%, 
which is in the range of 13-23% that has previously been reported.25-29,46,47  Our findings 
may be lower than what has previously been reported due to differences in our study 
population.  First many HCV clearance studies have been conducted in Europe with 
primarily White populations.26,29,46 Our anti-HCV-positive study population consisted of 
63% Black, 23% White, and 14% Hispanic, and, although not reaching statistical 
significance, those with a chronic HCV infection were more likely to be Black (62%) 
compared to White (26%).  Although race has not been associated with rates of HCV 
clearance in previous research,27,29,30 Soriano et al. found regional differences in HCV 
clearance in the EuroSIDA cohort, suggesting that clearance does not solely depend on 
viral, immunologic, or risk factors.26  Most previous HCV clearance research has been 
conducted outside of the US; the limited studies that have been conducted in the US have 
found a clearance rate of 13%.25,27  Further, our study consisted of a very heterogeneous 
HCV-positive population with respect to risk factor, consisting of 28% reporting 
heterosexual risk, 57% IDU risk, and 15% MSM risk.  Two studies have found IDU to be 
less likely to clear their infection,26,27 therefore our large proportion of subjects reporting 
sexual risk may have contributed to our lowered levels of clearance compared to other 
studies.  
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In this HIV-positive study population, we found that HBsAg positivity was significantly 
associated with a 16-fold increase in the odds of HCV clearance, which is similar to what 
others have reported.24-27,29  The confidence interval surrounding this estimate was quite 
wide (2.65-97.26), which is likely a reflection of our small sample size, underscoring the 
need for additional studies with larger sample size.  Taken together, these findings 
suggest there is an interaction between HBV and HCV that specifically influences HCV 
infection.  It has been hypothesized that HCV viral replication is inhibited non-
specifically by cytokines, such as interferon-γ, interferon-α, and tumor necrosis factor-α, 
produced as part of a HBV-specific T-cell response, thereby inducing HCV viral 
clearance.29,48 Viral interference may also be occurring; a study by Gaeta et al. showed 
that only 14% of subjects dually-infected with HBV and HCV had evidence of active 
replication of both infections.49 
 
Although our findings did not reach statistical significance, they also suggest that female 
sex and sexual risk compared to IDU risk were associated with increased HCV clearance.  
Others have reported an association between female sex and HCV clearance.25,26,29 
Sexual risk has been reported to be associated with increased HCV clearance,26,27 
although there has been conflicting evidence in the literature.29 Our limited sample size 
may have decreased our power to detect a statistically significant association between 
these factors and HCV clearance and contributed to very wide confidence intervals.  
Given this, the data are suggestive that heterosexual risk is greater among females 
compared to males.   
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Our study is limited in several ways.  First, results of HCV RNA tests were only available 
for 30% of our population.  This substantially decreased our sample size, which may have 
lead to insufficient power to statistically detect a meaningful difference in factors 
associated with HCV clearance and likely contributed to wide confidence intervals 
surrounding estimates.  However, our results are intriguing given what others have found 
with respect to female sex, sexual risk factor, and HBsAg positivity.  Although female 
sex and risk factor did not reach statistical significance significant on multivariate 
analysis, the large ORs warrant additional studies to further elucidate these relationships.  
In addition to limiting our sample size, with only 30% of our anti-HCV-positive 
population getting tested for HCV VL, it is possible this subpopulation was not 
representative of the entire HCV-positive population.  However, we feel the effects of  
potential sampling bias were minimal.  We found these populations to be similar with 
respect to their demographic, immunologic, and virologic characteristics.  Further, we 
found no differences in the average number of clinic visits (13.4 vs. 12.5) or time in the 
cohort (6.4 vs. 5.5 years) among those tested and not tested. 
 
Second, we relied on analysis of data previously collected during routine clinical care at a 
large HIV clinic.  Although this yielded over 10 years of clinical data, our HCV clearance 
analysis was limited to those who received HCV RNA viral load tests.  Further, subjects 
had a maximum of three HCV VL tests and average of 1.7 tests, so we were unable to 
require two consecutive undetectable HCV VL results in our HCV clearance definition.  
This may have overestimated our clearance rate, but other studies have used only one 
measurement given limited repeated HCV RNA tests available.26,27 Given the limited 
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number of repeated tests, we were unable to investigate re-infection (one of the 32 
subjects with a cleared infection were subsequently re-infected).  Also, we could not 
collect information on HCV genotype, interleukin 28B gene polymorphisms, alcohol 
consumption, and hepatitis C therapy, which could be important factors associated with 
HCV clearance.26,30,46,50  
 
Additionally, our study population was drawn from HIV-positive subjects attending an 
urban HIV clinic in the Northeast and may not be generalizable to other HIV-positive 
populations.  We had slightly higher proportion of IDUs in our study population (27 vs. 
22% nationally reported HIV risk profile) and a much larger proportion of subjects 
reporting heterosexual risk as the lone HIV risk factor (42 vs. 26% nationally).51 There 
have been discordant findings as to the role risk factor has on clearance, therefore the 
effect of these differences are hard to qualify. Further, as this study was conducted in a 
clinic population, it is possible that subjects included in our study may differ with respect 
to health-seeking behaviors, risky sexual and drug use behavior, and adherence to 
antiretroviral therapy than the general HIV population.52,53 Our study was further limited 
by its cross-sectional design, making it difficult to discern when HCV clearance actually 
occurred, assess the long-term effects of HCV suppression, or consider factors associated 
with re-infection with HCV following viral clearance. 
 
Although our study had limitations, we had a relatively large population of HIV-positive 
subjects with a history of HCV exposure a more heterogeneous study population 
compared to similar studies.28,46,47 We also had over 10 years of clinical data and an 
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average of over five years of follow-up for subjects, yielding relatively long-term 
repeated measures and clinical data on subjects.  
 
This study provided an updated report that supports the changing epidemiology of HCV 
among HIV-positive populations that has recently been discussed.41,45 Understanding the 
risk factors associated with HCV exposure and HCV clearance in HIV-positive 
populations is becoming an important issue, as HCV-related morbidity is increasing in 
this population.  In order to reduce the burden of HCV infection, clinical and public 
health policies should be focused on routine screening for HCV in HIV-positive 
populations and vice versa, regardless of risk profile.  A recent study by Linas et al. 
reported that HCV screening among HIV-positive MSM was not only cost effective, but 
it also extended life expectancy.54  In addition to antibody screening, HCV-positive 
patients should receive routine RNA tests to identify acute infections.  Our study 
population was limited by only 30% of subjects getting follow-up RNA tests, and other 
studies have found similar trends.50  Additionally, immediate HIV and HCV therapy 
should be considered when infections are identified, particularly given that those who are 
co-infected have lower clearance than those mono-infected.  Although there must be 
considerations for hepatoxicity due to HCV therapy among HIV-positive individuals, it 
has been demonstrated that the benefits of HCV therapy in co-infected patients outweigh 
the risk.55  This practice of early antiretroviral therapy could preserve immune function in 
co-infected to help avoid negative health outcomes associated with HCV infection. Given 
that HCV therapy is underused in this population,56 there are opportunities to improve on 
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this.  Further, identification of those more likely to develop chronic HCV infections can 
inform therapy decisions.   
 
In conclusion, we found a high seroprevalence of HCV in a HIV-positive population 
attending a large, urban HIV clinic.  HCV viral clearance occurred in 13% of those co-
exposed.  Factors associated with HCV clearance included female sex, sexual risk 
behaviors, and HBsAg positivity.  Further research studies, particularly those with a 
prospective study design, are warranted to further understand HCV clearance, especially 
in light of the changing epidemiology of HCV in HIV-positive populations.   
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Table 3-1. Summary of previous studies of HCV clearance among HIV-positive populations 
Author 
(Year) 
Study 
population 
Findings 
Comments 
% 
cleared Associated with clearance 
Clausen 
(2011)29 
N=327 
Denmark 
93% White 
 
23% • HBsAg+ (OR=7.6) 
• IDU vs. Heterosexual (OR=5.2) 
• MSM vs. Heterosexual 
(OR=10.2) 
• Female (OR=1.8) 
• Cross-sectional study 
• Not associated: race, AIDS, ART 
• Used 2 HCV RNA measurements 
Clausen 
(2011)46 
N=206 
Denmark 
23% • Three interleukin 28B (IL28B) 
polymorphisms (OR=0.3-0.4) 
• Cross-sectional study 
Labarga 
(2011)50 
N=895 
Spain 
93% White 
 
26% • IL28B polymorphisms 
associated with elevated HCV 
RNA (OR=6.8) 
• Cross-sectional study 
• Not associated: age, sex, risk, ethnicity, CD4 
count, HIV VL, HBsAg 
• Only 44% HCV RNA results 
Lunge 
(2011)30 
N=138 
Brazil 
25% • IL28B polymorphism associated 
with chronic HCV (OR=2.8) 
• Cross-sectional study 
• Not associated: sex, age, race, CD4 count, 
HIV VL, year of HIV diagnosis, HAART 
Thomson 
(2011)28 
N=112 
MSM 
UK 
15% • Baseline CD4 count (HR=2.7) 
• Decreased HIV VL (HR=1.8) 
• Elevated bilirubin (HR=5.0) 
• Elevated aminotransferase 
(HR=2.6) 
• Clearance only occurred in those 
with genotype1 
• Cohort study 
• Not associated:  age, HIV VL, HAART 
Van den Berg 
(2011)31 
N=106 
IDU 
Amsterdam 
33% • Female with IL28B 
polymorphism (OR=6.6) 
• Cross-sectional study 
• Not associated:  sex, ethnicity, year of HIV 
diagnosis, symptoms 
Wolff 
(2010)47 
N=202 
Brazil 
16%  • Cross-sectional prevalence study; did not 
look at predictors of HCV clearance 
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Shores 
(2008)27 
N=769 
Multisite (US 
and Europe) 
77% White 
13% • MSM (22%) vs. IDU (12%) 
• Heterosexual vs. IDU (OR=2.8) 
• HBsAg+ (OR=10.3) 
• Cross-sectional study 
• Not associated: sex, race 
• Used single HCV RNA measurement 
Soriano 
(2008)26 
N=1940 
EuroSIDA 
89% White 
 
23% • MSM vs. IDU (OR=2.8) 
• MSM vs. heterosexual (OR=2.0) 
• HBsAg+ (OR=2.9) 
• Female (OR=1.4) 
• Cohort study 
• Not associated: age 
• Used single HCV RNA test 
• Genotype may be associated 
• Detected regional differences 
Martin-
Carbonero 
(2007)24 
N=107 
Spain 
99% Male 
22% • HBsAg+ (OR=23) • Cross-sectional 
• Not associated:  age at HIV infection, current 
age, CD4 count, HIV VL, HAART 
Melendez-
Morales 
(2007)25 
N=478 
Hemophiliacs 
US 
86% non-Black 
13% • HBsAg+ (OR=11.2) 
• Female (OR=7.7) 
• Cohort study 
• Not associated:  alcohol, age at HCV 
diagnosis, age at HIV diagnosis, order of 
infection, CD4 count, HIV VL, AIDS 
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Table 3-2. Baseline population characteristics at entry into cohort (N=2,322 tested 
for anti-HCV) 
Characteristic 
Baseline population 
(N=2,322) 
N (%) 
Male sex 1447 (65.3) 
Race   
 Black 1585 (71.4) 
White 376 (16.9) 
Hispanic 260 (11.7) 
HIV risk group   
 Heterosexual 940 (42.4) 
Any IDU 595 (26.9) 
MSM 680 (30.7) 
Insurance type   
 Private 268 (12.7) 
Public 1273 (60.4) 
Uninsured 46 (2.2) 
Unknown 520 (24.7) 
Year of HIV diagnosis   
 < 1990 176 (9.2) 
1990-1999 877 (45.6) 
≥ 2000 869 (45.2) 
Age (years) (mean (SD)) 40.7 (9.9) 
Age group (years)   
 <30 743 (40.0) 
30-<40 665 (35.7) 
40-<50 328 (17.6) 
≥50 125 (6.7) 
HBsAg positivity 119 (14.7) 
AIDS 539 (24.1) 
CD4 count (cells/µL) (mean (SD)) 421 (284) 
CD4 count (cells/µL)   
 < 200  494 (22.5) 
200 - < 350 509 (23.2) 
≥ 350 1191 (54.3) 
HIV RNA (log10 copies/mL) (mean (SD)) 3.4 (1.3) 
HIV therapy at first anti-HCV-positive test   
 PI- and NNRTI-containing HAART 98 (4.8) 
PI-containing HAART 655 (32.2) 
NNRTI-containing HAART 488 (24.0) 
NRTI alone HAART 92 (4.5) 
Not on HAART 701 (22.3) 
On HAART  1333 (65.5) 
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Table 3-3. Prevalence of anti-HCV among 2,322 HIV-positive subjects 
Characteristic 
Anti-HCV-positive  (N=791) 
p-value* N Prevalence (%) 
Sex  
 Male 525 36.3 0.2556 Female 260 33.9 
Race  
 Black 496 31.3 
<0.0001 White 178 47.3 
Hispanic 114 43.9 
HIV risk group  
 Heterosexual 218 23.2 
<0.0001 Any IDU 451 75.8 
MSM 118 17.4 
Insurance type  
 Private 59 22.0 
<0.0001 Public 475 37.3 Uninsured 10 21.7 
Unknown 202 38.9 
Year of HIV diagnosis  
 < 1990 86 48.9 
<0.0001 1990-1999 321 36.6 
≥ 2000 234 26.9 
Age group at time of HIV diagnosis (years)  
 <30 188 25.3 
<0.0001  30-<40 246 37.0  40-<50 141 43.0 
 ≥50 56 44.8 
HBsAg positivity  
 Positive 41 34.5 0.0371 Negative 308 44.7 
AIDS   
 Yes 169 31.4 0.0228 No 622 36.7 
CD4 count (cells/µL)  
 < 200  181 36.6 
0.4328 200 - < 350 189 37.1 
≥ 350 408 34.3 
HIV RNA (copies/mL)   
 < 50 166 35.5 
0.1114 50 - < 1000 189 39.4 
≥ 1000 411 34.0 
HIV therapy  
 PI- and NNRTI-containing HAART 28 28.6 
0.0088 
PI-containing HAART 256 39.1 
NNRTI-containing HAART 162 33.2 
NRTI alone HAART 44 47.8 
Not on HAART 238 34.0 
On HAART  
 Yes 494 36.6 0.2951 No 234 34.2 
*χ test or Fisher’s exact test for categorical variables; Wilcoxon test for continuous variables 
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Table 3-4. Comparison of those without and without HCV RNA testing among anti-
HCV-positive subjects (n=791) 
Characteristic 
No available HCV 
VL (n=552) 
Available HCV VL 
(n=239) 
p-value * N (%) N (%) 
Sex  
 Male 367 (67.1) 158 (66.4) 0.8467  Female 180 (32.9) 80 (33.6) 
Race  
 Black 349 (63.6) 147 (61.5) 
0.1684 White 115 (20.9) 63 (26.4) 
Hispanic 85 (15.5) 29 (12.1) 
HIV risk group  
 Heterosexual 160 (29.1) 58 (24.4) 
0.3844 Any IDU 309 (56.3) 142 (59.7) 
MSM 80 (14.6) 38 (16.0) 
Insurance type  
 Private 41 (7.8) 18 (8.1) 
0.4949 Public 325 (62.1) 150 (67.3) Uninsured 7 (1.3) 3 (1.3) 
Unknown 150 (28.7) 52 (23.3) 
Year of HIV diagnosis  
 < 1990 55 (13.1) 31 (14.0) 
0.8664  1990-1999 213 (50.8) 108 (48.7) 
 ≥ 2000 151 (36.0) 83 (37.4) 
Age at first anti-HCV-positive test (years) (mean 
(SD)) 45.0 (8.5) 45.3 (8.3) 0.5917 
Age group at first anti-HCV-positive test (years)  
 <30 20 (3.6) 10 (4.2) 
0.7663  30-<40 115 (20.8) 43 (18.0)  40-<50 254 (46.0) 117 (49.0) 
 ≥50 163 (29.5) 69 (28.9) 
HBsAg positivity at first anti-HCV-positive test  
 Positive 30 (11.6) 9 (7.3) 0.1943 
 Negative 228 (88.4) 114 (92.7)  
AIDS at first anti-HCV-positive test   
 Yes 149 (27.0) 67 (28.0) 0.7629  No 403 (73.0) 172 (72.0) 
CD4 count at first anti-HCV-positive test 
(cells/µL) (mean (SD)) 418 (280) 452 (28.7) 0.1140 
CD4 count at first anti-HCV-positive test 
(cells/µL) 
 
 < 200  124 (23.6) 46 (19.9) 
0.3133  200 - < 350 125 (23.8) 50 (21.6) 
 ≥ 350 276 (52.6) 135 (58.4) 
HIV RNA at first anti-HCV-positive test (log10 
copies/mL) (mean (SD)) 3.4 (1.3) 3.2 (1.3) 0.7484 
HIV therapy at first anti-HCV-positive test  
 PI- and NNRTI-containing HAART 17 (3.4) 6 (2.8) 
0.0838 
PI-containing HAART 161 (32.0) 75 (34.9) 
NNRTI-containing HAART 110 (21.9) 33 (15.3) 
NRTI alone HAART 34 (6.8) 8 (3.37 
Not on HAART 181 (36.0) 93 (43.3) 
On HAART at first anti-HCV-positive test  322 (64.0) 122 (56.7) 0.0662 
*χ test or Fisher’s exact test for categorical variables; Wilcoxon test for continuous variables 
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Table 3-5. Demographic, immunologic, and virologic factors, associated with 
serologic evidence of HCV clearance among HIV-positive individuals (n=239) 
Characteristic 
Cleared infection 
(N=32) 
Persistent infection 
(N=207) 
 
 
 
N (%) N (%) p-value * 
Female sex 17 (53.1) 63 (30.6) 0.0120 
Race  
 Black 19 (59.4) 128 (61.8) 
0.8171 White 10 (31.3) 53 (25.6) 
Hispanic 3 (9.4) 26 (12.6) 
HIV risk group  
 Heterosexual 11 (35.5) 47 (22.7) 
0.3405 Any IDU 16 (51.6) 126 (60.9) 
MSM 4 (12.9) 34 (16.4) 
Insurance type  
 Private 2 (7.7) 16 (8.1) 
0.4481 Public 21 (80.8) 129 (65.5) Uninsured 0  3 (1.5) 
Unknown 3 (11.5) 49 (24.0) 
Year of HIV diagnosis  
 < 1990 4 (13.8) 27 (14.0) 
1.000 1990-1999 14 (48.3) 94 (48.7) 
≥ 2000 11 (37.9) 72 (37.3) 
Age at HIV diagnosis (years) (mean (SD)) 33.9 (6.4) 35.0 (9.5) 0.2538 
Age group at HIV diagnosis (years)  
 <30 10 (34.5) 54 (28.3) 
0.5240 30-<40 11 (37.9) 79 (41.4) 40-<50 8 (27.6) 45 (23.6) 
≥ 50 0  13 (16.8) 
HBsAg positivity at first anti-HCV-
positive test 
6 (33.3) 3 (2.9) <0.0001 
AIDS at first anti-HCV-positive test 7 (21.9) 60 (29.0) 0.4046 
CD4 count at first anti-HCV-positive test 
(cells/µL) (mean (SD)) 
510 (300) 443 (285) 0.2638 
CD4 count at first anti-HCV-positive test 
(cells/µL) 
 
 < 200  3 (10.0) 43 (21.4) 
0.3199 200 - < 350 8 (26.7) 42 (20.9) 
≥ 350 19 (63.3) 116 (57.7) 
HIV RNA at first anti-HCV-positive test 
(log10 copies/mL) (mean (SD)) 
3.2 (1.3) 3.0 (1.3) 0.6505 
HIV therapy at first anti-HCV-positive 
test 
 
 PI- and NNRTI-containing HAART 2 (7.4) 4 (2.1) 
0.2753 
PI-containing HAART 8 (29.6) 67 (35.6) 
NNRTI-containing HAART 5 (18.5) 28 (14.9) 
NRTI alone HAART 2 (7.4) 6 (3.2) 
Not on HAART 10 (37.0) 83 (44.1) 
On HAART at first anti-HCV-positive 
test 17 (63.0) 105 (55.9) 0.4855 
 *χ test or Fisher’s exact test for categorical variables; Wilcoxon test for continuous variables 
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Table 3-6.  Logistic regression modeling the odds of HCV clearance among anti-
HCV-positive and HIV-positive subjects with available HCV RNA viral loads 
(n=239)  
 
 
Characteristic 
Model 1 (Crude) 
(n=239) 
Model 2 (Adjusted) 
(n=122) 
p-value OR CI p-value OR CI 
Female sex 0.0142 2.57 1.21-5.47    
Race   
 White 0.4828 1.64 0.41-6.45    
 Black 0.7020 1.29 0.36-4.66    
 Hispanic -- 1.00 --    
HIV risk group   
 Heterosexual 0.1525 1.84 0.80-4.26 0.1049 2.70 0.81-9.00 
MSM 0.8973 0.93 0.29-2.95 0.5427 1.62 0.34-7.60 
Any IDU -- 1.00 -- -- 1.00 -- 
Insurance type *   
 Public 0.7368 1.30 0.28-6.08    
 Unknown 0.4559 0.49 0.08-3.20    
 Private -- 1.00 --    
Year of HIV diagnosis 0.6510 1.01 0.96-1.07    
Year of HIV diagnosis (group)   
 < 1990 0.8769 0.91 0.28-3.00    
 1990-1999 0.8267 0.92 0.41-2.03    
 ≥ 2000 -- 1.00 --    
Age at HIV diagnosis (per 10 year 
increase) 
0.5509 0.88 0.57-1.35    
HBsAg positivity at first anti-HCV-
positive test  
0.0002 17.00 3.76-76.91 0.0048 16.06 2.65-97.26 
AIDS at first anti-HCV-positive 
test 
0.4070 0.69 0.28-1.67    
CD4 count at first anti-HCV-
positive test (per 100 cells/µl 
increase) 
0.2355 1.08 0.95-1.23    
HIV RNA at first anti-HCV-
positive test (log10 copies/mL) 
0.5126 1.04 0.92-1.18    
HIV therapy at first anti-HCV-
positive test 
  
 PI-containing HAART 0.1290 0.24 0.04-1.52    
 NNRTI-containing HAART 0.2997 0.36 0.05-2.50    
 NRTI alone HAART 0.7333 0.67 0.07-6.87    
 Not on HAART 0.1253 0.24 0.04-1.49    
 PI- and NNRTI-containing 
HAART 
-- 1.00 --    
On HAART at first anti-HCV-
positive test 
0.4866 1.34 0.59-3.09    
 * uninsured insurance group (n=3) was excluded from this analysis because this group had no instances of HCV clearance 
 
  
105 
 
 
Table 3-7. Sex-stratified logistic regressions modeling the odds of HCV clearance 
among anti-HCV-positive and HIV-positive subjects with available HCV RNA viral 
loads (n=122) 
 
 
Characteristic 
Males 
(n=82) 
Females 
(n=40) 
p-value OR CI p-value OR CI 
HIV risk group   
 Heterosexual 0.6319 1.57 0.25-9.77 0.3257 2.63 0.38-17.99 
MSM` 0.5234 1.73 0.32-9.27    
Any IDU -- 1.00 -- -- 1.00 -- 
HBsAg positivity at first 
anti-HCV-positive test  0.0048 19.29 2.74-135.61 0.1407 10.50 0.46-239.78 
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4 THE IMPACT OF HEPATITIS B CO-INFECTION ON HIV DISEASE 
PROGRESSION AMONG A POPULATION OF INDIVIDUALS 
ATTENDING AN URBAN HIV CLINIC 
4.1 Abstract 
The negative health effects of co-infection with hepatitis B virus (HBV) among HIV-
positive populations is becoming a major public health concern as HIV-positive 
individuals are living longer, healthier lives.  Given similar routes of exposure, such as 
sexual contact and injection drug use, HBV co-infection among those that are HIV-
positive is common, with an estimated 6-9% of HIV-positive individuals chronically 
infected with HBV.  HIV has been shown to negatively impact the natural history of 
HBV disease, leading to more serious liver disease and death; the effect of HBV on HIV 
disease progression is less clear.   Using a Cox proportional hazards regression, we 
modeled the risk of progression to four outcomes (clinical AIDS, all-cause mortality, 
HIV virologic failure, and CD4 cell decline) by HBV status (resolved infection, chronic 
infection, and negative).  We found that HBV status negatively affected HIV disease 
progression, particularly time to clinical AIDS (chronic infection vs. resolved infection, 
HR=2.17; 95% CI, 0.92-5.09) and HIV virologic failure (HBV-negative vs. resolved 
infection, HR=1.49; 95% CI, 1.12-1.99).  We found no statistically significant association 
between HBV status and all-cause mortality.  We also found those with a resolved HBV 
infection had a slightly greater risk for a modest (10%) decline in CD4 cell count 
compared to those who were HBV-negative (HR=1.27; 95% CI, 1.04-1.54).  These 
findings highlight the growing burden of HBV/HIV infection, even in light of available 
HBV vaccine.  Given the high rates of HBV/HIV co-infection and the current debate on 
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the effect of HBV infection on HIV disease progression, these results highlight the need 
for additional studies investigating this relationship using large, prospective cohorts.   
 
4.2 Introduction 
HIV/AIDS continues to be a significant health concern in the United States (US).  At the 
end of 2008, there were an estimated 1.2 million American living with HIV/AIDS, 20% 
of which were undiagnosed.1  In the US, HIV is primarily transmitted through exposure 
to contaminated blood and semen, putting those who engage in male-to-male sexual 
contact and injection drug use at the greatest risk for infection.  Indeed, approximately 
three-quarters of infections are attributable to one or both of these modes of 
transmission.1 However, HIV infections acquired through heterosexual contact have 
increased over the past decade, which is now considered to be a major source of 
infection.  HIV infection disproportionately affects Blacks and Hispanics, with a 2-fold 
increase in prevalence in these groups compared to Whites.  Although the incidence of 
new HIV diagnoses has remained stable over the past few years,2 people are living longer 
with a HIV diagnosis due to widespread accessibility of highly active antiretroviral 
therapy (HAART) and identification of early diagnoses through routine testing.3-5  In 
2009, 90% of infected individuals survived longer than 36 months following a HIV 
diagnosis and 84% following an AIDS diagnosis.6  With HIV-infected individuals living 
longer, the negative health outcomes due to chronic conditions, such as liver disease from 
hepatitis B, are now a substantial public health concern.7  
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Similar to HIV, hepatitis B virus (HBV) is transmitted through percutaneous exposure 
(e.g., needle stick, blood transfusion), sexual contact, and perinatal exposure.8  In the US, 
transmission of HBV primarily occurs through unprotected sex.9  Although a vaccine has 
been available to prevent HBV for over two decades, there were an estimated 43,000 new 
HBV infections in the US in 2007, with the highest incidence observed in sexually active 
young adults and a higher incidence in Blacks and Hispanics compared to Whites.10 
Among adults, approximately 2-5% of acute infections develop into chronic infections 
(viral persistence), which can result in serious liver disease, including cirrhosis, liver 
failure, and hepatocellular carcinoma.8  It is estimated that 1.2-2 million Americans with 
a chronic HBV infection.11-13 
 
Due to similar routes of exposure, HBV co-infection among those that are HIV-positive 
is common, with an estimated 6-9% of HIV-positive individuals chronically infected with 
HBV.14 Co-infection prevalence rates are higher among men who have sex with men 
(MSM) (nearing 20%) and injection drug users (IDU) compared to other transmission 
groups.  HIV-induced impairment of the cell-mediated immunity leads to less HBV viral 
clearance, longer duration of HBeAg positivity (indicating ongoing viral replication and 
elevated viral loads), and more rapid progression to clinically significant liver disease, 
such as hepatocellular carcinoma and cirrhosis, and death.7,9,15,16  Even though HBV 
infection may lead to enhanced transcription and up-regulation of HIV,17 the impact of 
this interaction on clinical disease is less clear.  Findings from previous studies have 
suggested that HBV co-infection had no impact on HIV disease progression (Table 4-
1).18-24 For example, a large, multi-center European study of HIV/HBV co-infected 
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subjects found the incidence of new AIDS diagnoses was similar among HIV-positive 
patients that were HBsAg-positive compared to HBsAg-negative (incidence rate ratio 
(IRR)=0.9, 95% CI, 0.7-1.2).20 However, research also suggests that HBV co-infection 
does have a negative effect on HIV disease progression (Table 4-1).25-27  For example, a 
recent study by Chun at al. reported that co-infected had a negative impact on HIV-
related outcomes, specifically clinical AIDS or death.27 Here, the authors report an almost 
2-fold increase in the hazard for AIDS or death among those that had a chronic hepatitis 
B infection compared to those who were mono-infected with HIV.  Many of these 
previous HIV/HBV co-infection studies were conducted during the pre-HAART era18,19 
or have been limited by small sample size,25 an inability to account for baseline CD4 cell 
counts,25,26 were conducted in homogenous risk groups,22,25 or were unable to distinguish 
between a past infection and being HBV-negative.20,23 
 
The objective of this study was to assess the impact of viral HBV co-infection on the 
clinical progression of HIV and changes of virologic and immunologic disease indicators, 
specifically time to a new AIDS diagnosis, death from all causes, failure, and CD4 cell 
count decline. To achieve this, we conducted a retrospective survival analysis on HIV-
positive subjects attending a large urban HIV clinic.   
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4.3 Methods 
Study population 
All patients who had at least two visits at the Drexel University’s College of Medicine’s 
Partnership Comprehensive Care Practice between the years 2002 and 2011 were eligible 
for inclusion in the study (n=2,880).   This practice provides routine primary and 
specialty HIV medical care to all HIV-positive persons, regardless of their ability to pay, 
and is the largest comprehensive HIV primary care practice in Philadelphia, serving 
1,900 patients in 2010.  During the study period, subjects had an average of 13 visits over 
an average of 5.2 years.  The majority of subjects were enrolled in the clinic in the 2000s 
(70%).  At each clinic visit, patients had comprehensive laboratory work (e.g., CD4 
count, HIV VL, hepatitis testing), in accordance with clinical standards of care and 
practical guidelines at the time.  Subjects were excluded from the analysis if they were 
never tested for hepatitis B (n=695), or if their hepatitis infection could not be further 
classified into resolved or chronic (n=383).  This left a total study population of 1,802 
subjects. 
 
Hepatitis B exposure definitions 
Being HBV exposed was defined as having any positive lab result from at least one of the 
following HBV-related tests at any time from 2002-11: core antibody (IgM anti-HBc, 
IgG anti-HBc, or anti-HBc), surface antigen (HBsAg), e antigen (HBeAg), or HBV 
DNA.  These tests were chosen as they would more accurately capture individuals with a 
true hepatitis infection compared to relying on those with a positive antibody test only.  
Given the cost of hepatitis B antibody test, a provider in a clinic-setting may bypass an 
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antibody test and only test for one of the above tests to assess infectivity or infection 
status for individuals who self-report being hepatitis B-positive.  
 
All subjects were classified into mutually exclusive groups based on HBV status: 
resolved HBV infection (n=541); chronic HBV infection (n=51); and HBV-negative 
(n=1,210).   A resolved infection was defined as having concurrent (within 30 days) HBV 
core antibody and surface antibody reactivity.22,27  A chronic infection was defined as 
having two consecutive reactive HBsAg or HBV DNA tests.27   
 
Additional operational definitions 
A baseline date was defined for each mutually exclusive HBV exposure group.  For those 
with a chronic HBV infection, the date of the first positive HBV test listed above was 
used.  For those with a resolved HBV infection, the date of the concurrent positive tests 
for core antibody and surface antibody was used.  In instances were these tests were not 
conducted on the same day, the day of the second positive test was counted.  For those 
that were HBV-negative, the date of the first negative HBV test was used as the baseline 
date.   
  
HIV therapy was defined at two time points during the study: at baseline and at time of 
outcome or censoring.  Highly active antiretroviral therapy (HAART) was defined as any 
of the following combinations:  ≥ 2 protease inhibitors (PI) and ≥ 1 nucleoside reverse 
transcriptase inhibitor (NRTI), without a non-nucleoside reverse transcriptase inhibitor 
(NNRTI) (PI-containing HAART); ≥ 2 NNRTI and ≥ 1 NRTI, without PI (NNRTI-
containing HAART); ≥ 1 NNRTI and ≥ 2 NNRTI, without PI (NNRTI-containing 
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HAART); ≥ 1 PI and ≥1 NNRTI and ≥ 1 NRTI (PI- and NNRTI-containing HAART); 
and a fusion inhibitor, entry inhibitor, or integrase inhibitor, not meeting a definition 
above (other HAART).  Those not meeting one of the above definitions were considered 
not to be on HAART.  Initial HIV therapy was defined as medication taken within 3 
months of entry into the cohort.  Endpoint HIV therapy was defined as therapy at time of 
endpoint.  To improve statistical efficiency, all HAART categories were collapsed into 
one category and included as a separate variable in multivariate analysis (Model 2). 
 
CD4 cell count was also defined at two time points, baseline and endpoint.  If available, 
the CD4 cell count taken on the baseline date was used for the baseline value (n=1,617; 
95% (HBV).  If this was not available, then subsequent values were used.  If the 
difference between the first two values following the baseline date was ≤ 10% and both 
were within six months of baseline, then the mean of these values was used as the 
baseline value (n=20; 1%).  If the difference was greater than 10%, then the first value 
following baseline was used, as long as it was within six months of the baseline date 
(n=74; 4%).  Thirty-one subjects did not meet any of the criteria above and therefore had 
a missing baseline CD4 cell count value.  Endpoint CD4 cell count was defined as the 
CD4 cell count taken at time of outcome or censoring.   
 
HIV RNA viral load (VL) was also defined at two time points, baseline and endpoint.  A 
similar approach was used to define baseline HIV VL as is describe above for baseline 
CD4, resulting in 91% with a VL taken on the baseline date. Twenty-eight subjects did 
not meet any of the criteria above and therefore had a missing baseline HIV VL.  
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Endpoint HIV VL was defined as the HIV VL taken at the time of outcome or censoring. 
HIV VL values were transformed to the log scale. 
 
Baseline values were also defined for age and hepatitis C virus (HCV) positivity.  
Baseline age was defined as the age on the baseline date.  HCV positivity was defined as 
having a reactive core antibody test within 30 days of baseline date.   
 
Outcome definitions 
Four outcomes of interest were identified.  Onset of clinical AIDS was defined as a 
diagnosis of an opportunistic infection (OI) or AIDS-defining event using the 1993 
Centers for Disease Control and Prevention classification, including a CD4 count < 200 
cells/µl, pneumocystis carinii pneumonia, cytomegalovirus, herpes simplex, pulmonary 
tuberculosis, Kaposi’s sarcoma, toxoplasmosis, crypotococcosis, candidiasis, and 
mycobacterium avium complex.28  In this population, 51 (46%) of those meeting this 
endpoint did so by reaching a CD4 cell count < 200 cells/µl.  Death from any cause was 
available in the data.  We could not use AIDS-related death as an outcome, as cause of 
death was not available in the data.   HIV virologic failure was defined as a HIV VL 
result > 1,000 copies/ml.  CD4 cell decline was defined in two ways: a decline of CD4 
count of at least 10% or 25% in CD4 count from baseline on two consecutive visits. Only 
those at risk for each outcome were eligible to reach the outcome as an endpoint.  For 
example, only those with a HIV VL < 1000 were eligible to reach virologic failure.  All 
subjects were followed until they achieved each of the outcomes.  All other subjects were 
censored at 5.6 years (2,043 days).  Although there was additional follow-up time 
119 
  
 
available for a small number of subjects, there was considerable subject drop-off after 
this period and using this date ensured that at least 90% of subjects were being followed 
for each outcome (i.e., the smallest of the 90th percentiles for follow-up time for each 
outcome of interest). 
 
Analysis 
Three HBV exposure groups (resolved infection, chronic infection, and negative) were 
summarized using descriptive statistics.  For continuous variables, means were presented 
with standard deviations and were compared with Wilcoxon tests. For categorical 
variables, differences in proportions were compared with χ tests.  Exact methods (e.g., 
Fisher’s exact test) were used with small cell counts.  A two-sided alpha level of 0.05 was 
used to determine statistical significance.   
 
Kaplan Meier (KM) curves were generated for each combination of hepatitis exposure 
and event to univariately assess differences in survival for each event using the log-rank 
test.  In order to adjust to potential confounders, a Cox proportional hazards (PH) model 
was used to assess the risk of event.  A Cox PH model test was chosen over other 
survival models because of its semi-parametric properties, meaning it does not assume 
the distribution of the baseline hazard function.29  The following factors were assessed as 
potential confounders: demographics (sex, race, HIV risk group, age, year of HIV 
diagnosis and type of insurance); HIV antiretroviral therapy; HIV VL; CD4 count; and 
hepatitis C positivity.  Insurance status (private, public, uninsured, or unknown) was used 
as a proxy for socioeconomic status.30,31  By definition, confounders have to be 
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associated with both the exposure and the outcome.32  Therefore, the statistical 
significance of each potential confounder to HBV status was assessed using a χ test 
for categorical variables or a Wilcoxon test for continuous variables.33  Next, potential 
confounders were assessed univariately in a regression model to determine if they were 
statistically associated with the outcome of interest.   A backward selection approach was 
used to build the final Cox proportional hazards model. The first step of this process 
involves building an initial regression model that contains the exposure of interest plus all 
potential confounders that reached statistical significance at an alpha level of 0.10.32  
Next, variables were removed from the model one at a time based on the corresponding 
p-value and the model was re-run.  This process continued iteratively until only variables 
reaching statistical significance at an alpha level of 0.05 were included in the model.  
This backward selection approach was modified to allow investigators to include 
variables that did not reach statistical significance (i.e., “force in”), but were thought to 
be a potential confounder due to prior knowledge.   The following variables were forced 
into the models: age (outcome of all-cause mortality); and HIV therapy at endpoint 
(outcome of virologic failure).  Additionally, if HIV therapy broken into discrete HAART 
categories reached statistical significance, the corresponding collapsed variable was 
forced into the alternate analysis, and vice versa.  In an attempt to build the most 
parsimonious regression model, regression model building also used the 10% change-in-
estimate approach to identify variables that confounded the relationship between HCV 
status and the outcome of interest.  Here, variables were considered potential confounders 
if they changed the main effect estimate by more than 10% when they were removed.32   
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Once all potential confounders were identified using the modified backward selection 
approach described above, diagnostics were performed to evaluate the PH assumption for 
each variable.29  To assess this assumption, the log-log survival (LLS) curve was plotted 
with survival time in days on the horizontal axis for each variable (see Appendix C).  If 
the stratum-specific curves were parallel, indicating the survival functions did not vary 
with time, then the variable was considered to be time-independent.  When visual 
inspection of the LLS was inconclusive or revealed time dependence, a goodness of fit 
test was run to test the statistical significance of the PH assumption, by looking for a 
correlation between the Schoenfeld residuals and the ranking of the individual failure 
times.  In this analysis, the null hypothesis is that the correlation is zero, therefore if the 
p-value was < 0.05, then there was enough statistical evidence to say that the PH 
assumption is violated for that variable.  For time-dependent variables, the LLS curves 
were used to determine the most appropriate time cut-offs to define areas of varying 
survival functions and create heavyside functions for those variables.  Each time-
dependent variable was tested univariately in the model for statistical significance.  
Statistically significant time dependent variables were included in the final extended Cox 
PH model.   From the PH model, hazard ratios (HR) were generated with 95% confidence 
intervals (CIs).  For all univariate and multivariate analyses, an alpha of 0.05 was used to 
determine statistical significance.   
 
All analyses were conducted in SAS 9.2. This study was approved by the Drexel College 
of Medicine Institutional Review Board (IRB).  
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4.4 Results 
Among 1,802 HIV-positive subjects who were classified with a HBV exposure, 541 
(30%) had evidence of a past infection (i.e., resolved infection), 51 (3%) had a chronic 
infection, and 1210 (67%) were HBV-negative.  Those in the chronic HBV group were 
predominantly male (80%), black (78%), and reported MSM risk behavior (47%) (Table 
4-2).  There were significant differences in the following demographic characteristics 
according to HBV status: sex (p=0.0002), race (p=0.0120), HIV risk group (p=0.0002), 
insurance type (p=0.0230), and age (<0.0001).  There were also significant differences by 
anti-HCV positivity (p=0.0011), with the smallest HCV seroprevalence among the HBV-
negative group, year of HIV diagnosis (p=0.0015), baseline CD4 count, with those with a 
chronic infection having the lowest value across the groups (p=0.0135), baseline HIV 
VL, with those with a chronic infection having the highest value across the groups 
(p<0.0001), and baseline HIV therapy (p<0.0001).  Significant differences of endpoint 
CD4, VL, and HIV therapy varied across the five outcomes.   
 
Among study subjects, a > 10% decline in CD4 cell count was the most common 
outcome (40% of subjects) followed by HIV virologic failure (36%), a > 25% decline in 
CD4 cell count (24%), onset of clinical AIDS diagnosis (11%), and death from all causes 
(7%) (Table 4-3).  The average follow-up times for new AIDS diagnosis, all-cause 
mortality, HIV virologic failure, and 25% and 10% CD4 cell decline was 940 days, 1,165 
days, 801 days, and 1,033 days, and 890 days, respectively.   
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Figures 4-1 through 4-5 show the Kaplan Meier (KM) survival curves for HBV exposure 
groups and each of the outcomes of interest.  From Figure 4-1, it appears that those with a 
chronic HBV infection have a lower survival to clinical AIDS, compared to those with a 
resolved infection and who were HBV-negative (p=0.0214).  For a 25% or 10% decrease 
in CD4 cell count, there is a similar survival across the three HBV groups for the first 3.5 
years of follow-up; after this time, chronic infections appear to have worse survival 
compared to those who are HBV-negative or have a resolved HBV infection (Figures 4-4 
and 4-5, p=0.6253 and p=0.4001, respectively).  There appears to be no difference in 
survival from all-cause mortality across the three hepatitis B exposure groups (Figure 4-
2, p=0.9317).  Figure 4-3 shows that those with a resolved infection have a greater 
survival from virologic failure compared to those with a chronic infection and who are 
HBV-negative (p=0.0017). 
 
Clinical AIDS 
Results from the Cox PH model are shown in Table 4-4.  Without adjustment for possible 
confounders (Model 1), a chronic HBV infection was significantly associated with 
increased risk of a new AIDS diagnosis compared to a resolved HBV infection 
(HR=2.99; 95% CI, 1.35-6.61).  The following variables were also associated with 
increased risk for clinical AIDS: public or unknown insurance compared to private 
insurance (HR=1.89, 95% CI, 1.04-3.41, and HR=2.11, 95% CI, 1.09-4.10, respectively); 
a more recently diagnosed HIV infection (HR=0.96, 95% CI, 0.93-0.99); lower baseline 
and endpoint CD4 cell count (HR=0.75, 95% CI, 0.68-0.82, and HR=0.73, 95% CI, 0.67-
0.79, respectively); higher baseline and endpoint HIV VL (HR=1.16, 95% CI, 1.09-1.24, 
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and HR=1.18, 95% CI, 1.12-1.24); and not being on HAART at time of endpoint 
(HR=4.55, 95% CI, 2.63-8.33).   
 
Results from multivariate Model 2 suggests that having a chronic HBV infection is 
associated with a greater than 3-fold increased risk for developing clinical AIDS 
compared to those with a resolved HBV infection (HR=3.51; 95% CI, 1.42-8.65), when 
adjusted for year of HIV diagnosis, baseline and endpoint HIV VL, and being on 
HAART at endpoint (Table 4-4).  The data also suggest that those who were HBV-
negative had a probable increased risk for clinical AIDS when compared to those who 
had a resolved HBV infection (HR=1.31), although this did not reach statistical 
significance (95% CI, 0.74-2.31).  Additional factors significantly related to progression 
to clinical AIDS included an earlier HIV diagnosis (HR=1.04 per 1 year decrease; 95% 
CI, 1.01-1.08), higher baseline and endpoint HIV VL (HR=1.39 per log10 copies/mL 
increase; 95% CI, 1.17-1.64, and HR=1.42 per log10 copies/mL increase; 95% CI, 1.23-
1.64, respectively), and not being on HAART at time of endpoint (HR=3.13; 95% CI, 
1.61-5.88).  Results from multivariate models 2 and 3 had similar results with respect to 
magnitude of effect and statistical significance for the exposure variable of interest and 
the confounders (see Appendix B).   Visual inspection of the LLS curves and results from 
the goodness of fit test did not identify any variables that violated the PH assumption (see 
Appendix C for LLS curves for each variable in Model 2).  There was no significant 
difference in risk between chronic infections and HBV-negative groups on multivariate 
analysis (data not shown). 
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When using the change-in-estimate approach to identify confounders of the relationship 
between HBV status and onset of clinical AIDS, none of the factors identified in model 2 
changed the estimate at least 10% when removed from the model.  Therefore, no 
confounders were identified using this approach.  Here, chronic HBV infection was 
associated with a 3-fold increase in the hazard of onset of clinical AIDS compared to 
those who were anti-HCV-negative, although this did not reach statistical significance 
(HR=2.99; 95% CI, 1.35-6.61). 
 
All-cause mortality 
Results from the Cox PH model modeling the risk for all-cause mortality are shown in 
Table 4-5.  Anti-HCV positivity was found to be time-dependent, with varying survival 
functions ±700 days of follow-up (see Appendix C).  Univariate analysis (Model 1) 
shows the following were statistically associated with increased risk for all-cause 
mortality: reporting IDU as a HIV risk factor compared to heterosexual contact 
(HR=1.80, 95% CI, 1.19-2.71); having unknown insurance compared to private insurance 
(HR=21.59, 95% CI, 10.29-45.29); older age (HR=1.44 per 10 year increase, 95% CI, 
1.22-1.71); being anti-HCV-positive (HR=2.85 when at least 700 days of follow-up, 95% 
CI, 1.79-4.52); lower baseline CD4 cell count (HR=0.78 per 100 cells/µl decrease, 95% 
CI, 0.72-0.84); higher baseline HIV VL (HR=1.09 per log10 copies/mL, 95% CI, 1.03-
1.16); and being on HAART at baseline (HR=1.66, 95% CI, 1.04-2.67). 
 
Multivariate analysis (Model 2) shows there is no statistical difference in the risk of death 
from all-causes comparing those with a chronic HBV infection and those that are HBV-
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negative to those with a resolved infection, adjusted for type of insurance, baseline age, 
baseline CD4 count, anti-HCV positivity, and baseline and endpoint HAART (Table 4-5).  
The following factors remained significantly associated with increased risk for all-cause 
mortality on multivariate analysis: having unknown insurance compared to private 
insurance (HR=25.08, 95% CI, 10.64-59.09); older age (HR=1.49 per 10 year increase, 
95% CI, 1.21-1.82); being anti-HCV-positive at baseline only for events occurring after 
700 days of follow-up (HR=2.38, 95% CI, 1.46-3.88); lower baseline CD4 cell count 
(HR=1.30 per 100 cells/µL decrease), 95% CI, 1,19-1.43); and not being on HAART at 
endpoint (HR=2.78, 95% CI, 1.02-7.14).  Results from multivariate models 2 and 3 had 
similar results with respect to magnitude of effect and statistical significance for the 
exposure variable of interest and the confounders (see Appendix B).  Model 3 showed 
that being on PI- and NNRTI-containing HAART increased risk for death compared to 
PI-containing HAART, NNRTI-containing HAART, and not being on HAART 
(HR=3.33, HR=2.27, and HR=4.35, respectively). This association remained insignificant 
when chronic and resolved infections were compared to those that were HBV-negative on 
multivariate analysis (data not shown). 
 
When using the change-in-estimate approach to identify confounders of the relationship 
between HBV status and all-cause mortality, age, anti-HCV positivity, baseline CD4 
count, and baseline and endpoint HAART were identified of confounders.  Adjusted for 
these factors, there was no statistical difference in the risk of all-cause mortality based on 
HBV status. 
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Virologic failure 
Table 4-6 shows the following variables were univariately associated with risk of 
virologic failure (Model 1): reporting heterosexual compared to MSM HIV risk behavior 
(HR=1.56, 95% CI, 1.19-2.08); having public or unknown insurance compared to private 
insurance (HR=1.54, 95% CI, 1.10-2.14, and HR=1.56, 95% CI, 1.04-2.33, respectively); 
younger age (HR=1.23 per 10 year decrease, 95% CI, 1.10-1.39); lower baseline and 
endpoint CD4 (HR=1.06 per 100 cells/µl decrease, 95% CI, 1.02-1.10, and HR=1.27 per 
100 cells/µl decrease, 95% CI, 1.20-1.32, respectively); higher baseline HIV VL 
(HR=1.40 per log10 copies/mL, 95% CI, 1.26-1.56); and not being on HAART at 
endpoint (HR=2.70, 95% CI, 1.82-4.17). 
 
Multivariate analysis (Model 2) shows that those who are HBV-negative have a 1.5-fold 
increased risk for virologic failure compared to those with a resolved HBV infection 
(HR=1.51, 95% CI, 1.32-2.01) (Table 4-6).  No significant association was identified 
between those with a chronic and resolved HBV infection.  The following factors were 
significantly associated with increased risk for mortality on multivariate analysis: having 
public compared to private insurance (HR=1.48, 95% CI, 1.04-2.09); higher baseline 
CD4 (HR=1.10 per 100 cells/µl increase); and lower endpoint CD4 (HR=1.35 per 100 
cells/µl decrease, 95% CI, 1.27-1.43).  The results further show a probable relationship 
between being on HAART at endpoint and risk for mortality, although this did not reach 
statistical significance (HR=1.47, 95% CI, 0.93-2.33).  Results from multivariate models 
2 and 3 had similar results with respect to magnitude of effect and statistical significance 
for the exposure variable of interest and the confounders (see Appendix B).   Visual 
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inspection of the LLS curves and results from the goodness of fit test did not identify any 
variables that violated the PH assumption (see Appendix C for LLS curves for each 
variable in Model 2).  There was no significant difference in risk between chronic 
infections and HBV-negative groups on multivariate analysis (data not shown). 
 
When using the change-in-estimate approach to identify confounders of the relationship 
between HBV status and virologic failure, insurance, baseline CD4 count and endpoint 
HAART were identified as confounders.  When adjusted for these factors, those who 
were HBV-negative had a 1.5-fold increase in risk for virologic failure compared to those 
who had a resolved HBV infection (HR=1.16; 95% CI, 1.17-2.20). 
 
CD4 cell decline 
Table 4-7 shows the following variables are univariately associated with increased risk 
for a 10% decline in CD4 count from baseline: higher endpoint HIV VL (HR=1.18 per 
log10 copies/mL increase), 95% CI, 1.15-1.21, respectively); lower baseline HIV VL 
(HR=1.03 per log10 copies/mL decrease, 95% CI, 1.00-1.16), and not being on HAART 
at baseline and endpoint (HR=1.22, 95% CI, 1.02-1.47, and HR=3.03, 95% CI, 2.38-3.85, 
respectively). 
 
Multivariate analysis (model 2) shows that having a resolved HBV infection was 
significantly associated with an increased risk of a 10% CD4 count decline, compared to 
those who are HBV-negative (HR=1.27, 95% CI, 1.04-1.54) (Table 4-7).  The 
relationship between a chronic infection and a resolved infection did not reach statistical 
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significance.   Factors that remained significantly associated with risk of CD4 cell decline 
on multivariate analysis included: higher endpoint HIV VL (HR=1.16 per log10 
copies/mL, 95% CI, 1.13-1.19), and not being on HAART at endpoint (HR=1.43, 95% 
CI, 1.06-1.96).  Results from multivariate models 2 and 3 had similar results with respect 
to magnitude of effect and statistical significance for the exposure variable of interest and 
the confounders (see Appendix B).  Visual inspection of the LLS curves and results from 
the goodness of fit test did not identify any variables that violated the PH assumption (see 
Appendix C for LLS curves for each variable in Model 2).  There was no significant 
difference in risk between chronic infections and HBV- groups on multivariate analysis 
(data not shown). 
 
When using the change-in-estimate approach to identify confounders of the relationship 
between HBV status and decline in CD4 count, none of the factors associated with the 
outcome changed the main effects by more than 10% when they were removed from the 
model.  Therefore, when adjusted for no confounders, those with a resolved HBV 
infection had a slight increase in risk of CD4 decline compared to those who were HBV 
negative (HR=1.25; 95% CI, 1.03-1.49).   
 
Analysis using a CD4 cell count decline of at least 25% as an endpoint yielded similar 
results with respect to magnitude of association between hepatitis B exposure and CD4 
cell decline, however these results did not reach statistical significance (see Appendix B).   
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4.5 Discussion 
The prevalence of chronic HBV in this HIV-positive population attending an urban HIV 
clinic was 3%, which is lower than the 6-9% prevalence seen recently in European 
studies20,21,26 and US studies of MSM,22 but similar to what was reported in a recent US 
study.27 The findings of this study suggest that HBV exposure status impacts time to 
clinical AIDS, virologic failure, and CD4 cell count decline, but is not associated with 
differences in risk of all-cause mortality.  In this HIV-positive clinic population, we 
found that having a resolved HBV infection was most protective against progression to 
clinical AIDS and virologic failure when compared to having a chronic HBV infection or 
being HBV-negative, respectively.  Specifically, we found that having a chronic HBV 
infection was associated with a 3.5-fold greater risk of new AIDS diagnosis and being 
HBV-negative was associated with a 1.5 times greater risk for HIV virologic failure, 
compared to a resolved infection.  Further, being HBV-negative was associated with a 
decreased risk of both a 10% and 25% decline in CD4 cell count.  We found no 
association between HBV exposure group and risk of all-cause mortality. 
 
Compared to those with evidence of a past HBV infection, those with a chronic infection 
had over a 3-fold increased risk for new AIDS diagnosis.  It has been suggested that 
subjects with a chronic hepatitis B infection may be in a persistent state of immune 
activation, possibly leading to up-regulation of HIV.17  Recently, Chun et al. also 
reported a significant association with HBV on HIV clinical outcomes,27 finding an 
almost 2-fold increase in the risk among those with a chronic infection compared to 
HBV-negative (HR=1.8).  However, they used a composite endpoint of clinical AIDS, 
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excluding CD4 count, or death from any cause, making our results not directly 
comparable. However, given that we found no association with HBV infection and all-
cause mortality, differences in classification may have artificially decreased the 
magnitude of effect in Chun’s study.  Additionally, they excluded CD4 count less than 
200 cells/µL from this composite outcome, while we included it in our clinical AIDS 
definition.  However, we did not see the same association with the outcome of CD4 
decrease, suggesting that acquiring opportunistic infections, not immunologic failure, that 
was driving our finding. 
 
Additionally, although not reaching statistical significance, our findings suggest a 
possible slight increase in risk of AIDS for those who were HBV-negative compared to 
those that had resolved their HBV infection.  Although the mechanism behind this is 
unknown, it is possible that viral clearance of a HBV infection is indicative of greater 
cell-mediated immune response, than what has been previously observed in HIV-positive 
individuals, which may subsequently offer protection against development of 
opportunistic infections.  This may also indicate less replication of HIV, which could 
account for our findings suggesting those with a resolved infection were at least risk of 
progression to virologic failure compared to other HBV groups. 
 
We found no association between HBV status and death from all causes, which is 
different from what others have reported.20,22 Interestingly, Model 3 for this outcome 
showed that being on PI- and NNRTI-containing HAART increased risk for death 
compared to PI-containing HAART, NNRTI-containing HAART, and not being on 
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HAART (HR=3.33, HR=2.27, and HR=4.35, respectively).  Further inspection of the 
data revealed that those on PI- and NNRTI-containing HAART had a lower average 
baseline CD4 cell count compared to those on NNRTI-containing HAART (380 vs. 436 
cells/µl; p=0.0338) and compared to those not on HAART (380 vs. 471 cells/µl; 
p<0.0001).  Although this does not explain the protective effect of being on PI-containing 
HAART, this does indicate that those on PI- and NNRTI-containing HAART were 
somewhat less healthy at entry into the cohort which may explain their increased risk for 
death.  The observed association could also be due to unmeasured confounders such as 
drug adherence or lifestyle factors.   
 
In contrast to findings above, we found that those with a resolved infection were at 
increased risk for development of a modest (10%) decline in CD4 cell counts compared 
to those who were HIV-negative. Although the reason for this is unknown, the magnitude 
of effect was quite small (HR=1.27), and this effect was not substantiated when we used 
less modest decrease of 25% from baseline.  We saw no difference in the risk of 
progression to a 25% decline in CD4 cell count.  Others have reported no difference in 
risk of CD4 decline, although a wide array of outcomes definitions were used and short 
follow-up times can decrease the opportunity to observe the decline.19,20,22,24  
 
Although our study suggests that HBV co-infection among HIV-positive individuals may 
impact clinical progression to AIDS, virologic failure, and CD4 cell decline, it is limited 
in a number of ways.  First, the retrospective nature of the study relied on data that had 
previously been collected through routine clinical care, resulting in the possibility of 
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residual confounders due to unmeasured factors.  For example, the data did not contain 
reliable information on HBV therapy, some of which are known to have a direct effect on 
HIV.9  Further, we were not able to ascertain the possible impact of behavior data, such 
as drug and alcohol use, in the relationship between HBV co-infection and HIV disease 
progression.  We also did not have cause of death data available.  HBV directly causes 
mortality, and previous studies have found that the many of deaths in co-infected 
individuals were liver-related.22,34 Additionally, we sought out to use insurance type as a 
proxy for socioeconomic status, as has been done in previous research.30,31 However, 
26% of our study population did not have insurance information available, leading to the 
possibility of misclassification of this factor (e.g., those classified as having unknown 
insurance may truly be uninsured).  In the mortality analysis, none of the 38 subjects who 
were uninsured died during follow-up.  However, misclassification of true uninsured 
persons to a category of unknown insurance could have underestimated the mortality rate 
in this population. This group was associated with a remarkable 25-fold increase in all-
cause mortality compared to those with private insurance.  Further inspection of the data 
found that on average, these subjects were older (40 vs. 38 years; p=0.0002), Hispanic 
(14 vs. 6%; p=0.0017), and reported IDU as the primary HIV risk group (25 vs. 12%; 
p=0.0341).  The significant difference in the proportion reporting IDU suggests that 
perhaps these individuals were dying to causes un-related to HIV, such as drug overdose.  
However, this information could not be gleaned from the data.   
 
Although the data contained up to 50 repeated measures for CD4 cell count and HIV 
RNA levels and 33 for initial hepatitis B test, we had a limited number of repeated 
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hepatitis testing for HBsAg (11), anti-HBc (6), and anti-HBs (7).  We were able to 
classify those with a chronic infection with two consecutive tests, but were restricted to 
using one test for classification of a resolved infection.  
 
This study was conducted within an urban HIV clinic in the Northeast and may not be 
generalizable to other HIV-positive populations.  Although we had a similar distribution 
of IDUs in our population (22% compared to 22% nationally),6 we had a much larger 
proportion of subjects reporting heterosexual risk as the lone HIV risk factor (46% in our 
study to 26% nationally).   Further, as this study was conducted in a clinic population, it 
is possible that subjects included in our study may differ with respect to health-seeking 
behaviors, risky sexual behavior, and adherence to antiretroviral therapy than the general 
HIV population.35,36 
 
Although our study had limitations, we had a larger and more heterogeneous population 
of HIV-positive subjects in which to assess HBV exposure status compared to similar 
studies.19,21-23,25,26  For example, some previous studies only included MSM in their study 
population.18,22,25  Further, we had over 10 years of clinical data and an average of 2.6 
years of follow-up for subjects, yielding relatively long-term repeated measures and 
clinical data on subjects.  We also had the ability to distinguish between past and present 
HBV infections using serological markers, which some previous work was unable to 
do.25   
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We found that HBV co-infection can negatively impact HIV outcomes, specifically 
clinical progression to AIDS.  This underscores the need on both a population and 
individual level to decrease the burden of co-infections by reducing the number of new 
HBV infections among HIV-positive individuals and vice versa.  Existing mechanisms, 
such as condom education and distribution, pre-exposure prophylaxis, and treatment of 
serodiscordant partners can be further implemented to reduce co-infection rates.  Further, 
although a HBV vaccine has been available for years, those with HIV have been shown 
to have a decreased immune response to the vaccine,37 and low rates of complete 
administration has been seen among HIV-positive populations.38.  Recent research, 
however, has indicated that non-standard HBV vaccine administration may be more 
effective in mounting an immune response in HIV-positive individuals.39  Widespread 
acceptance and implementation of this administration may be the key for improving 
decreasing HBV transmission among HIV-positive populations. Further, routine 
screening for HBV among HIV populations is important for therapeutic decisions, as 
chronic HBV is often asymptomatic.   
 
In conclusion, we found HBV co-infection impacted HIV disease progression, 
specifically for clinical progression to AIDS, virologic failure, and modest decline in 
CD4 cell count.  As use of effective HAART increases, the negative health impacts of 
viral co-infections, such as hepatitis B, are becoming a substantial public health concern.  
Increased screening for hepatitis B and widespread of vaccination against hepatitis B 
among high-risk individuals remains a primary component of reducing the burden of a 
hepatitis B co-infection among HIV-positive individuals. 
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4.6 Tables and Figures 
 
 
 
Table 4-1.  Summary of previous studies of the impact of HBV co-infection on HIV disease progression 
Author 
(Year) 
Study 
populatio
n 
Findings: impact on 
Comments AIDS 
Death 
 AIDS or death 
Change in 
HIV VL 
Change in 
CD4 count 
Chun 
(2012)27 
N=2352 
HIV+ 
US 
Military 
cohort 
-- -- 
Chronic vs. 
HBV- 
(HR=1.8) 
-- -- 
• Prospective study (Cox PH) 
• 17k person-years follow-up 
• Did not include CD4 count 
< 200 in AIDS definition 
Hoffmann 
(2009)22 
N=816 
HIV+ 
MACS 
MSM 
On 
HAART 
No impact 
AIDS-related, 
chronic vs. 
HBV- 
(IRR=2.7) 
Non-AIDS 
related, chronic 
vs. HBV- 
(HR=4.1) 
-- No impact No impact 
• Prospective study 
• Median follow-up: 7 years 
Omland 
(2008)21 
N=3180 
HIV+ 
Denmark 
On 
HAART 
-- 
All-cause 
mortality, 
Chronic vs. 
HBV- 
(MRR=1.5) 
Liver-related 
mortality, 
chronic vs. 
HBV- 
(MRR=4.0) 
AIDS-related 
mortality, 
chronic vs. 
HBV- 
(MRR=1.7) 
-- No impact No impact 
• Prospective study (Cox PH) 
• 16k person-years follow-up 
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Konopnicki 
(2005)20 
N=9802 
HIV+ 
EuroSIDA 
No impact 
All-cause 
mortality, 
HBsAg+ vs. 
HBsAg- 
(IRR=1.5) 
Liver-related 
mortality, 
HBsAg+ vs. 
HBsAg- 
(IRR=3.6) 
-- No impact No impact 
• Prospective study 
• 5 years follow-up 
Law 
(2004)23 
N=692 
HIV+ 
Thailand 
-- -- No impact No impact No impact 
• Prospective study (Cox PH) 
• 48 weeks follow-up 
Lincoln 
(2003)24 
N=2086 
HIV+ 
Australia 
-- -- No impact No impact No impact 
• Prospective study (Cox PH) 
• 2 years follow-up 
Ockenga 
(1997)26 
N=232 
HIV+ 
Germany 
AIDS 
-- 
Decreased 
survival HBV+ 
vs. HBV- (212 
vs. 439 days) 
-- -- -- 
• Prospective study 
• 1.5 years follow-up 
Siniccio 
(1997)19 
N=347 
HIV+ 
Italy 
No impact -- -- -- No impact 
• Prospective study (Cox PH) 
• 3.5 years follow-up 
Eskild 
(1992)25 
N=80 
Norway 
MSM 
HBV+ vs. 
HBV- 
(RR=3.6) 
-- -- -- -- 
• Prospective study (Cox PH) 
• 5 years follow-up 
 
Solomon 
(1990)18 
N=4,498 
HIV+ 
MACS 
MSM 
No impact -- -- -- No impact 
• Prospective study (Cox PH) 
• 2.5 years follow-up 
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Table 4-2.  Population characteristics by HBV status  (N=1,802) 
Characteristic 
Resolved HBV 
infection (N=541) 
Chronic HBV 
infection (N=51) 
HBV-negative 
(N=1,210) 
 
 
p-value * N (%) N (%) N (%) 
Male sex 373 (69.7) 41 (80.3) 733 (60.9) 0.0002 
Race  
 Black 420 (78.2) 39 (78.0) 852 (70.7) 
0.0120 White 69 (12.8) 7 (14.0) 205 (17.0) 
Hispanic 48 (8.9) 4 (8.0) 148 (12.3) 
HIV risk group  
 Heterosexual 215 (39.7) 15 (29.4) 586 (48.3) 
0.0002 Any IDU 146 (27.0) 12 (23.5) 245 (20.4) 
MSM 180 (33.3) 24 (47.1) 368 (30.7) 
Insurance type  
 Private 57 (11.2) 6 (12.8) 166 (14.4) 
0.0230 Public 338 (66.4) 27 (57.4) 641 (55.7) Uninsured 12 (2.4) 0  31 (2.7) 
Unknown 102 (20.0) 14 (29.8) 312 (27.1) 
Age at baseline (years) (mean 
(SD)) 
40.4 (7.5) 40.4 (7.5) 39.6 (8.8) <0.0001 
Anti-HCV positivity at baseline 175 (33.8) 13 (27.1) 272 (24.6) 0.0011 
Year of HIV diagnosis  
 < 1990 42 (9.5) 5 (10.2) 63  (6.2) 
0.0015 1990-1999 219 (49.3) 26  (53.1) 427 (42.2) 
≥ 2000 183 (41.2) 18 (36.7) 522 (51.6) 
CD4 count at baseline (cells/µL) 
(mean (SD))  
461 (291) 352 (231) 441 (302) 0.0135 
HIV RNA at baseline (log10 
copies/mL) (mean (SD)) 
3.0 (1.4) 3.3 (1.4) 3.2 (1.4) <0.0001 
HIV therapy at baseline  
 PI- and NNRTI-containing 
HAART 
90 (18.2) 11 (23.4) 102 (9.4) 
<0.0001 PI-containing HAART 208 (42.0) 10 (21.3) 378 (34.9) NNRTI-containing HAART 111 (22.4) 14 (29.8) 299 (27.6) 
NRTI alone HAART 10 (2.0) 8 (17.0) 44 (4.1) 
Not on HAART 76 (15.4) 4 (8.5) 261 (24.1) 
On HAART at baseline 419 (84.6) 36 (78.3) 823 (75.9) 0.0203 
At endpoint – clinical AIDS  
 CD4 count (cells/µL) (mean 
(SD)) 
461 (296) 363 (215) 456 (300) 0.0781 
HIV RNA (log10 copies/mL) 
(mean (SD)) 
2.7 (1.4) 3.1 (1.5) 2.8 (1.4) 0.0045 
HIV therapy  
 PI- and NNRTI-containing 
HAART 
124 (25.1) 14 (29.8) 236 (21.9) 
0.0145 PI-containing HAART 228 (46.2) 20 (42.6) 445 (41.3) NNRTI-containing HAART 113 (22.9) 12 (25.5) 339 (31.4) 
NRTI alone HAART 9 (1.8) 1 (2.1) 30 (2.8) 
Not on HAART 20 (4.0) 0  28 (2.6) 
On HAART 474 (96.0) 47 (100.0) 1050 (97.4) 0.0943 
At endpoint – all-cause mortality  
 CD4 count (cells/µL) (mean 
(SD)) 
455 (216) 509 (300) 527 (304) 0.2828 
HIV RNA (log10 copies/mL) 
(mean (SD)) 
2.3 (1.3) 2.5 (1.3) 2.5 (1.3) <0.0001 
HIV therapy  
 PI- and NNRTI-containing 
HAART 
131 (26.5) 14 (29.8) 242 (22.4) 
0.0100 PI-containing HAART 242 (49.0) 20 (42.6) 455 (42.2) 
NNRTI-containing HAART 113 (22.9) 12 (25.5) 330 (30.6) 
NRTI alone HAART 8 (1.6) 1 (2.1) 30 (2.8) 
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Not on HAART 0  0  21 (1.9) 
On HAART 494 (100.0) 47 (100.0) 1057 (98.1) 0.0694 
At endpoint – HIV virologic 
failure 
 
 CD4 count (cells/µL) (mean 
(SD)) 
488 (316) 405 (256) 458 (295) 0.0770 
HIV therapy  
 PI- and NNRTI-containing 
HAART 
124 (25.1) 16 (34.0) 228 (21.2) 
0.0134 PI-containing HAART 241 (48.8) 17 (36.2) 448 (41.6) NNRTI-containing HAART 116 (23.5) 10 (21.3) 344 (31.9) 
NRTI alone HAART 9 (1.8) 2 (4.3) 29 (2.7) 
Not on HAART 4 (0.8) 2 (4.3) 29 (2.7) 
On HAART 490 (992.) 45 (95.7) 1049 (97.3) 0.2228 
At endpoint – 25% CD4 cell 
decline 
 
 CD4 count (cells/µL) (mean 
(SD)) 
480 (303) 425 (229) 473 (300) 0.6134 
HIV RNA (log10 copies/mL) 
(mean (SD)) 
2.5 (1.4) 2.9 (1.5) 2.8 (1.4) <0.0001 
HIV therapy  
 PI- and NNRTI-containing 
HAART 
123 (24.9) 13 (27.7) 220 (20.4) 
0.0270 PI-containing HAART 239 (48.4) 19 (40.4) 436 (40.4) NNRTI-containing HAART 116 (23.5) 11 (23.4) 336 (31.1) 
NRTI alone HAART 8 (1.6) 3 (6.4) 32 (3.0) 
Not on HAART 8 (1.6) 1 (2.1) 55 (5.1) 
On HAART 486 (98.4) 46 (97.9) 1024 (94.9) 0.0118 
At endpoint – 10% CD4 cell 
decline 
 
 CD4 count (cells/µL) (mean 
(SD)) 
475 (297) 399 (231) 465 (294) 0.2215 
HIV RNA (log10 copies/mL) 
(mean (SD)) 
2.6 (1.4) 3.1 (1.5) 2.9 (1.4) <0.0001 
HIV therapy  
 PI- and NNRTI-containing 
HAART 
116 (23.5) 13 (27.7) 203 (18.8) 
0.0141 PI-containing HAART 232 (47.0) 19 (40.4) 435 (40.3) NNRTI-containing HAART 114 (23.1) 11 (23.4) 336 (31.1) 
NRTI alone HAART 10 (2.0) 3 (6.4) 32 (3.0) 
Not on HAART 22 (4.5) 1 (2.1) 73 (6.8) 
On HAART 472 (95.5) 46 (97.9) 1006 (93.2) 0.0938 
*χ2 test or Fisher’s exact test for categorical variables; Wilcoxon test for continuous variables 
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Table 4-3. Summary of outcomes by HBV status (n=1,802) 
 New AIDS 
diagnosis 
All-cause 
mortality 
HIV virologic 
failure 
25% CD4 cell 
count decline 
10% CD4 cell 
count decline 
No. at 
risk 
N 
(%) 
No. at 
risk 
N 
(%) 
No. at 
risk 
 
N (%) 
No. at 
risk 
 
N (%) 
No. at 
risk 
 
N (%) 
Hepatitis B 
status 1,307 140 (11) 1,802 124 (7) 903 321 (36) 1,571 384 (24) 1,571 622 (40) 
 Chronic 38 9 (24) 51 4 (8) 22 10 (45) 47 9 (19) 47 18 (38) 
Resolved 373 47 (13) 541 33 (6) 305 79 (26) 470 116 (25) 470 193 (41) 
Negative 896 84 (9) 1,210 87 (7) 576 232 (40) 1,054 259 (25) 1,054 411 (39) 
 
 
141 
  
 
 
Table 4-4. Cox proportional hazards regression modeling risk of clinical AIDS 
 
Characteristic 
Model 1 (Crude) Model 2 (Adjusted) 
p-value HR CI p-value HR CI 
Exposure groups   
 Chronic HBV 0.0069 2.99 1.35-6.61 0.0064 3.51 1.42-8.65 
HBV-negative 0.1480 1.45 0.88-2.38 0.3555 1.31 0.74-2.31 
Resolved HBV -- 1.00 -- -- 1.00 -- 
Insurance   
 Public 0.0358 1.89 1.04-3.41    
Uninsured 0.6501 1.41 0.32-6.27    
Unknown 0.0278 2.11 1.09-4.10    
Private -- 1.00 --    
Year of HIV diagnosis (per 1 
year increase) 
0.0121 0.96 0.93-0.99 0.0215 0.96 0.93-0.99 
Baseline HIV RNA (per log10 
copies/mL increase) 
<0.0001 1.16 1.09-1.24 0.0002 1.39 1.17-1.64 
Endpoint HIV RNA (per log10 
copies/mL increase) 
<0.0001 1.18 1.12-1.24 <0.0001 1.42 1.23-1.64 
On HAART at endpoint <0.0001 0.22 0.12-0.38 0.0008 0.32 0.17-0.62 
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Table 4-5. Cox proportional hazards regression modeling risk of all-cause mortality 
 
Characteristic 
Model 1 (Crude) Model 2 (Adjusted) 
p-value HR CI p-value HR CI 
Exposure groups   
 Chronic HBV 0.7074 1.17 0.51-2.67 0.8530 1.11 0.38-3.18 
HBV-negative 0.9024 1.03 0.68-1.56 0.4872 1.18 0.75-1.86 
Resolved HBV -- 1.00 -- -- 1.00 -- 
HIV risk group   
 IDU  0.0053 1.80 1.19-2.71    
MSM  0.9560 1.01 0.65-1.59    
Heterosexual -- 1.00 --    
Insurance   
 Public 0.0674 2.00 0.95-4.21 0.3605 1.50 0.63-3.54 
Uninsured 0.9784 0.00 0.00-. 0.9793 0.00 0.00-. 
Unknown <0.0001 21.59 10.29-45.29 <0.0001 25.08 10.64-59.09 
Private -- 1.00 -- -- 1.00 -- 
Baseline age (10 years) <0.0001 1.44 1.22-1.71 0.0001 1.49 1.21-1.82 
Hepatitis C positivity at baseline     
 < 700 days of follow-up 0.7712 1.10 0.57-2.16 0.5022 0.77 0.36-1.65 
≥ 700 days of follow-up <0.0001 2.85 1.79-4.52 0.0005 2.38 1.46-3.88 
Baseline CD4 count (per 100 
cells/µL increase) 
<0.0001 0.78 0.72-0.84 <0.0001 0.77 0.70-0.84 
Baseline HIV RNA (per log10 
copies/mL increase) 
0.0022 1.09 1.03-1.16    
Being on HAART at baseline 0.0356 1.66 1.04-2.67 0.0334 1.92 1.05-3.49 
Being on HAART at endpoint 0.7382 0.82 0.26-2.59 0.0443 0.36 0.14-0.98 
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Table 4-6.  Cox proportional hazards regression modeling risk of virologic failure 
 
Characteristic 
Model 1 (Crude) Model 2 (Adjusted) 
p-value HR CI p-value HR CI 
Exposure groups     
 Chronic HBV 0.1291 1.61 0.87-2.98 0.1860 1.58 0.80-3.09 
HBV-negative 0.0004 1.64 1.24-2.15 0.0049 1.51 1.13-2.01 
Resolved HBV -- 1.00 -- -- 1.00 -- 
HIV risk group   
 IDU  0.1058 0.80 0.60-1.05    
MSM  0.0011 0.64 0.48-0.84    
Heterosexual -- 1.00 --    
Insurance   
 Public 0.0112 1.54 1.10-2.14 0.0280 1.48 1.04-2.09 
Uninsured 0.3418 0.57 0.18-1.83 0.3610 0.52 0.12-2.14 
Unknown 0.0307 1.56 1.04-2.33 0.0711 1.48 0.97-2.27 
Private -- 1.00 -- -- 1.00 -- 
Baseline age (per 10 year 
increase) 
0.0004 0.81 0.72-0.91    
Baseline CD4 count (per 100 
cells/µL increase) 
0.0023 0.94 0.91-0.98 <0.0001 1.10 1.05-1.15 
Endpoint CD4 count (per 
100 cells/µL increase) 
<0.0001 0.79 0.76-0.83 <0.0001 0.74 0.70-0.79 
On HAART at endpoint <0.0001 0.37 0.24-0.55 0.0938 0.68 0.43-1.07 
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Table 4-7.  Cox proportional hazards regression modeling risk of 10% CD4 cell 
decline 
 
Characteristic 
Model 1 (Crude) Model 2 (Adjusted) 
p-value HR CI p-value HR CI 
Exposure groups   
 Chronic HBV 0.4433 0.85 0.55-1.30 0.1596 0.72 0.46-1.14 
HBV-negative 0.1951 0.89 0.74-1.66 0.0164 0.79 0.65-0.96 
Resolved HBV -- 1.00 -- -- 1.00 -- 
Baseline HIV RNA (per log10 
copies/mL increase) 
0.0238 0.97 0.95-1.00 -- -- -- 
On HAART at baseline 0.0318 0.82 0.68-0.98 -- -- -- 
Endpoint HIV RNA (per log10 
copies/mL increase) 
<0.0001 1.18 1.15-1.21 <0.0001 1.16 1.13-1.19 
On HAART at endpoint <0.0001 0.33 0.26-0.42 0.0189 0.70 0.51-0.94 
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Figure 4-1. Kaplan-Meier survival curve – HBV and onset of clinical AIDS 
Log-rank p-value=0.0214  
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Figure 4-2. Kaplan-Meier survival curve – HBV and all-cause mortality 
Log-rank p-value=0.9317  
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Figure 4-3. Kaplan-Meier survival curve – HBV and virologic failure 
Log-rank p-value=0.0017  
  
148 
  
 
 
Figure 4-4. Kaplan-Meier survival curve – HBV and 25% decline in CD4 cell count 
Log-rank p-value=0.6253  
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Figure 4-5. Kaplan-Meier survival curve – HBV and 10% decline in CD4 cell count 
 
Log-rank p-value=0.4001.   
  
150 
  
 
4.8 List of references 
 
 
 
 
1. Centers for Disease Control and Prevention. HIV surveillance--United States, 
1981-2008. MMWR Morb Mortal Wkly Rep. Jun 3 2011;60(21):689-693. 
2. Prejean J, Song R, Hernandez A, et al. Estimated HIV incidence in the United 
States, 2006-2009. PLoS One. 2011;6(8):e17502. 
3. Murphy EL, Collier AC, Kalish LA, et al. Highly active antiretroviral therapy 
decreases mortality and morbidity in patients with advanced HIV disease. Ann 
Intern Med. Jul 3 2001;135(1):17-26. 
4. Schwarcz SK, Hsu LC, Vittinghoff E, Katz MH. Impact of protease inhibitors and 
other antiretroviral treatments on acquired immunodeficiency syndrome survival 
in San Francisco, California, 1987-1996. Am J Epidemiol. Jul 15 
2000;152(2):178-185. 
5. Chou R, Huffman LH, Fu R, Smits AK, Korthuis PT. Screening for HIV: a 
review of the evidence for the U.S. Preventive Services Task Force. Ann Intern 
Med. Jul 5 2005;143(1):55-73. 
6. Centers for Disease Control and Prevention. HIV Surveillance Report 20102012. 
7. Dore GJ, Cooper DA. The impact of HIV therapy on co-infection with hepatitis B 
and hepatitis C viruses. Curr Opin Infect Dis. Dec 2001;14(6):749-755. 
8. Feldman R, Friedman, L., Brandt, L.,, ed Sleisenger and Fordtran's 
Gastrointestinal and Liver Disease: Pathophysiology, diagnosis, managment. 9th 
ed. Philadelphia, PA: Saunders Elsevier; 2010. 
9. Sulkowski MS. Viral hepatitis and HIV coinfection. J Hepatol. Feb 
2008;48(2):353-367. 
10. Centers for Disease Control and Prevention. Viral hepatitis surveillance, United 
States 2009: National Center for HIV/AIDS, viral hepatitis, STD & TB 
prevention;2009. 
11. Centers for Disease Control and Prevention. Incidence of acute hepatitis B--
United States, 1990-2002. MMWR Morb Mortal Wkly Rep. Jan 2 2004;52(51-
52):1252-1254. 
12. Gish RG, Gadano AC. Chronic hepatitis B: current epidemiology in the Americas 
and implications for management. J Viral Hepat. Dec 2006;13(12):787-798. 
151 
  
 
13. Cohen C, Evans AA, London WT, Block J, Conti M, Block T. Underestimation of 
chronic hepatitis B virus infection in the United States of America. J Viral Hepat. 
Jan 2008;15(1):12-13. 
14. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 
2006;44(1 Suppl):S6-9. 
15. McMahon BJ. Natural history of chronic hepatitis B. Clin Liver Dis. Aug 
2010;14(3):381-396. 
16. Gilson RJ, Hawkins AE, Beecham MR, et al. Interactions between HIV and 
hepatitis B virus in homosexual men: effects on the natural history of infection. 
AIDS. Apr 1997;11(5):597-606. 
17. Benhamou Y. Hepatitis B in the HIV-coinfected patient. J Acquir Immune Defic 
Syndr. Jul 1 2007;45 Suppl 2:S57-65; discussion S66-57. 
18. Solomon RE, VanRaden M, Kaslow RA, et al. Association of hepatitis B surface 
antigen and core antibody with acquisition and manifestations of human 
immunodeficiency virus type 1 (HIV-1) infection. Am J Public Health. Dec 
1990;80(12):1475-1478. 
19. Sinicco A, Raiteri R, Sciandra M, et al. Coinfection and superinfection of 
hepatitis B virus in patients infected with human immunodeficiency virus: no 
evidence of faster progression to AIDS. Scand J Infect Dis. 1997;29(2):111-115. 
20. Konopnicki D, Mocroft A, de Wit S, et al. Hepatitis B and HIV: prevalence, 
AIDS progression, response to highly active antiretroviral therapy and increased 
mortality in the EuroSIDA cohort. AIDS. Mar 24 2005;19(6):593-601. 
21. Omland LH, Weis N, Skinhoj P, et al. Impact of hepatitis B virus co-infection on 
response to highly active antiretroviral treatment and outcome in HIV-infected 
individuals: a nationwide cohort study. HIV Med. May 2008;9(5):300-306. 
22. Hoffmann CJ, Seaberg EC, Young S, et al. Hepatitis B and long-term HIV 
outcomes in coinfected HAART recipients. AIDS. Sep 10 2009;23(14):1881-
1889. 
23. Law WP, Duncombe CJ, Mahanontharit A, et al. Impact of viral hepatitis co-
infection on response to antiretroviral therapy and HIV disease progression in the 
HIV-NAT cohort. AIDS. May 21 2004;18(8):1169-1177. 
24. Lincoln D, Petoumenos K, Dore GJ. HIV/HBV and HIV/HCV coinfection, and 
outcomes following highly active antiretroviral therapy. HIV Med. Jul 
2003;4(3):241-249. 
152 
  
 
25. Eskild A, Magnus P, Petersen G, et al. Hepatitis B antibodies in HIV-infected 
homosexual men are associated with more rapid progression to AIDS. AIDS. Jun 
1992;6(6):571-574. 
26. Ockenga J, Tillmann HL, Trautwein C, Stoll M, Manns MP, Schmidt RE. 
Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value. J 
Hepatol. Jul 1997;27(1):18-24. 
27. Chun HM, Roediger MP, Hullsiek KH, et al. Hepatitis B Virus Coinfection 
Negatively Impacts HIV Outcomes in HIV Seroconverters. J Infect Dis. Jan 
2012;205(2):185-193. 
28. Centers for Disease Control and Prevention. 1993 revised classification system 
for HIV infection and expanded surveillance case definition for AIDS among 
adolescents and adults. MMWR Recomm Rep. Dec 18 1992;41(RR-17):1-19. 
29. Kleinbaum DG, Klein M. Survival analysis: a self-learning text. 2nd ed. New 
York, NY: Springer; 2005. 
30. DelBello MP, Lopez-Larson MP, Soutullo CA, Strakowski SM. Effects of race on 
psychiatric diagnosis of hospitalized adolescents: a retrospective chart review. J 
Child Adolesc Psychopharmacol. Spring 2001;11(1):95-103. 
31. Schechter MS, Shelton BJ, Margolis PA, Fitzsimmons SC. The association of 
socioeconomic status with outcomes in cystic fibrosis patients in the United 
States. Am J Respir Crit Care Med. May 2001;163(6):1331-1337. 
32. Rothman KJ, Greenland S, Lash TL. Modern Epidemiology. 3rd ed. New York, 
NY: Lippencott Williams & Wilkins; 2008. 
33. Vittinghoff E, Glidden DV, Shiboski SC, McCulloch CE. Regression Methods in 
Biostatistics: Linear, logistic, survival, and repeated measures models. New 
York, NY: Springer; 2005. 
34. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected 
with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. Aug 
14-28 2006;166(15):1632-1641. 
35. Stephenson JM, Imrie J, Davis MM, et al. Is use of antiretroviral therapy among 
homosexual men associated with increased risk of transmission of HIV infection? 
Sex Transm Infect. Feb 2003;79(1):7-10. 
36. Diamond C, Richardson JL, Milam J, et al. Use of and adherence to antiretroviral 
therapy is associated with decreased sexual risk behavior in HIV clinic patients. J 
Acquir Immune Defic Syndr. Jun 1 2005;39(2):211-218. 
153 
  
 
37. Pasricha N, Datta U, Chawla Y, et al. Immune responses in patients with HIV 
infection after vaccination with recombinant Hepatitis B virus vaccine. BMC 
Infect Dis. 2006;6:65. 
38. Bailey CL, Smith V, Sands M. Hepatitis B vaccine: a seven-year study of 
adherence to the immunization guidelines and efficacy in HIV-1-positive adults. 
Int J Infect Dis. Nov 2008;12(6):e77-83. 
39. Launay O, van der Vliet D, Rosenberg AR, et al. Safety and immunogenicity of 4 
intramuscular double doses and 4 intradermal low doses vs standard hepatitis B 
vaccine regimen in adults with HIV-1: a randomized controlled trial. JAMA. Apr 
13 2011;305(14):1432-1440. 
 
 
 
 
154 
  
 
5 THE IMPACT OF HEPATITIS C CO-INFECTION ON HIV DISEASE 
PROGRESSION AMONG A POPULATION OF INDIVIDUALS 
ATTENDING AN URBAN HIV CLINIC 
 
5.1 Abstract 
Given shared routes of exposure, such as injection drug use, HCV co-infection is 
common among HIV-positive populations, with co-infection rates among HIV-positive 
individuals of approximately 25-30%.  Further, HIV-positive individuals are less likely to 
spontaneously clear their HCV infection compared to their HIV-negative counterparts.  
HIV has been shown to negatively impact progression of HCV, leading to more serious 
liver disease and related mortality.  However, the impact of HCV on HIV disease 
progression is less clear.  To investigate this relationship, we conduced a survival 
analysis using Cox proportional hazards regressions to model the risk of progression to 
four outcomes (clinical AIDS, all-cause mortality, HIV virologic failure, and a decline in 
CD4 count) based on HCV status (cleared infection, chronic infection, and HCV-
negative).  Among 1,680 HIV-positive patients attending a large, urban HIV clinic from 
2002-11, we found the prevalence of chronic HCV co-infection was 12%.  We found that 
HCV status may be related to faster progression to clinical AIDS and all-cause mortality 
(HR=1.46 and HR=1.67, respectively), although these did not reach statistical 
significance.  We also found that having a cleared HCV infection was associated with 
increased risk for progression to virologic failure compared to being HCV-negative 
(HR=2.70; 95% CI, 1.11-6.67).  We found no association between HCV status and 
decline in CD4 count.  Given high rates of co-infection coupled with decreased HCV 
viral clearance among HIV-positive individuals, a fuller understanding of the impact on 
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clinical HIV disease is important.  To achieve this, large prospective studies, especially 
those that include behavior data, are needed.   
 
5.2 Introduction 
HIV/AIDS continues to be a significant health concern in the United States (US), with an 
estimated 1.2 million American living with HIV/AIDS in 2008.  Co-infection with 
hepatitis C virus (HCV) is common among HIV-positive individuals, given their shared 
routes of exposure, such as percutaneous exposure (e.g., needle stick, blood transfusion), 
sexual contact, and perinatal exposure.1 It has been estimated that 25-30% of HIV 
infected individuals are co-infected with HCV.2  This is especially true among injection 
drug users (IDUs), with an estimated co-infection prevalence of 72-95%.   In the absence 
of HIV infection, it is estimated that approximately 20-25% of HCV infections will 
spontaneously clear, with the remaining developing into chronic infections.3-7 However, 
this percentage is reduced in HIV-positive populations (13-25%),8-14 leading to more 
rapid progression to HCV-related liver disease, including fibrosis, cirrhosis, and end 
stage liver disease, and increased mortality.4   
 
Although the incidence of new HIV diagnoses has remained stable over the past few 
years,15 people with HIV are living longer due to widespread accessibility of highly 
active antiretroviral therapy (HAART) and early identification of infections through 
routine testing.16-18  In 2009, 90% of infected individuals survived longer than 36 months 
following a HIV diagnosis and 84% following an AIDS diagnosis.19  With HIV-infected 
individuals living longer, the negative health outcomes due to chronic conditions, such as 
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liver disease from hepatitis C, are now a substantial public health concern.20-25 Being co-
infected with HIV and HCV has been shown to negatively impact the natural history of 
HCV disease progression, which can result in more rapid progression to liver fibrosis, 
cirrhosis, and liver-related death.26-28  However, the effect of HCV on HIV disease 
progression is less clear (Table 5-1). For example, a large longitudinal study within the 
Swiss HIV Cohort found an increased risk for AIDS or death among those co-infected 
with HCV (hazard ratio (HR)=1.7; 95% confidence interval (CI) 1.3-2.3).21  Decreased 
survival was also reported within another large longitudinal study recently conducted 
(relative risk (RR)=1.5; 95% CI, 1.2-1.9).29 However, other large longitudinal studies did 
not find similar results.  For example, a study conducted within a US HIV clinic found no 
association between HCV serostatus and risk for an AIDS defining illness (HR=1.03; 
95% CI, 0.86-1.23), death (HR=1.05; 95% CI, 0.85-1.30), or CD4 decline to < 200 
cells/µL (HR=1.28; 95% CI, 0.98-1.68).30  A large study conducted within the EuroSIDA 
study group also reported no association between HCV serostatus and AIDS or death 
(incidence rate ratio (IRR)=1.06; 95% CI, 0.89-1.28).31  Differences in previous findings 
may be due to differences between underlying populations, such as size, risk profile, and 
geographic location, and the ability to control for behavior confounders such as alcohol 
use. 
 
The objective of this study was to assess the impact of viral hepatitis C co-infection on 
the clinical progression of HIV and changes of virologic and immunologic disease 
indicators, specifically time to a new AIDS diagnosis, death from all causes, virologic 
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failure, and CD4 cell count decline.  To achieve this, we conducted a retrospective 
survival analysis on HIV-positive subjects attending a large urban HIV clinic.   
 
5.3 Methods 
Study population 
All patients who had at least two visits at the Drexel University’s College of Medicine’s 
Partnership Comprehensive Care Practice between the years 2002 and 2011 were eligible 
for inclusion in the study (n=2,880).   This practice provides routine primary and 
specialty HIV medical care to all HIV-positive persons, regardless of their ability to pay, 
and is the largest comprehensive HIV primary care practice in Philadelphia, serving 
1,900 patients in 2010. At each clinic visit, patients had comprehensive laboratory work 
(e.g., CD4 cell count, HIV viral load (VL), hepatitis testing), in accordance with clinical 
standards of care and practical guidelines at the time.  Subjects were excluded from the 
analysis if they were never tested for hepatitis C antibody (n=648), or if their hepatitis 
infection could not be further classified into resolved or chronic (n=552).  This left a total 
study population of 1,680 subjects. 
 
Hepatitis C exposure definitions 
Being HCV-positive was defined as having a positive HCV antibody (anti-HCV) test at 
any time from 2002-11. All subjects were classified into the following mutually exclusive 
groups based on HCV status: cleared infection (n=32), defined as having no detectable 
HCV RNA VL at any time after having a positive anti-HCV test; chronic infection 
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(n=207), defined as having detectable HCV VL following a positive anti-HCV test; and 
HCV-negative (1,441).  
 
Additional definitions 
A baseline date was defined for each mutually exclusive HCV exposure status group.  
For those with a chronic HCV infection, the date of the first positive anti-HCV test was 
used.  For those with a resolved HCV infection, the date of the first test result with 
undetectable HCV RNA VL was used.  For those that were HCV-negative, the date of the 
first negative HCV test was used as the baseline date.   
  
HIV therapy was defined at two time points during the study: at baseline and at time of 
outcome or censoring.  Highly active antiretroviral therapy (HAART) was defined as any 
of the following combinations:  ≥ 2 protease inhibitors (PI) and ≥ 1 nucleoside reverse 
transcriptase inhibitor (NRTI), without a non-nucleoside reverse transcriptase inhibitor 
(NNRTI) (PI-containing HAART); ≥ 2 NNRTI and ≥ 1 NRTI, without PI (NNRTI-
containing HAART); ≥ 1 NNRTI and ≥ 2 NNRTI, without PI (NNRTI-containing 
HAART); ≥ 1 PI and ≥1 NNRTI and ≥ 1 NRTI (PI- and NNRTI-containing HAART); 
and a fusion inhibitor, entry inhibitor, or integrase inhibitor, not meeting a definition 
above (other HAART). Those not meeting one of the above definitions were considered 
not to be on HAART.  Initial HIV therapy was defined as medication taken within 3 
months of entry into the cohort.  Endpoint HIV therapy was defined as therapy at time of 
endpoint.  To improve statistical efficiency, all HAART categories were collapsed into 
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one category and included as a separate variable in multivariate analysis (Model 2) while 
specific HAART categories were used in Model 3 of the multivariate analysis. 
 
CD4 cell count was also defined at two time points, baseline and endpoint.  If available, 
the CD4 cell count taken on the baseline date was used for the baseline value (n=1,559; 
94%).  If this was not available, then subsequent values were used.  If the difference 
between the first two values following the baseline date was ≤ 10% and both were within 
six months of baseline, then the mean of these values was used as the baseline value 
(n=18; 1%).  If the difference was greater than 10%, then the first value following 
baseline was used, as long as it was within six months of the baseline date (n=74; 4%).  
Twenty-eight subjects did not meet any of the criteria above and therefore had a missing 
baseline CD4 cell count value.  Endpoint CD4 cell count was defined as the CD4 cell 
count taken at time of outcome or censoring.   
 
HIV RNA VL was also defined at two time points, baseline and endpoint.  A similar 
approach was used to define baseline HIV VL as is describe above for baseline CD4 cell 
count, resulting in 92% of subjects with a VL taken on the baseline date.  Fifty-six 
subjects did not meet any of the criteria above and therefore had a missing baseline HIV 
VL.  Endpoint HIV VL was defined as the HIV VL taken at the time of outcome or 
censoring.  HIV VL values were transformed to the log scale. 
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Baseline values were also defined for age, and hepatitis B virus (HBV) and HBsAg 
positivity.  Baseline age was defined as the age on the baseline date.  HBV and HBsAg 
positivity was defined as having a reactive test within 30 days of baseline date.   
 
Outcome definitions 
Four outcomes of interest were identified.  Onset of clinical AIDS was defined as a 
diagnosis of an opportunistic infection or AIDS-defining event using the 1993 Centers for 
Disease Control and Prevention classification, including a CD4 count < 200 cells/µl, 
pneumocystis carinii pneumonia, cytomegalovirus, herpes simplex, pulmonary 
tuberculosis, Kaposi’s sarcoma, toxoplasmosis, crypotococcosis, candidiasis, and 
mycobacterium avium complex.32  In this population, 46% of subjects reached this 
outcome definition due to a decreased CD4 cell count.  Death from any cause was 
provided in the data.  We could not use AIDS-related death as an outcome, as cause of 
death was not available in the data.   HIV virologic failure was defined as a HIV VL 
result ≥ 1,000 copies/ml.  CD4 cell decline was defined in two ways: a decline of CD4 
count of at least 10% or 25% in CD4 count from baseline on two consecutive visits. Only 
those at risk for each outcome were eligible to reach the outcome as an endpoint.  For 
example, only those with a HIV VL < 1000 were eligible to reach virologic failure.  All 
subjects were followed until they achieved each of the outcomes.  All other subjects were 
censored at 5.6 years (2,043 days).  Although there was additional follow-up time 
available for a small number of subjects, there was considerable subject drop-off after 
this period and using this date ensured that at least 90% of subjects were being followed 
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for each outcome (i.e., the smallest of the 90th percentiles for follow-up time for each 
outcome of interest). 
 
Analysis 
Three HCV exposure groups (resolved infection, chronic infection, and negative) were 
summarized using descriptive statistics.  Due to small sample size, only chronic infection 
and HCV-negative groups could be summarized and analyzed the endpoints of clinical 
AIDS and all-cause mortality.  For continuous variables, means were presented with 
standard deviations and were compared with Wilcoxon tests. For categorical variables, 
differences in proportions were compared with χ tests.  Exact methods (e.g., Fischer’s 
exact test) were used with small cell counts.  A two-sided alpha level of 0.05 was used to 
determine statistical significance.   
 
Kaplan Meier (KM) curves were generated for each combination of hepatitis exposure 
and event to univariately assess differences in survival for each event using the log-rank 
test.  In order to adjust to potential confounders, a Cox proportional hazards (PH) model 
was used to assess the risk of event.  A Cox PH model test was chosen over other 
survival models because of its semi-parametric properties, meaning it does not assume 
the distribution of the baseline hazard function.33  The following factors were assessed as 
potential confounders: demographics (sex, race, HIV risk group, age, year of HIV 
diagnosis and type of insurance); HIV antiretroviral therapy; HIV VL; CD4 cell count; 
and hepatitis B positivity.  Insurance status (private, public, uninsured, or unknown) was 
used as a proxy for socioeconomic status.34,35  By definition, confounders have to be 
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associated with both the exposure and the outcome.36  Therefore, the statistical 
significance of each potential confounder to HCV status was assessed using a χ test 
for categorical variables or a Wilcoxon test for continuous variables.37  Next, potential 
confounders were assessed univariately in a regression model to determine if they were 
statistically associated with the outcome of interest.   A backward selection approach was 
used to build the final Cox PH model. The first step of this process involves building an 
initial regression model that contains the exposure of interest plus all potential 
confounders that reached statistical significance at an alpha level of 0.10.36  Next, 
variables were removed from the model one at a time based on the corresponding p-value 
and the model was re-run.  This process continued iteratively until only variables 
reaching statistical significance at an alpha level of 0.05 were included in the model.  
This backward selection approach was modified to allow investigators to include 
variables that did not reach statistical significance (i.e., “force in”), but were thought to 
be a potential confounder due to prior knowledge.   The following variables were forced 
into the models: age (outcome of all-cause mortality); and HIV therapy at endpoint 
(outcome of virologic failure).  Additionally, if HIV therapy broken into discrete HAART 
categories reached statistical significance, the corresponding collapsed variable was 
forced into the alternate analysis, and vice versa.  In an attempt to build the most 
parsimonious regression model, regression model building also used the 10% change-in-
estimate approach to identify variables that confounded the relationship between HCV 
status and the outcome of interest.  Here, variables were considered potential confounders 
if they changed the main effect estimate by more than 10% when they were removed.36   
 
163 
  
 
Once all potential confounders were identified using the modified backward selection 
approach described above, diagnostics were performed to evaluate the PH assumption for 
each variable.33  To assess this assumption, the log-log survival (LLS) curve was plotted 
with survival time in days on the horizontal axis for each variable (see Appendix C).  If 
the stratum-specific curves were parallel, indicating the survival functions did not vary 
with time, then the variable was considered to be time-independent.  When visual 
inspection of the LLS was inconclusive or revealed time dependence, a goodness of fit 
(GOF) test was run to test the statistical significance of the PH assumption, by looking 
for a correlation between the Schoenfeld residuals and the ranking of the individual 
failure times.  In this analysis, the null hypothesis is that the correlation is zero, therefore 
if the p-value was < 0.05, then there was enough statistical evidence to say that the PH 
assumption is violated for that variable.  For time-dependent variables, the LLS curves 
were used to determine the most appropriate time cut-offs to define areas of varying 
survival functions and create heavyside functions for those variables.  Each time-
dependent variable was tested univariately in the model for statistical significance.  
Statistically significant time dependent variables were included in the final extended Cox 
PH model.   From the PH model, hazard ratios were generated with 95% confidence 
intervals.  For all univariate and multivariate analyses, an alpha of 0.05 was used to 
determine statistical significance.   
 
All analyses were conducted in SAS 9.2. This study was approved by the Drexel College 
of Medicine Institutional Review Board (IRB).  
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5.4 Results 
In this population of 1,680 HIV-positive individuals attending an urban HIV clinic, we 
found the prevalence of chronic HCV infection to be 12.3%, and an additional 1.9% of 
individuals had evidence of a past HCV infection and 85.7% were HCV-negative.  
During the study period, subjects had an average of 13.4 clinic visits over an average of 
5.1 years.  Those in the chronic HCV group were predominantly male (69.4%), Black 
(61.8%), and reported IDU risk behavior (60.9%) (Table 5-2).  Comparing the three 
exposure groups, there were significant differences in the following demographic 
characteristics: sex (p=0.0389), race (p<0.0001), HIV risk group (p<0.001), insurance 
type (p=0.0388), and age (p<0.0001).  There were also significant differences by HBV 
positivity (p=0.0011), with the smallest HBV prevalence among the HCV-negative group 
(38.7%), HBsAg positivity (p=0.0025), year of HIV diagnosis (p=0.0010), and all HIV 
therapy at each of the outcomes of interest, but not at baseline.   
 
Among study subjects, a > 10% decline in CD4 cell count was the most common 
outcome (38% of subjects) followed by HIV virologic failure (35%), a > 25% decline in 
CD4 cell count (25%), a new AIDS diagnosis (10%), and death from all causes (6%) 
(Table 2).  The average follow-up times for new AIDS diagnosis, all-cause mortality, 
HIV virologic failure, and 25% and 10% CD4 cell decline was 967 days, 1,187 days, 822 
days, and 1,059 days, and 933 days, respectively.   
 
Figures 5-2 through 5-5 show the KM survival curves for each of the outcome of interest, 
stratified by HCV exposure status. From Figure 5-2, it appears that those with a chronic 
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HCV infection have a lower survival to clinical AIDS, compared to those with a resolved 
infection and who were HCV-negative. Similarly, for all-cause mortality, survival 
appeared to differ based on HCV status after three years of follow-up, with those with a 
resolved HCV infection having the greatest survival (Figure 5-2, p=0.1357).  There 
seems to be a difference for a 25% decrease in CD4 cell count, with those with a resolved 
infection having the greatest survival (Figure 5-4, p=0.0133), but only for the more 
modest 10% decrease in CD4 count outcome after approximately two years of follow-up 
(Figure 5-5, p=0.0273).  Figure 5-3 shows that the association between HCV status and 
HIV virologic failure is unclear (p=0.9136). 
 
Clinical AIDS 
Results from the Cox PH model for the risk of developing clinical AIDS are shown in 
Table 3.  Insurance type was found to be time-dependent, with varying survival functions 
±550 days of follow-up (see Appendix C).  Without adjustment for possible confounders 
(Model 1), a chronic HCV infection was borderline significantly associated with 
increased risk of a new AIDS diagnosis compared to those who were HCV-negative 
(HR=1.52; 95% CI, 0.95-2.41). The following variables were also associated with 
increased risk for clinical AIDS: public compared to private insurance when follow-up 
time was less than 550 days (HR=5.59; 95% CI, 1.73-18.01); unknown compared to 
private insurance; and higher baseline and endpoint HIV VL (HR=1.27 per log10 
increase; 95% CI, 1.11-1.36, and HR=1.54 per log10 increase, 95% CI, 1.36-1.74, 
respectively).  
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When adjusted for other significant factors, results from multivariate Model 2 suggests 
that those with a chronic HCV infection had a probable increased risk for clinical AIDS 
when compared to those who were HCV-negative (HR=1.46), although this did not reach 
statistical significance (95% CI, 0.91-2.32) (Table 3).  Additionally, being on public or 
unknown insurance were associated with increased risk for progression to clinical AIDS. 
Results from multivariate models 2 and 3 had similar results with respect to magnitude of 
effect and statistical significance for the exposure variable of interest and the 
confounders, with the exception that being on a PI- and NNRTI-containing HAART 
regimen at endpoint was significantly associated with increased risk for AIDS compared 
to NNRTI-containing HAART (HR=3.13; 95% CI, 1.19-8.33) (see Appendix B).  
  
When using the change-in-estimate approach to identify confounders of the relationship 
between HCV status and onset of clinical AIDS, none of the factors identified in model 2 
changed the estimate at least 10% when removed from the model.  Therefore, no 
confounders were identified using this approach.  Here, chronic HCV was associated with 
a 1.5-fold increase in the risk of onset of clinical AIDS compared to those who were anti-
HCV-negative, although this did not reach statistical significance (HR=1.52; 95% CI, 
0.95-2.41). 
 
All-cause mortality 
Results from the Cox PH model modeling the risk for all-cause mortality are shown in 
Table 4.  Univariate analysis (Model 1) shows that having a chronic HCV infection is 
borderline significantly associated with increased risk for all-cause mortality (HR=1.67; 
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95% CI, 0.99-2.76).  Additionally, the following were statistically associated with 
increased risk for all-cause mortality: having public or unknown insurance compared to 
private insurance (HR=2.92; 95% CI, 1.16-7.37, and HR=34.64, 95% CI, 13.75-87.29); 
older age (HR=1.43 per 10 year increase, 95% CI, 1.18-1.74); more recent HIV diagnosis 
(HR=1.05 per 1 year increase; 95% CI, 1.00-1.11); lower baseline CD4 count (HR=1.33 
per 100 cells/µl increase; 95% CI, 1.22-1.47); higher baseline HIV VL (HR=1.27 per 
log10 increase; 95% CI, 1.10-1.47); being on HAART at baseline (HR=1.92; 95% CI, 
1.12-3.30); and not being on HAART at endpoint (HR=2.94, 95% CI, 1.79-4.76) (Table 
4).    
 
Multivariate analysis (Model 2) shows an potential increased risk for death among those 
with a chronic infection compared to those who were HCV-negative (HR=1.67), adjusted 
for type of insurance, baseline age, year of HIV diagnosis, and endpoint HAART 
although this did not reach statistical significance (95% CI, 0.82-3.36) (Table 4).  The 
following factors remained significantly associated with increased risk for all-cause 
mortality on multivariate analysis: having unknown insurance compared to private 
insurance (HR=45.92, 95% CI, 10.62-198.61); older age (HR=1.85, 95% CI, 1.37-2.51); 
having a more recent HIV diagnosis (HR=1.08 per 1 year increase; 95% CI, 1.02-1.14); 
and not being on HAART at endpoint (HR=4.17; 95% CI, 1.96-8.33).  Results from 
multivariate models 2 and 3 had similar results with respect to magnitude of effect and 
statistical significance for the effect of HCV exposure group and the confounders on all-
cause mortality, with the exception that type of endpoint HAART was no longer 
statistically associated with the outcome (see Appendix B).  Visual inspection of the LLS 
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curves and results from the goodness of fit test did not identify any variables that violated 
the PH assumption (see Appendix C for LLS curves for each variable in Model 2).   
 
When the change-in-estimate approach was used, insurance, age, and year of HIV 
diagnosis changed the estimate more than 10% when they were removed from the model.  
Adjusted for these confounders, the data suggested those with a chronic HCV infection 
had an increased risk for all-cause mortality compared to those who were anti-HCV-
negative, although this did not reach statistical significance (HR=1.60; 95% CI, 0.83-
3.05). 
 
Virologic failure 
Table 5 shows the following variables were univariately associated with risk of virologic 
failure (Model 1): reporting heterosexual compared to MSM HIV risk behavior 
(HR=1.45, 95% CI, 1.14-1.89); having public or unknown insurance compared to private 
insurance (HR=1.36, 95% CI, 1.00-1.85, and HR=1.72, 95% CI, 1.18-2.50, respectively); 
younger age (HR=1.27 per 10 year decrease, 95% CI, 1.43-1.12); lower baseline and 
endpoint CD4 cell count (HR=1.05; 95% CI, 1.01-1.09, per 100 cells/µl decrease, and 
HR=1.19, 95% CI, 1.18-1.28, per 100 cells/µl decrease, respectively); and not being on 
HAART at endpoint (HR=2.22, 95% CI, 1.61-3.03). 
 
Multivariate analysis (Model 2) shows that those who cleared their HCV infection had a 
2.7-fold increase for virologic failure (95% CI, 1.11-6.67) compared to those who were 
HCV-negative, when adjusted for potential confounders (Table 5).  Additionally, those 
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that cleared their HCV infection had an increased risk of failure compared to those with a 
chronic infection, although this did not reach statistical significance (HR=2.44; 95% CI, 
0.95-6.25).  The following factors were significantly associated with increased risk for 
virologic failure on multivariate analysis: reporting MSM versus heterosexual risk 
(HR=1.45; 95% CI, 1.10-1.89); having unknown insurance status compared to private 
insurance (HR=1.71, 95% CI, 1.14-2.55); younger age (HR=1.20 per 10 year decrease, 
95% CI, 1.06-1.37); lower endpoint CD4 (HR=1.20 per 100 cells/µl decrease; 95% CI, 
1.15-1.27); and not being on HAART at endpoint (HR=1.82, 95% CI, 1.30-2.50). Results 
from multivariate models 2 and 3 had similar results with respect to magnitude of effect 
and statistical significance for the exposure variable of interest and the confounders (see 
Appendix B).    Visual inspection of the LLS curves and results from the goodness of fit 
test did not identify any variables that violated the PH assumption (see Appendix C for 
LLS curves for each variable in Model 2).   
 
When using the change-in-estimate approach, endpoint CD4 count and being on HAART 
at endpoint changed the main effect estimates by at least 10% when removed from the 
model.  Adjusted for these confounders, the data suggested that those with a resolved 
HCV infection had greater risk for virologic failure compared to those with a chronic 
infection and those who were anti-HCV-negative, although these did not reach statistical 
significance (HR=2.27; 95% CI, 0.88-5.88, and HR=2.17; 95% CI, 0.88-5.26, 
respectively). 
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CD4 cell decline 
Table 6 shows the following variables are univariately associated with increased risk for 
a 25% decline in CD4 count from baseline: having unknown compared to private 
insurance (HR=1.70; 95% CI, 1.20-2.40); higher endpoint HIV VL (HR=1.74 per log10 
increase; 95% CI, 1.62-1.86); and not being on HAART at endpoint (HR=1.43; 95% CI, 
1.14-1.79).  
 
Multivariate analysis (model 2) shows there was no significant difference in the risk of a 
25% decline in CD4 count from baseline between those with a chronic HCV infection or 
who were HCV-negative compared to those who cleared their infection, adjusted for 
other associated factors (Table 6).  Factors that remained significantly associated with 
risk of CD4 cell decline on multivariate analysis included: unknown compared to private 
insurance (HR=1.73; 95% CI, 1.21-2.48); younger age (HR=1.12 per 10 year decrease; 
95% CI, 1.01-1.27); and not being on HAART at baseline (HR=1.39; 95% CI, 1.11-1.75).  
Results from multivariate models 2 and 3 had similar results with respect to magnitude of 
effect and statistical significance for the exposure variable of interest and the confounders 
(see Appendix B).   Visual inspection of the LLS curves and results from the goodness of 
fit test did not identify any variables that violated the PH assumption (see Appendix C for 
LLS curves for each variable in Model 2).   
 
When using the change-in-estimate approach, only being on HAART at endpoint 
changed the HCV status effect estimates by at least 10% when removed. Adjusted for this 
confounder, there was no significant difference in the risk of a 25% decline in CD4 count 
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from baseline between those with a chronic HCV infection or who were HCV-negative 
compared to those who cleared their infection (HR=2.93; 95% CI, 0.71-12.04, and 
HR=2.27; 95% CI, 0.56-9.10). 
 
Analysis using a CD4 cell count decline of at least 10% as an endpoint yielded similar 
results with respect to magnitude of association between hepatitis C exposure and CD4 
cell decline, however these results did not reach statistical significance (see Appendix B).   
5.5 Discussion 
The seroprevalence of HCV in this HIV-positive population attending a large, urban HIV 
clinic was 34%.  This is consistent with findings from previous research; studies with a 
low proportion of IDUs have found HCV prevalence to be 15-16%,25,38 while a large 
study comprised of 36% IDUs reported HCV prevalence to be 37%.21   The findings of 
this study suggest that HCV status impacts time to clinical AIDS, and virologic failure, 
but is not associated with differences in risk of all-cause mortality or a decline in CD4 
cell count.  In this HIV-positive clinic population, we found that having a chronic HCV 
infection as associated with an almost 50% increase in risk of clinical AIDS compared to 
those who were HCV-negative.  Additionally, those with a resolved HCV infection were 
at the greatest risk for virologic failure.   
 
Our findings suggest that compared to those who were HCV-negative, those with a 
chronic infection had almost a 1.5-fold increased risk for new AIDS diagnosis and 1.7-
fold increased risk for all-cause mortality, although these did not reach statistical 
significance.  This is consistent with previous research consisting of a study of 238 HIV 
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infected patients that reported an increased risk for AIDS of comparable magnitude 
(HR=1.64; 95% CI, 1.06-2.55).39   Further, a study conducted using the Swiss HIV 
Cohort reported a 1.7-fold increase in risk of the composite endpoint of clinical AIDS or 
death among those co-infected with HCV.21  A recent study that specifically looked at the 
effect of HCV status on subjects with AIDS reported a 50% increase in risk for mortality 
(RR=1.5; 95% CI, 1.2-1.9).29  However, in light of these findings, the effect of HCV 
infection on progression of clinical AIDS or death is still debatable, as multiple 
longitudinal studies have reported no association with HCV co-infection.30,31,40-43  Some 
of these studies are limited by small sample size,21,30,39-43 short follow-up periods, and 
limited HIV VL data.39,41 
 
Interestingly, when modeling the risk for AIDS, multivariate Model 3 showed that being 
on PI- and NNRTI-containing HAART at endpoint increased the risk for AIDS compared 
to NNRTI-containing HAART (HR=3.13).  Further inspection of the data revealed that 
those on PI- and NNRTI-containing HAART had a lower average baseline CD4 cell 
count compared to those on NNRTI-containing HAART (426 vs. 475 cells/µl; p=0.0751).  
Although this does not explain the protective effect of being on PI-containing HAART, 
this does indicate that those on PI- and NNRTI-containing HAART were somewhat less 
healthy at entry into the cohort which may explain their increased risk for death. 
 
Few studies have assessed the effect of HCV co-infection on changes in HIV VL.  Of the 
few that did, no significant association was reported.21,31,43 However, these studies differ 
from the current analysis in that only used HCV serostatus (i.e., anti-HCV-positive), 
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while we were able to further distinguish and analyze subjects that cleared their infection 
and those that had a chronic infection.  We found those with a resolved HCV infection 
had quicker progression to virologic failure compared to those who were HCV-negative. 
We also noted younger age was associated with an increased risk for virologic failure.  
This could be due to non-adherence in this group, which has been previously been 
reported.44,45 It has been hypothesized that this may be due to lifestyle differences, a 
decreased awareness of one’s own mortality leading to less motivation to care for one’s 
health, and the survivor effect.46 However, adherence was not measurable in our study 
population.   
 
Similar to what others have reported, we found no association between HCV status and 
changes in CD4 cell count, although a wide array of outcome definitions have been 
previously used, making it challenging to directly compare results.30,31,39,41,43  
 
Although our study suggests that HCV co-infection among HIV-positive individuals may 
impact clinical progression to AIDS, survival, and virologic failure, it is limited in a 
number of ways.  First, we relied on analysis of data previously collected during routine 
clinical care at a large HIV clinic.  The inability to investigate the possible impact of 
potentially important factors, such as active injection drug use, alcohol use, HCV therapy, 
and HCV genotype, which may have resulted in residual confounding due to unmeasured 
factors.21,43,44,47,48 Further, as mentioned above, we did not have cause of death data 
available.  HCV directly causes mortality, and previous studies have found that the many 
of deaths in co-infected individuals were liver-related.29,49 Additionally, we sought out to 
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use insurance type as a proxy for socioeconomic status, as has been done in previous 
research.34,35 However, 23% of our study population did not have insurance information 
available, leading to the possibility of misclassification of this factor.  This group was 
associated with a remarkable 45-fold increase in all-cause mortality compared to those 
with private insurance.  Further inspection of the data found that these subjects were 
more likely to report IDU as their HIV risk behavior (18 vs.10%; p=0.0101) and had a 
higher average HIV RNA VL at time of endpoint (i.e., death or censoring)  (2.9 vs. 2.1 
log10 copies/mL; p<0.0001).  They were also less likely to be on a HAART regimen at 
time of endpoint (44 vs. 88%; p<0.0001). The significant difference in the proportion 
reporting IDU suggests that perhaps these individuals were dying to causes un-related to 
HIV, such as drug overdose.  However, this information could not be gleaned from the 
data.  Also, although not measureable in this population, active drug users are more likely 
to be non-adherent to prescribed HAART,50 which may affect virologic control and 
ultimately mortality. Additionally, if those with unknown insurance were truly uninsured 
or on public insurance, lack of private insurance could be a marker for being less healthy 
and therefore unable to be employed.  However, the data did that support this, as there 
was no statistical difference in baseline CD4 count between those with private insurance 
and those with unknown insurance (470 vs. 460 cells/µL; p=0.6168).   
 
Although subjects had up to nine repeated measures for HCV antibody test, subjects had 
a maximum of three HCV VL tests and average of 1.7 tests available in the dataset, so we 
were unable to require two consecutive undetectable HCV VL results in our HCV 
clearance definition.  This may have led to misclassification of chronicity, but other co-
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infection studies have used only one measurement given limited repeated HCV RNA 
tests available.8,12    
 
This study was conducted within an urban HIV clinic in the Northeast and may not be 
generalizable to other HIV-positive populations.  Although we had a similar distribution 
of IDUs in our population (17% compared to 22% nationally),19 we had a much larger 
proportion of subjects reporting heterosexual risk as the lone HIV risk factor (47% in our 
study to 26% nationally).   Further, as this study was conducted in a clinic population, it 
is possible that subjects included in our study may differ with respect to health-seeking 
behaviors, risky sexual behavior, and adherence to antiretroviral therapy than the general 
HIV population.51,52 
 
Despite these limitations, our study contributes the existing knowledge base.  We had a 
larger and more heterogeneous population of HIV-positive subjects in which to assess the 
impact of HCV status compared to previous studies.39-42,53-55 Our 10 years of clinical data 
contained up to 50 repeated measures for CD4 cell count and HIV RNA levels and nine 
for HCV antibody test,  The average follow-up for subjects was 2.7 years, which is longer 
than previous studies.21,30,42,43,53  Further, some previous research based exposure status 
on anti-HCV only, without considering the effect of chronic or resolved infections.21,31  
 
We found a high prevalence of HCV co-infection among HIV-positive subjects attending 
an urban HIV clinic.  Our findings showed that HCV co-infection can negatively impact 
HIV outcomes, specifically clinical progression to AIDS and survival.  This underscores 
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the need on both a population and individual level to decrease the burden of co-infections 
by reducing the number of new HCV infections among HIV-positive individuals and vice 
versa.   This can be accomplished by broad based routine screening for HCV among 
HIV-positive populations. In addition to screening, positive findings must be effectively 
communicated to patients; a recent study found that one-third of those co-infected were 
unaware of their HCV infection.29 Heightened HCV awareness will also be important to 
reduce potentially harmful behaviors, such as active injection drug use and heavy alcohol 
use.  Fully understanding viral hepatitis co-infections among those infected with HIV can 
aid therapeutic decisions for both viruses.  This will particularly be important as co-
infected individuals will live longer and have the potential to suffer from increased 
morbidity due to HCV.  
 
In conclusion, we found HCV co-infection impacted HIV disease progression, 
specifically for clinical progression to AIDS, survival, and virologic failure.  As use of 
effective HAART increases and those infected with HIV have increased survival, the 
negative health impacts of viral co-infections, such as hepatitis C, will continue to be a 
substantial public health concern.  Increased screening for hepatitis C among HIV-
positive individuals and thoughtful implementation of HCV and HIV therapy to further 
reduce HIV-related morbidity and mortality remains a primary component of reducing 
the burden of a hepatitis C co-infection among HIV-positive individuals. 
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5.6 Tables and Figures 
 
 
 
Table 5-1. Summary of studies on the impact of HCV co-infection on HIV disease progression 
Author 
(Year) 
Study 
population 
Findings: impact on 
Comments AIDS 
Death 
 
AIDS or 
death 
Change in 
HIV VL 
Change in 
CD4 count 
Branch 
(2012)29 
N=2,025 HIV+ 
US 
-- 
Chronic vs. 
HBV- 
HR=1.5, 
among those 
with AIDS 
-- -- -- 
• Prospective study (Cox PH) 
• 6.1 years follow-up 
(median) 
Sullivan 
(2006)43 
N=10,481 HIV+ 
US 
 
-- -- No impact No impact No impact 
• Prospective study (Cox PH) 
• 1.9 years follow-up 
(median) 
• HCV diagnosis from 
medical chart notes, not 
necessarily available lab 
results 
Rockstroh 
(2005)31 
N=5,957 HIV+ 
EuroSIDA 
-- 
Liver-
related, 
HCV+ vs. 
HCV- 
(IRR=11.7) 
No impact No impact No impact 
• Prospective study (Cox PH) 
• 3.5 years follow-up 
(median) 
• Used HCV serostatus 
• CD4 count definition - 
>50% increase 
Sulkowski 
(2002)30 
N=1,955 HIV+ 
US No impact No impact -- -- No impact 
• Prospective study (Cox PH) 
• 2.1 years follow-up 
(median) 
Greub 
(2000)21 
N=3,111 HIV+ 
Swiss HIV 
Cohort 
-- -- 
HCV+ vs. 
HCV- 
(HR=1.7) 
No impact 
Increased 
CD4 count 
(HR=0.8) 
• Prospective study (Cox PH) 
• 2.3 years of follow-up 
• Used HCV serostatus 
Staples 
(1999)40 
N=350 HIV+ 
US -- No impact -- -- -- 
• Prospective study (Cox PH) 
• Up to 12 years follow-up 
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Macias 
(1998)42 
N=328 HIV+ 
Spain 
On HAART 
-- No impact -- -- -- 
• Prospective study (Cox PH) 
• 2.3 years follow-up 
(median) 
Piroth 
(1998)39 
N=238 HIV+ 
France HCV+ vs. 
HCV- 
(HR=1.6) 
-- -- -- No impact 
• Prospective study (Cox PH) 
• 3 years follow-up (median) 
• No HIV VL data 
• Used 50% decrease for CD4 
response 
Ockenga 
(1997)53 
N=232 HIV+ 
Germany 
-- 
Decreased 
survival 
HCV+ vs. 
HCV- (267 
vs. 439 
days) 
-- -- -- 
• Prospective study 
• 1.5 years follow-up 
Sabin 
(1997)54 
N=111 HIV+ 
UK 
Hemophiliacs 
Genotype 1 
vs. others 
(HR=2.9) 
Genotype 1 
vs. others 
(HR=3.0) 
-- -- -- 
• Prospective study (Cox PH) 
Dorrucci 
(1995) 
41 
N=416 HIV+ 
UK 
No impact -- -- -- -- 
• First longitudinal study 
• 2.5 years follow-up 
(median) 
• No information on HIV VL 
Wright 
(1994)55 
N=512 HIV+ 
US 
83% MSM 
 
-- No impact -- -- -- 
• Prospective study (Cox PH) 
• 2.3 years follow-up (mean) 
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Table 5-2. Population characteristics by HCV status (N=1,680) 
Characteristic 
Resolved HCV 
infection (N=32) 
Chronic HCV 
infection 
(N=207) 
HCV-negative 
(N=1,441) 
 
 
p-value 
comparing 
3 groups* 
p-value  
comparing 
chronic HCV 
and HCV-
negative* 
N (%) N (%) N (%) 
Male sex 15 (46.9) 143 (69.4) 922 (64.5) 0.0389 0.1642 
Race  
 Black 19 (59.4) 128 (61.8) 1089 (76.0) 
<0.0001 <0.0001 White 10 (31.3) 53 (25.6) 198 (13.8) 
Hispanic 3 (9.4) 26 (12.6) 146 (10.2) 
HIV risk group  
 Heterosexual 11 (35.5) 47 (22.7) 722 (50.6) 
<0.0001 <0.0001 Any IDU 16 (51.6) 126 (60.9) 144 (10.1) 
MSM 4 (12.9) 34 (16.4) 562 (39.4) 
Insurance type  
 Private 2 (7.7) 16 (8.1) 209 (15.4) 
0.0388 0.0347 Public 21 (80.8) 129 (65.5) 798 (58.6) Uninsured 0  3 (1.5) 36 (2.6) 
Unknown 3 (11.5) 49 (24.9) 318 (23.4) 
Age at baseline (years) (mean (SD)) 45.3 (8.3) 45.4 (8.3) 40.0 (10.2) <0.0001 <0.0001 
HBV positivity at baseline 20 (64.5) 116 (61.4) 515 (38.7) 0.0011 0.0003 
HBsAg positivity at baseline 6 (20.0) 6 (3.3) 86 (6.8) 0.0025 0.0756 
Year of HIV diagnosis  
 < 1990 4 (13.8) 27 (14.0) 90 (7.0) 
0.0010 0.0003 1990-1999 14 (48.3) 94  (48.7) 556 (43.4) 
≥ 2000 11 (37.9) 72 (37.3) 635 (49.6) 
CD4 count at baseline (cells/µL) 
(mean (SD)) 
485 (291) 445 (279) 440 (288) 0.6745 0.7357 
HIV RNA at baseline (log10 
copies/mL) (mean (SD)) 
3.0 (1.3) 3.2 (1.4) 2.9 (1.2) 0.4020 0.3299 
HIV therapy at baseline  
 PI- and NNRTI-containing HAART 2 (7.1) 6 (3.1) 58 (4.5) 
0.1182 0.0499 
PI-containing HAART 15 (53.6) 92 (48.2) 504 (38.7) 
NNRTI-containing HAART 6 (21.4) 38 (19.9) 375 (28.8) 
NRTI alone HAART 1 (3.6) 6 (3.1) 49 (3.8) 
Not on HAART 4 (14.3) 49 (25.7) 315 (24.2) 
On HAART at baseline 24 (85.7) 142 (74.3) 986 (75.8) 0.4231 0.6647 
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At endpoint – clinical AIDS  
 CD4 count (cells/µL) (mean (SD)) 441 (242) 438 (285) 460 (301) 0.6135 0.3245 
HIV RNA (log10 copies/mL) (mean 
(SD)) 
2.8 (1.4) 2.8 (1.4) 2.7 (1.4) 0.8339 0.9912 
HIV therapy  
 PI- and NNRTI-containing 
HAART 
0  1 (0.5) 26 (2.0) 
0.0280 0.0464 PI-containing HAART 14 (58.3) 77 (40.7) 425 (33.2) NNRTI-containing HAART 2 (8.3) 41 (21.7) 307 (23.9) 
NRTI alone HAART 0  0  30 (2.3) 
Not on HAART 8 (33.3) 70 (37.0) 494 (38.5) 
On HAART 16 (66.7) 119 (63.0) 788 (61.5) 0.8159 0.6928 
At endpoint – all-cause mortality  
 CD4 count (cells/µL) (mean (SD)) 520 (251) 486 (273) 521 (293) 0.3549 0.1566 
HIV RNA (log10 copies/mL) (mean 
(SD)) 
2.4 (1.3) 2.4 (1.3) 2.3 (1.4) 0.6059 0.9855 
HIV therapy  
 PI- and NNRTI-containing 
HAART 
0  1 (0.5) 29 (2.3) 
0.0350 0.0205 PI-containing HAART 15 (68.2) 100 (53.5) 567 (45.1) NNRTI-containing HAART 3 (13.6) 39 (20.9) 362 (28.8) 
NRTI alone HAART 0  1 (0.5) 28 (2.2) 
Not on HAART 4 (18.2) 46 (24.6) 272 (21.6) 
On HAART 18 (81.8) 141 (75.4) 986 (78.4) 0.5983 0.3592 
At endpoint – HIV virologic failure  
 CD4 count (cells/µL) (mean (SD)) 582 (279) 461 (284) 467 (300) 0.0605 0.8818 
HIV therapy  
 PI- and NNRTI-containing 
HAART 
0  1 (0.5) 28 (2.2) 
0.0121 0.0036 PI-containing HAART 9 (36.0) 65 (34.4) 310 (23.9) NNRTI-containing HAART 2 (8.0) 24 (12.7) 265 (20.4) 
NRTI alone HAART 0  2 (1.1) 29 (2.2) 
Not on HAART 14 (56.0) 97 (51.3) 665 (51.3) 
On HAART 11 (44.0) 92 (48.7) 632 (48.7) 0.8960 0.9896 
At endpoint – 25% CD4 cell decline  
 CD4 count (cells/µL) (mean (SD)) 533 (275) 429 (278) 484 (296) 0.0115 0.0073 
HIV RNA (log10 copies/mL) (mean 
(SD)) 
2.8 (1.4) 2.7 (1.4) 2.7 (1.5) 0.2582 0.1202 
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 HIV therapy  
 PI- and NNRTI-containing 
HAART 
5 (18.5) 19 (9.7) 229 (17.5) 
<0.0001 <0.0001 PI-containing HAART 13 (48.2) 61 (31.1) 423 (32.3) NNRTI-containing HAART 3 (11.1) 27 (13.8) 304 (23.2) 
NRTI alone HAART 0  2 (1.0) 26 (2.0) 
Not on HAART 6 (22.2) 84 (42.9) 326 (24.9) 
On HAART 21 (77.8) 109 (55.6) 982 (75.1) 0.0118 <0.0001 
At endpoint – 10% CD4 cell decline  
 CD4 count (cells/µL) (mean (SD)) 524 (287) 433 (270) 477 (289) 0.0509 0.0291 
HIV RNA (log10 copies/mL) (mean 
(SD)) 
2.8 (1.4) 2.7 (1.4) 2.7 (1.5) 0.4512 0.4484 
HIV therapy  
 PI- and NNRTI-containing 
HAART 
0  0  47 (3.3) 
0.0007 0.0010 PI-containing HAART 11 (50.0) 103 (54.5) 528 (43.1) NNRTI-containing HAART 2 (9.1) 40 (21.2) 378 (30.8) 
NRTI alone HAART 0  4 (2.1) 44 (3.6) 
Not on HAART 9 (40.9) 42 (22.2) 276 (22.5) 
On HAART 13 (59.1) 147 (77.8) 997 (81.3) 0.0974 0.8664 
*χ test or Fisher’s exact test for categorical variables; Wilcoxon test for continuous variables 
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Table 5-3. Summary of outcomes by HCV status (N=1,680) 
 New AIDS diagnosis All-cause mortality HIV virologic failure 25% CD4 cell count decline 
10% CD4 cell count 
decline 
No. at 
risk 
 
N (%) 
No. at 
risk 
 
N (%) 
No. at 
risk 
 
N (%) 
No. at 
risk 
 
N (%) 
No. at 
risk 
 
N (%) 
Hepatitis C 
status 1,186 122 (10.3) 1,680 100 (6.0) 868 306 (35.3) 1,470 368 (25.0) 1,470 563 (38.3) 
 Chronic 147 22 (15.0) 207 18 (8.7) 115 40 (34.8) 183 60 (32.8) 183 85 (46.4) 
Resolved 24 0 32 1 (3.1) 17 5 (29.4) 26 3 (11.5) 26 9 (34.6) 
Negative 1,015 100 (9.9) 1,441 81 (5.6) 736 261 (35.5) 1,261 305 (24.2) 1,261 469 (37.2) 
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Table 5-4. Cox proportional hazards regression modeling risk of clinical AIDS 
 
Characteristic 
Model 1 (Crude) Model 2 (Adjusted) 
p-value HR CI p-value HR CI 
HCV status   
 Chronic HCV 0.0786 1.52 0.95-2.41 0.1145 1.46 0.91-2.32 
HCV-negative -- 1.00 -- -- 1.00 -- 
Insurance (<550 days follow-up time)   
 Public 0.0040 5.59 1.73-18.01 0.0041 5.55 1.72-17.90 
Uninsured 0.3789 2.76 0.29-26.55 0.3730 2.80 0.29-26.90 
Unknown 0.0117 4.93 1.43-17.04 0.0184 4.49 1.29-15.63 
Private -- 1.00 -- -- 1.00 -- 
Insurance (≥ 550 days follow-up time)       
 Public 0.2301 1.57 0.75-3.27 0.2512 1.54 0.74-3.23 
Uninsured 0.9767 0.00 0.00-. 0.9774 0.00 0.00-. 
Unknown 0.0286 2.59 1.10-6.08 0.0386 2.47 1.05-5.80 
Private -- 1.00 -- -- 1.00 -- 
Year of HIV diagnosis 0.0085 0.96 0.93-0.99  
Baseline HIV RNA (per log10 
copies/mL increase) 
0.0005 1.27 1.11-1.46  
Endpoint HIV RNA (per log10 
copies/mL increase) 
<0.0001 1.54 1.36-1.74  
On HAART at endpoint 0.2279 0.72 0.42-1.23 0.1822 0.69 0.40-1.19 
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Table 5-5. Cox proportional hazards regression modeling risk of all-cause mortality 
 
Characteristic 
Model 1 (Crude) Model 2 (Adjusted) 
p-value HR CI p-value HR CI 
HCV status   
 Chronic HCV 0.0537 1.67 0.99-2.76 0.1553 1.67 0.82-3.36 
HCV-negative -- 1.00 -- -- 1.00 -- 
Insurance   
 Public 0.0235 2.92 1.16-7.37 0.1529 2.92 0.67-12.69 
Uninsured 0.9833 0.00 0.00-. 0.9896 0.000 0.00-. 
Unknown <0.0001 34.64 13.75-87.29 <0.0001 45.92 10.62-198.61 
Private -- 1.00 -- -- 1.00 -- 
Baseline age (per 10 year 
increase) 
0.0003 1.43 1.18-1.74 <0.0001 1.85 1.37-2.51 
Year of HIV diagnosis (per 1 
year increase) 
0.0482 1.05 1.00-1.11 0.0065 1.08 1.02-1.14 
Baseline CD4 count (per 100 
cells/µL increase) 
<0.0001 0.75 0.68-0.82  
Baseline HIV RNA (per log10 
copies/mL increase) 
0.0013 1.27 1.10-1.47  
On HAART at baseline 0.0179 1.92 1.12-3.30  
On HAART at endpoint <0.0001 0.34 0.21-0.56 0.0002 0.24 0.12-0.51 
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Table 5-6.  Cox proportional hazards regression modeling risk of virologic failure 
 
Characteristic 
Model 1 (Crude) Model 2 (Adjusted) 
p-value HR CI p-value HR CI 
HCV status     
 Chronic HCV 0.7149 0.84 0.33-2.13 0.0637 0.41 0.16-1.05 
HCV-negative 0.7919 0.89 0.37-2.15 0.0284 0.37 0.15-0.90 
Resolved HCV -- 1.00 -- -- 1.00 -- 
HIV risk group   
 IDU  0.0849 0.76 0.54-1.03 0.1336 0.75 0.52-1.09 
MSM  0.0036 0.69 0.53-0.88 0.0070 0.69 0.53-0.91 
Heterosexual -- 1.00 -- -- 1.00 -- 
Insurance   
 Public 0.0482 1.36 1.00-1.85 0.0696 1.35 0.98-1.88 
Uninsured 0.1948 0.51 0.19-1.41 0.2307 0.49 0.15-1.58 
Unknown 0.0046 1.72 1.18-2.50 0.0090 1.71 1.14-2.55 
Private -- 1.00 -- -- 1.00 -- 
Baseline age (per 10 year increase) <0.0001 0.79 0.70-0.89 0.0048 0.83 0.73-0.94 
Baseline CD4 count (per 100 
cells/µL increase) 
0.0237 0.95 0.92-0.99  
Endpoint CD4 count (per 100 
cells/µL increase) 
<0.0001 0.82 0.78-0.85 <0.0001 0.83 0.79-0.87 
On HAART at endpoint <0.0001 0.45 0.33-0.62 0.0004 0.55 0.40-0.77 
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Table 5-7.  Cox proportional hazards regression modeling risk of 25% CD4 cell 
decline 
Characteristic 
Model 1 (Crude) Model 2 (Multivariate) 
p-value HR CI p-value HR CI 
HCV status     
 Chronic HCV 0.0925 2.71 0.85-8.63 0.1708 2.69 0.65-11.05 
HCV-negative 0.2862 1.86 0.60-5.79 0.3212 2.02 0.50-8.15 
Resolved HCV -- 1.00 -- -- 1.00 -- 
Insurance     
 Public 0.0614 1.31 0.99-1.74 0.0788 1.30 0.97-1.73 
 Uninsured 0.4608 1.32 0.63-2.76 0.3501 1.42 0.68-2.98 
 Unknown 0.0031 1.70 1.20-2.40 0.0029 1.73 1.21-2.48 
 Private -- 1.00 -- -- 1.00 -- 
Baseline age (per 10 year 
increase) 
0.0817 0.91 0.82-1.01 0.0384 0.89 0.79-0.99 
On HAART at baseline 0.1450 0.84 0.67-1.06    
Endpoint VL (log10 copies/mL 
increase) 
<0.0001 1.74 1.62-1.86    
On HAART at endpoint 0.0021 0.70 0.56-0.88 0.0044 0.72 0.57-0.90 
 
 
 
  
187 
  
 
 
Figure 5-1. Kaplan-Meier survival curve – HCV and onset of clinical AIDS 
Log-rank p-value=0.0816 
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Figure 5-2. Kaplan-Meier survival curve – HCV and all-cause mortality 
Log-rank p-value=0.1357 
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Figure 5-3. Kaplan-Meier survival curve – HCV and virologic failure 
Log-rank p-value=0.9136 
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Figure 5-4. Kaplan-Meier survival curve – HCV and 25% decline in CD4 cell count 
Log-rank p-value=0.0133 
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Figure 5-5. Kaplan-Meier survival curve – HCV and 10% decline in CD4 count 
Log-rank p-value=0.0273 
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6 DISCUSSION AND RECOMMENDATIONS 
6.1 Summary of findings 
In this population attending a large, urban HIV clinic, we found the prevalence of HBV 
co-infection was 44% and chronic HBV was 3%.  The chronic HBV estimate is lower 
than the 6-9% prevalence seen recently in European studies1-3 and US studies of MSM,4 
but similar to what was reported in a recent US study.5  We found the prevalence of HCV 
co-infection was 34%, which is consistent with findings from previous research; studies 
with a low proportion of IDUs have found HCV prevalence to be 15-16%,6,7 while a large 
study comprised of 36% IDUs reported HCV prevalence to be 37%.8  We found similar 
factors associated with each hepatitis co-infection, including IDU risk behavior and older 
age.  We also identified male sex, MSM behavior, and earlier HIV diagnosis to be 
associated with HBV co-infection, and lower socioeconomic status, earlier HIV 
diagnosis, and being White to be associated with HCV co-infection.  In a sub-analysis, 
we found that Black race, a more recent HIV diagnosis, and younger age were associated 
with sexually transmitted HCV.    
 
Additionally, the findings of this study suggest that HBV exposure status impacts time to 
clinical AIDS, virologic failure, and CD4 cell count decline, but is not associated with 
differences in risk of all-cause mortality.  We found that having a resolved HBV infection 
was most protective against progression to clinical AIDS and virologic failure when 
compared to having a chronic HBV infection or being HBV-negative, respectively.  
Specifically, we found that having a chronic HBV infection was associated with a 2.2-
fold greater risk of new AIDS diagnosis and being HBV-negative was associated with a 
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1.5 times greater risk for HIV virologic failure, compared to a resolved infection.  
Further, being HBV-negative was associated with a decreased risk of both a 10% and 
25% decline in CD4 cell count.  We found no association between HBV exposure group 
and risk of all-cause mortality.  Further, the findings of this study also suggest that HCV 
status impacts time to clinical AIDS, and virologic failure, but is not associated with 
differences in risk of all-cause mortality or a decline in CD4 cell count.  In this HIV-
positive clinic population, we found that having a chronic HCV infection as associated 
with an almost 50% increase in risk of clinical AIDS compared to those who were HCV-
negative.  Additionally, those with a resolved HCV infection were at the greatest risk for 
virologic failure.   
 
6.2 Hepatitis B co-infection 
Although sexual transmission is usually associated with HBV infection, we were not 
surprised to also find a high prevalence among IDU in our population, as percutaneous 
exposure is an highly effective mode of HBV transmission.9  When adjusted for sex, year 
of HIV diagnosis, age, HCV positivity, and HAART, those with IDU risk and MSM risk 
had an increased risk of HBV co-infection of similar magnitude (approximately 40% 
greater odds of infection compared to heterosexual contact).  Nine percent of our IDU 
population also reported MSM behavior, which could also have contributed to our 
increased rates in the IDU population.  In addition to male sex, risk group, year of HIV 
diagnosis, age, and HAART, being HCV-positive was also significantly associated with 
HBV co-infection.  This is likely attributable to their shared risk factors.  Additionally, 
over 75% of HBV/HCV dually infected subjects reported IDU or MSM risk behavior, 
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which could elevate rate of co-infection in our study population.  We also found that 
being on a PI- and NNRTI-containing HAART regimen was associated with increased 
HBV co-infection compared to a NNRTI-HAART regimen.  This does not seem to be 
attributable to a higher proportion of IDU or MSMs in this population (63 vs. 66%).  This 
group also has similar proportion of subjects on a lamivudine-containing HAART 
regimen (42 vs. 41%).  The NNRTI-HAART group was somewhat less healthy upon 
entry into the cohort (mean CD4 count 440 vs. 364 cells/µl), however we did not find 
CD4 count to be associated with HBV co-infection.  Our finding was more likely due to 
unmeasured confounders in our population, such as drug adherence specifically to 
regimens containing agents effective against HBV or factors associated with overall 
health. 
 
The prevalence of chronic hepatitis B in our population was consistent to what has 
recently been reported in a HIV-positive population with access to healthcare (2.7%).5  
However, together, these estimates are substantially lower than what has previously been 
reported in the literature.  In the pre-HAART and -vaccine era, the prevalence of chronic 
HBV ranged from 7-9%.3,10 Even as recent as a decade ago, the reported prevalence of 
chronic HBV was quite high (6-9%).1,2,11-13 Our estimates could be lower for a number of 
reasons.  First, it may reflect a true shift in the epidemiology of HBV/HIV co-infection 
due to increased vaccinations in the HIV-positive population.  However, recent data from 
the National Health Interview Survey showed that HBV coverage among high-risk 
individuals in 2010 remained steady at about 42% compared to 2008.14  However, our 
clinic-based population may not be representative of the general HIV-positive population.   
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HBV vaccination rates have been reported to be greater in clinic settings compared to 
other healthcare settings or no health care.15 Current guidelines recommend all adults 
seeking healthcare at a high-risk setting (such as HIV clinic) receive the HBV vaccine.16  
Given that this HIV clinic is not the only place for our subjects to receive healthcare and 
not all of the subjects had extensive hepatitis B serology testing performed, our data may 
not hold complete information on hepatitis B vaccine coverage in our population.  
However, we did identify at least 40% of subjects had either received hepatitis B vaccine 
in the clinic during the study period or had serological evidence of a hepatitis immunity 
due to vaccine.  This fairly high level of vaccine coverage likely caused our smaller 
prevalence estimates than what has previously been reported.  Studies that have reported 
high vaccine coverage (22%) also reported lower HBV prevalence,5 while studies with 
low vaccination rates (5%) reported much higher HBV prevalence.11  Additionally, we 
required two positive HBsAg measurements to define a chronic infection while other 
studies with higher prevalence rates only required one,1 leading to the potential for 
misclassification of chronicity.  
 
Similar to what has previously been reported, we found the prevalence of chronic HBV to 
be highest among men and those reporting MSM or IDU risk factors, and lowest among 
Hispanics.11 Due to our low levels of HBV prevalence in general in this population, we 
may have been limited in our ability to reach statistical significance when comparing 
categories of factors potentially related to chronic HBV.  We also found that 9% of all 
HBV-positive individuals went on to develop a chronic infection, which is consistent to 
what has been previously reported in the literature.5 
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Compared to those with evidence of a past HBV infection, those with a chronic infection 
had over a 2-fold increased risk for new AIDS diagnosis.  It has been suggested that 
subjects with a chronic hepatitis B infection may be in a persistent state of immune 
activation, possibly leading to up-regulation of HIV.17  Recently, Chun et al. also 
reported a significant association with HBV on HIV clinical outcomes,5 finding an almost 
2-fold increase in the risk among those with a chronic infection compared to HBV-
negative (HR=1.8).  However, they used a composite endpoint of clinical AIDS, 
excluding CD4 count, or death from any cause, making our results not directly 
comparable. However, given that we found no association with HBV infection and all-
cause mortality, differences in classification may have artificially decreased the 
magnitude of effect in Chun’s study.  Additionally, they excluded CD4 count less than 
200 cells/µL from this composite outcome, while we included in in our clinical AIDS 
definition.  However, we did not see the same association with the outcome of CD4 
decrease, suggesting that acquiring opportunistic infections, not immunologic failure, that 
was driving our finding. 
 
Additionally, although our findings did not reach statistical significance, they suggest a 
possible slight increase in risk of AIDS for those who were HBV-negative compared to 
those that had resolved their HBV infection.  Although the mechanism behind this is 
unknown, it is possible that viral clearance of a HBV infection is indicative of a more 
functional cell-mediated immune response, than what has been previously observed in 
HIV-positive individuals, which may subsequently offer protection against development 
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of opportunistic infections.  This may also indicate less replication of HIV, which could 
account for our findings suggesting those with a resolved infection were at least risk of 
progression to virologic failure compared to other HBV groups. 
 
We found no association between HBV status and death from all causes, which is 
different from what others have reported.1,4 Interestingly, Model 3 for this outcome 
showed that being on PI- and NNRTI-containing HAART increased risk for death 
compared to PI-containing HAART, NNRTI-containing HAART, and not being on 
HAART (HR=3.33, HR=2.27, and HR=4.35, respectively).  Further inspection of the 
data revealed that those on PI- and NNRTI-containing HAART had a lower average 
baseline CD4 cell count compared to those on NNRTI-containing HAART (380 vs. 436 
cells/µl; p=0.0338) and compared to those not on HAART (380 vs. 471 cells/µl; 
p<0.0001).  Although this does not explain the protective effect of being on PI-containing 
HAART, this does indicate that those on PI- and NNRTI-containing HAART were 
somewhat less healthy at entry into the cohort, which may explain their increased risk for 
death. 
 
In contrast to findings above, we found that those with a resolved infection were at 
increased risk for development of a modest (10%) decline in CD4 cell counts compared 
to those who were HIV-negative. Although the reason for this is unknown, the magnitude 
of effect was quite small (HR=1.27), and this effect was no substantiated when we used 
less modest decrease of 25% from baseline.  We saw no difference in the risk of 
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progression to a 25% decline in CD4 cell count.  Others have reported no difference in 
risk of CD4 decline, although a wide array of outcomes definitions were used.1,4,18,19  
 
6.3 Hepatitis C co-infection 
In this population, HCV co-infection was significantly associated with White race, IDU 
risk behaviors, and lower socioeconomic status, as indicated by being on public 
compared to private insurance.  Given the primary mode of HCV transmission in the US 
is through injection drug use, it is not surprising that we found that subjects reporting 
IDU behavior had significantly higher prevalence of HIV/HCV co-infection (76%) 
compared to other risk groups, which is similar to what other studies have found (73-
92%).7,8,20  We also found that subjects < 30 years old at time of HIV diagnosis had the 
lowest prevalence of HCV (25%).  This finding could be attributable to a variety of 
reasons.  First, this age group may exhibit less risky behavior once they learn of their 
HIV diagnosis, thereby reducing their risk of acquiring HCV.  Unfortunately, this is not 
measureable in this population and research indicates that HCV infection usually 
precedes HIV infection.21  Second, it is possible that individuals in this group had a 
shorter duration of time in the clinic, which may lead to decreased opportunity for HCV 
testing.  However, those aged < 30 years had only slightly less follow-up time on average 
than those ≥ 30 years (5.8 vs. 6.4 years).  Further, they had an average of 1.6 anti-HCV 
tests compared to an average of 1.7 for those ≥ 30 years.  Therefore, these differences 
likely did not affect HCV prevalence in this age group. The most likely explanation for 
this difference is that 44% of this group reported heterosexual contact and an additional 
37% reported MSM behavior as their primary HIV risk group, which are groups known 
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to have less HCV co-infection than IDU groups.  Similar to HBV, we found that certain 
types of HAART regimens were associated with higher risk of HCV co-infection.  
Further investigation of the data revealed these groups were similar with respect to risk 
factor and baseline CD4 cell count, indicating unmeasured confounders may be the 
reason for this difference. 
 
Similar to what has previously been reported, we found the prevalence of chronic HCV to 
be highest among Whites, men, those reporting IDU risk factors, those of lower 
socioeconomic status, older age, those with an earlier HIV diagnosis, and HBV 
positivity.22-24  Given the small proportion of subjects that cleared their HCV infection, 
we may have been limited in our ability to reach statistical significance when comparing 
categories of factors potentially related to chronic HCV.  We also found that 87% of all 
HCV-positive individuals went on to develop a chronic infection, which is consistent to 
what has been previously reported in the literature.24-27 
 
Overall, the prevalence of HCV clearance in this HCV/HIV-positive population was 
13%, which is in the range of 13-23% that has previously been reported.22-28  Our 
findings may be lower than what has previously been reported due to differences in our 
study population.  First many HCV clearance studies have been conducted in Europe with 
primarily White populations.22,23,28 Our HCV-positive study population consisted of 63% 
Black, 23% White, and 14% Hispanic, and although they did not reach statistical 
significance, our findings showed that those with a chronic HCV infection were more 
likely to be Black (62%) compared to White (26%).  Although race has not been 
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associated with rates of HCV clearance in previous research,23,25,29 Soriano et al. found 
regional differences in HCV clearance in the EuroSIDA cohort, suggesting that clearance 
does not solely depend on viral, immunologic, or risk factors.22  Most previous HCV 
clearance research has been conducted outside of the US; the limited studies that have 
been conducted in the US have found a clearance rate of 13%.24,25 Further, our study 
consisted of a very heterogeneous HCV-positive population with respect to risk factor, 
consisting of 28% reporting heterosexual risk, 57% IDU risk, and 15% MSM risk.  Two 
studies have found IDU to be less likely to clear their infection,22,25 therefore our large 
proportion of subjects reporting sexual risk may have contributed to our lowered levels of 
clearance compared to other studies.  
 
In this study population, we found that HBsAg positivity was significantly associated 
with a 16-fold increase in the odds of HCV clearance, which is similar to what others 
have reported.22-25,30 The confidence interval surrounding this estimate was quite wide 
(2.65-97.26), which is likely a reflection of our small sample size, underscoring the need 
for additional studies with larger sample size.  Taken together, these findings suggest 
there is an interaction between HBV and HCV that specifically influences HCV 
infection.  It has been hypothesized that HCV viral replication is inhibited non-
specifically by cytokines, such as interferon-, interferon-, and tumor necrosis factor-
, produced as part of a HBV-specific T-cell response, thereby inducing HCV viral 
clearance.23,31 Viral interference may also be occurring; a study by Gaeta et al. showed 
that only 14% of subjects dually-infected with HBV and HCV had evidence of active 
replication of both infections.32 
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Although our findings did not reach statistical significance, they also suggest that female 
sex and sexual risk compared to IDU risk were associated with increased HCV clearance.  
Others have reported an association between female sex and HCV clearance.22-24  Sexual 
risk has been reported to be associated with increased HCV clearance,22,25 although there 
has been conflicting evidence in the literature.23 Our limited sample size may have 
decreased our power to detect a statistically significant association between these factors 
and HCV clearance. 
 
We had a unique opportunity to conduct a sub-analysis on a large group of HIV-positive 
individuals who reported only sexual risk as their risk factor for HIV, and therefore 
presumably for HCV as well.  Our co-infection prevalence was slightly greater among 
those reporting sexual exposure (17-23%) than what has been reported previously (4-
14%).7,8,20 Sexual transmission of HCV has been recently been discussed in the literature 
as an important factor for HCV transmission, especially among both HIV-positive33-37 
and -negative38 MSM and women who report heterosexual sex with an IDU partner.39  A 
recent study from the Swiss HIV Cohort reported the incidence of HCV in MSM 
increased 16-fold from 0.23 per 100 person-years in 1998 to 4.09 per 100 person-years in 
2011.40  Increased prevalence of high-risk sexual behavior in these groups has coincided 
with widespread access to HAART41,42 and the perception that HAART-inducted 
virologic control reduces HIV infectivity.43   Our findings confirm the changes in risk 
factors associated with HIV/HCV co-infection that has recently been acknowledged.21 
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In our sub-analysis, we found that Black race had an almost 4-fold increased odds of 
sexual transmission of HCV compared to Whites.  This may be attributable to under-
reporting of true IDU risk; 25% our clinic population reported IDU risk compared to 35% 
city-wide in Philadelphia.44  Additionally, a more recent HIV diagnosis and younger age 
were found to be significantly associated with sexual transmission of HCV.  We found 
those reporting sexual risk factors were more likely to have a history of a syphilis 
infection (12 vs. 5%; p=0.0174), although this did not remain statistically significant on 
multivariate analysis.  This could be due to our small sample size (only 360 subjects were 
tested for syphilis); limited testing for other ulcerative STIs (e.g., herpes simplex virus) 
did not allow us to assess these important potential factors.  These finings are consistent 
with findings from the Swiss HIV Cohort study, which found that those with MSM 
transmission of HCV had a higher prevalence of a concurrent syphilis infection (5 vs. 
2%).45 Unlike a recent study, we did not find an association between HCV transmission 
and high HIV RNA viral loads on multivariate analysis.46 In addition to limited STI data, 
we were unable to assess specific sexual or drug use risk factors that have previously 
been associated with sexual transmission of HCV in similar populations.  Recent 
epidemiologic studies with access to behavior data identified unsafe sexual practices,33,45 
especially those that caused mucosal damage in the rectum (e.g., fisting),47,48 were in the 
setting of group sex, or during use of non-injection recreational drugs33,35,36,48 (i.e., 
amphetamines) to be highly associated with an increased risk of HCV transmission. 
These studies suggest that having HIV is a marker for more traumatic sexual practices 
that put individuals at increased risk for HCV, rather than HIV affecting the 
infectiousness of HCV.35  
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Our findings suggest that compared to those who were HCV-negative, those with a 
chronic infection had almost a 1.5-fold increased risk for new AIDS diagnosis and 1.7-
fold increased risk for all-cause mortality, although these did not reach statistical 
significance.  This is consistent with previous research consisting of a study of 238 HIV 
infected patients that reported an increased risk for AIDS of comparable magnitude 
(HR=1.64; 95% CI, 1.06-2.55).49   Further, a study conducted using the Swiss HIV 
Cohort reported a 1.7-fold increase in risk of the composite endpoint of clinical AIDS or 
death among those co-infected with HCV.8  A recent study that specifically looked at the 
effect of HCV status on subjects with AIDS reported a 50% increase in risk for mortality 
(RR=1.5; 95% CI, 1.2-1.9).50  However, in light of these findings, the effect of HCV 
infection on progression of clinical AIDS or death is still debatable, as multiple 
longitudinal studies have reported no association with HCV co-infection.51-56  Some of 
these studies are limited by small sample size,8,49,51-54,56 short follow-up periods, and 
limited HIV VL data.49,53 
 
Interestingly, when modeling the risk for AIDS, multivariate Model 3 showed that being 
on PI- and NNRTI-containing HAART at endpoint increased the risk for AIDS compared 
to NNRTI-containing HAART (HR=3.13).  Further inspection of the data revealed that 
those on PI- and NNRTI-containing HAART had a lower average baseline CD4 cell 
count compared to those on NNRTI-containing HAART (426 vs. 475 cells/µl; p=0.0751).  
Although this does not explain the protective effect of being on PI-containing HAART, 
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this does indicate that those on PI- and NNRTI-containing HAART were somewhat less 
healthy at entry into the cohort, which may explain their increased risk for death. 
 
Few studies have assessed the effect of HCV co-infection on changes in HIV VL.  Of the 
few that did, no significant association was reported.8,55,56 However, these studies differ 
from the current analysis in that only used HCV serostatus (i.e., anti-HCV-positive), 
while we were able to further distinguish and analyze subjects that cleared their infection 
and those that had a chronic infection.  We found those with a resolved HCV infection 
had quicker progression to virologic failure compared to those who were HCV-negative. 
We also noted younger age was associated with an increased risk for virologic failure.  
This could be due to non-adherence in this group, which has been previously been 
reported.57,58 It has been hypothesized that this may be due to lifestyle differences, a 
decreased awareness of one’s own mortality leading to less motivation to care for one’s 
health, and the survivor effect.59 However, adherence was not measurable in our study 
population.   
 
Similar to what others have reported, we found no association between HCV status and 
changes in CD4 cell count, although a wide array of outcome definitions have been 
previously used, making it challenging to directly compare results.49,51,53,55,56  
 
6.4 Limitations and strengths 
Although our study consisted of 10 years of clinical data among a population of 2,880 
HIV-positive individuals, it is limited in several ways.  First, we relied on analysis of data 
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previously collected during routine clinical care at a large HIV clinic, therefore our 
assessment of the factors associated with viral hepatitis co-infections, sexual transmission 
of HCV, and HCV viral clearance was limited to available data.  We could not collect 
information on recreational drug use, including active injection drug use, and alcohol use; 
specific sexual practices; complete hepatitis B vaccination rates; comprehensive history 
of STIs, specifically those cause genital ulcers, such as herpes simplex virus; interleukin 
28B gene polymorphisms; HCV genotype; and hepatitis B and C therapy, which could be 
important factors associated with co-infection and rates of HCV clearance, and HIV 
disease progression.8,11,22,28,29,35,56,57,60-63  We also had no information on adherence to 
prescribed HAART regimens.  Lack of information on these potentially important factors 
may have lead to residual confounding.  For our survival analysis, we also did not have 
cause of death data available.  Both HBV and HCV directly cause mortality, and previous 
studies have found that the many of deaths in co-infected individuals were liver-
related.4,50,64 
 
We were also limited in our ability to classify all HBV and HCV-positive subjects as 
either having a resolved or chronic infection.  Although the data contained up to 33 
repeated measures for initial hepatitis B tests, we had a limited number of repeated 
hepatitis testing for HBsAg (11), anti-HBc (6), and anti-HBs (7).  We were able to 
classify those with a chronic infection with two consecutive tests, but were restricted to 
using one test for classification of a resolved infection.  Additionally, subjects had a 
maximum of three HCV VL tests and average of 1.7 tests, so we were unable to require 
two consecutive undetectable HCV VL results in our HCV clearance definition.  This 
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may have overestimated our clearance rate, but other studies have used only one 
measurement given limited repeated HCV RNA tests available.22,25   
 
Further, our secondary data analysis limited our assessment of HCV clearance to those 
who received HCV RNA VL tests.  Only 30% of our HCV-positive population had HCV 
RNA VL test results available.  This substantially decreased our sample size, which may 
have lead to insufficient power to statistically detect a meaningful difference in factors 
associated with HCV clearance and likely contributed to wide confidence intervals 
surrounding estimates.  However, our results are intriguing given what others have found 
with respect to female sex, sexual risk factor, and HBsAg positivity.  Although female 
sex and risk factor did not reach statistical significance on multivariate analysis, the large 
ORs warrant additional studies to further elucidate these relationships.  In addition to 
limiting our sample size, with only 30% of our HCV-positive population getting tested 
for HCV VL, it is possible this subpopulation was not representative of the entire HCV-
positive population.  However, we feel the effects of potential sampling bias were 
minimal.  These populations were found to be similar with respect to their demographic, 
immunologic, and virologic characteristics.  Further, we found no differences in the 
average number of clinic visits (13.4 vs. 12.5) or time in the cohort (6.4 vs. 5.5 years) 
among those tested and not tested. 
 
Additionally, we sought out to use insurance type as a proxy for socioeconomic status, 
which has been done in previous research.65,66 However, 23-30% of our study population 
in each analysis did not have insurance information available, leading to the possibility of 
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misclassification of this factor.  With respect to the HBV and HCV survival analyses, this 
group was associated with a remarkable 25-fold and 45-fold increase in all-cause 
mortality compared to those with public insurance, respectively.  In each analysis, 
subjects in this group were more likely to report IDU as their HIV risk behavior (25 vs. 
12% for the HBV analysis; p=0.0341, and 18 vs. 10% for the HCV analysis; p=0.0101).  
The significant difference in the proportion reporting IDU suggests that perhaps these 
individuals were dying to causes un-related to HIV, such as drug overdose.  However, 
this information could not be gleaned from the data.  In the HCV analysis, they were also 
less likely to be on a HAART regimen at time of endpoint (44 vs. 88%; p<0.0001). 
Although not measureable in this population, active drug users are more likely to be non-
adherent to prescribed HAART,67 which may affect prescribing practices, virologic 
control, and ultimately mortality.  
 
Additionally, our study population was drawn from HIV-positive subjects attending a 
single urban HIV clinic in the Northeast and may not be generalizable to other HIV-
positive populations.  We had slightly higher proportion of IDUs in our study population 
(25 vs. 22% nationally reported HIV risk profile) and a much larger proportion of 
subjects reporting heterosexual risk as the lone HIV risk factor (44 vs. 26% nationally).68  
This may be due in part to our large proportion of Black subjects (69%) compared to the 
race profile of HIV-positive individuals nationwide (48% are Black).69  The larger 
proportion of heterosexual, normally considered “low risk” for HBV and HCV may have 
lowered our prevalence estimates.  Misclassification of HIV risk, with those subjects with 
true MSM or IDU risk reporting heterosexual risk only may have lead to an increased 
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association with heterosexual risk.  Further, there have been discordant findings as to the 
role risk factor has on clearance, therefore the effect of these differences are hard to 
qualify.  As this study was conducted in a clinic population, it is possible that subjects 
included in our study may differ with respect to health-seeking behaviors, risky sexual 
and drug use behavior, vaccination coverage and adherence to antiretroviral therapy than 
the general HIV population,15,70,71 which may cause an underestimation of the true 
prevalence rates.   
 
Our study was further limited by its cross-sectional design, which may not accurately 
reflect the rate of chronic infections due to loss of detectable antibody among those who 
recover form their infection.72  It was also difficult to discern when HCV clearance 
actually occurred, assess the long-term effects of HCV suppression, or consider re-
infection with HCV following viral clearance.  
 
Despite these limitations, our study adds to the current knowledge base on viral hepatitis 
in urban HIV-positive populations.  Compared to many other studies of co-exposed 
subjects, we had a fairly large and heterogeneous population, with respect to sex, race, 
and HIV risk factor.26-28.2-4,13,19,49,52-54,73-75    For example, some previous studies only 
included MSM in their study population.4,73,76  We In the prospective analyses on the 
impact of viral hepatitis infection on HIV disease progression, our 10 years of clinical 
data yielded over 50 repeated values for CD4 count and HIV VL.  This long-term clinical 
data also generated repeated values for HBV and HCV serologic tests, which enabled the 
distinction between chronic and resolved infections, rather than relying on serostatus 
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alone. .8,55  For example, a few studies on the impact of HCV on HIV disease progression 
relied solely on anti-HCV positivity.  We followed patients for over 5 years, with the 
average time to censor or outcome of more than 2.5 years, which is longer than what 
other studies have used. 3,8,13,18,51,54,56,76   
 
6.5 Public health impact 
Our findings highlight the burden of HBV and HCV co-infections among HIV-positive 
individuals.   Understanding the risk factors associated with co-infection in HIV-positive 
populations is becoming an important issue, as hepatitis-related morbidity has increased 
markedly in this population.6,8,77-80 This study also provided an updated report that 
supports the changing epidemiology of HIV/HCV co-infections that has recently been 
discussed.21,40 Understanding the risk factors associated with HCV co-infection and HCV 
clearance in HIV-positive populations is becoming an important issue, as HCV-related 
morbidity is increasing in this population.  We also found that HBV and HCV co-
infection can negatively impact HIV outcomes, specifically clinical progression to AIDS, 
all-cause mortality, and HIV virologic failure.  This underscores the need on both a 
population and individual level to decrease the burden of co-infections by reducing the 
number of new HBV and HCV infections among HIV-positive individuals and vice 
versa.  Existing mechanisms, such as condom education and distribution, pre-exposure 
prophylaxis, and treatment of serodiscordant partners can be further implemented to 
reduce co-infection rates.  Further, although a HBV vaccine has been available for years, 
those with HIV have been shown to have a decreased immune response to the vaccine,81 
and low rates of complete administration has been seen among HIV-positive 
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populations.82.  Recent research, however, has indicated that non-standard HBV vaccine 
administration may be more effective in mounting an immune response in HIV-positive 
individuals.83  Widespread acceptance and implementation of this administration may be 
the key for improving decreasing HBV transmission among HIV-positive populations. 
Further, routine screening for HBV and HCV in HIV-positive populations and vice versa, 
regardless of risk profile should be considered. A recent study by Linas et al. reported 
that HCV screening among HIV-positive MSM was not only cost effective, but it also 
extended life expectancy.84  It is essential that these antibody screening results are 
communicated to patients; a recent study found that one-third of those co-infected were 
unaware of their HCV infection.50  Heightened HCV awareness will also be important to 
reduce potentially harmful behaviors, such as active injection drug use and heavy alcohol 
use.  In addition to serostatus screening, routine HBsAg tests for all HBV-positive 
patients and RNA tests for all HCV-positive patients should be performed. Our study 
population was limited by only 30% of subjects getting follow-up RNA tests, and other 
studies have found similar trends.60  Additionally, immediate HBV, HCV, and HIV 
therapy should be considered when infections are identified, as chronic infections may be 
asymptomatic and those that have HCV are less likely to clear their infection, in order to 
preserve the immune function of affected individuals and reduce negative health 
outcomes associated with hepatitis infections. Although there must be considerations for 
hepatoxicity due to hepatitis therapy among HIV-positive individuals, it has been 
demonstrated that the benefits of hepatitis therapy in co-infected patients outweigh the 
risks under certain circumstances.85 Further, understanding potentially modifiable factors 
that are associated with HCV clearance is important, especially given the changing 
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epidemiology of the HIV/HCV co-infections. All of these efforts will be particularly be 
important as co-infected individuals will live longer and have the potential to suffer from 
increased morbidity due to viral hepatitis infections.  
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7 APPENDIX A: LOGISTIC REGRESSION DIAGNOSTICS: LOG-LINEAR 
GRAPHS 
 
 
 
 
7.1 Modeling odds of HBV co-exposure 
 
 
 
 
 
 
 
 
 
 
 
226 
 
 
7.2 Modeling odds of HCV co-exposure 
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7.3 Modeling odds of HBV/HCV co-exposure
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7.4 Modeling odds of sexual transmission of HCV 
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7.5 Modeling odds of HCV clearance 
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8 APPENDIX B: SUPPLEMENTAL COX PROPORTIONAL HAZARD 
MODELS 
 
 
 
8.1 Hepatitis B exposure status 
 
 
8.1.1  Cox proportional hazards regression modeling risk of clinical AIDS 
 Model 3 (Multivariate) 
Characteristic p-value HR CI 
Exposure groups  
 Chronic HBV 0.0053 3.62 1.47-8.94 
HBV-negative 0.3680 1.30 0.73-2.30 
Resolved HBV -- 1.00 -- 
Year of HIV diagnosis (per 1 year 
increase) 
0.0242 0.96 0.93-1.00 
Baseline HIV (per log10 copies/mL 
increase)  
0.0004 1.37 1.15-1.62 
Endpoint HIV therapy  
 PI-containing HAART 0.1582 1.46 0.86-2.48 
NNRTi-containing HAART 0.6292 0.85 0.45-1.63 
NRTI alone HAART 0.5038 0.50 0.07-3.77 
Not on HAART 0.0005 5.49 2.63-11.44 
PI- and NNRTI-containing HAART -- 1.00 -- 
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8.1.2 Cox proportional hazards regression modeling risk of all-cause mortality 
 Model 3 (Adjusted) 
Characteristic p-value HR CI 
Exposure groups    
 Chronic HBV 0.5283 1.32 0.55-3.16 
HBV-negative 0.1665 1.41 0.87-2.29 
Resolved HBV -- 1.00 -- 
Insurance    
 Public 0.4843 1.36 0.57-3.24 
Uninsured 0.9798 0.00 0.00-. 
Unknown <0.0001 24.87 10.54-58.72 
Private -- 1.00 -- 
Baseline age (per 10 year increase) 0.0014 1.41 1.14-1.74 
Anti-HCV positivity    
 Follow-up time < 700 days 0.8089 0.91 0.42-1.96 
 Follow-up time ≥ 700 days 0.0001 2.68 1.63-4.42 
Baseline CD4 (per 100 cells/µl count increase) <0.0001 0.76 0.69-0.84 
Initial HIV therapy    
 PI-containing HAART 0.0216 0.301 0.11-0.84 
 NNRTi-containing HAART 0.0495 0.44 0.20-1.00 
 NRTI alone HAART 0.1200 0.27 0.05-1.40 
 Not on HAART 0.0052 0.23 0.08-0.65 
 PI- and NNRTI-containing HAART -- 1.00 -- 
 Endpoint HIV therapy    
 PI-containing HAART 0.1140 2.05 0.84-5.01 
 NNRTi-containing HAART 0.7268 0.87 0.38-1.95 
 NRTI alone HAART 0.0120 8.99 1.62-49.90 
 Not on HAART 0.2709 2.26 0.53-9.62 
 PI- and NNRTI-containing HAART -- 1.00 -- 
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8.1.3 Cox proportional hazards regression modeling risk of virologic failure 
 Model 3 (Multivariate) 
Characteristic p-value HR CI 
Exposure groups    
 Chronic HBV 0.1737 1.55 0.83-2.90 
HBV-negative 0.0050 1.52 1.14-2.03 
Resolved HBV -- 1.00 -- 
Insurance    
 Public 0.0753 1.38 0.97-1.96 
 Uninsured 0.3325 0.49 0.12-2.06 
 Unknown 0.1719 1.35 0.88-2.08 
 Private -- 1.00 -- 
Baseline CD4 (per 100 cells/µl increase) <0.0001 1.10 1.04-1.15 
Endpoint CD4 (per 100 cells/µl increase) <0.0001 0.75 0.71-0.79 
Endpoint HIV therapy    
 PI-containing HAART 0.2920 1.18 0.87-1.60 
 NNRTi-containing HAART 0.2888 0.82 0.58-1.18 
 NRTI alone HAART 0.0748 1.74 0.95-3.21 
 Not on HAART 0.0920 1.53 0.93-2.50 
 PI- and NNRTI-containing HAART -- 1.00 -- 
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8.1.4 Cox proportional hazards regression modeling risk of 10% CD4 cell decline 
 Model 3 (Multivariate) 
Characteristic p-value HR CI 
Exposure groups    
 Chronic HBV 0.1624 0.73 0.46-1.14 
HBV-negative 0.0182 0.79 0.65-0.96 
Resolved HBV -- 1.00 -- 
Endpoint HIV VL (per log10 
copies/mL increase) 
<0.0001 1.16 1.13-1.19 
Endpoint HIV therapy    
 PI-containing HAART 0.8932 0.99 0.79-1.23 
 NNRTi-containing HAART 0.7336 0.96 0.75-1.23 
 NRTI alone HAART 0.9429 0.98 0.59-1.63 
 Not on HAART 0.0459 1.41 1.01-1.98 
 PI- and NNRTI-containing 
HAART 
-- 1.00 -- 
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8.1.5 Cox proportional hazards regression modeling risk of 25% CD4 cell decline 
 Model 1 (Crude) Model 2 (Adjusted) Model 3 (Adjusted) 
Characteristic p-value HR CI p-value HR CI p-value HR CI 
Exposure groups        
 Chronic HBV 0.4119 0.79 0.45-1.39 0.2151 0.70 0.40-1.23 0.1805 0.68 0.38-1.20 
HBV-negative 0.4588 0.92 0.72-1.16 0.0678 0.80 0.63-1.02 0.2594 0.87 0.68-1.11 
Resolved HBV -- 1.00 -- -- 1.00 -- -- 1.00 -- 
Insurance          
 Public 0.0896 1.28 0.96-1.70 0.0695 1.32 0.98-1.78 0.2285 1.21 0.89-1.64 
 Uninsured 0.8548 0.93 0.40-2.14 0.1667 1.82 0.78-4.26 0.1605 1.85 0.78-4.35 
 Unknown 0.1260 1.32 0.92-1.90 0.0125 1.61 1.11-2.35 0.0226 1.57 1.07-2.30 
 Private -- 1.00 -- -- 1.00 -- -- 1.00 -- 
Anti-HCV positivity 0.0071 1.36 1.09-1.70 -- -- -- 0.0417 1.27 1.01-1.60 
Initial HIV therapy          
 PI-containing 
HAART 
0.9780 1.01 0.70-1.45 -- -- -- 0.1966 0.71 0.42-1.20 
 NNRTi-containing 
HAART 
0.0683 0.69 0.69-1.03 -- -- -- 0.0098 0.51 0.31-0.85 
 NRTI alone 
HAART 
0.5101 1.21 1.21-2.16 -- -- -- 0.3775 0.69 0.31-1.56 
 Not on HAART 0.4328 1.16 1.16-1.68 -- -- -- 0.0059 0.46 0.27-0.80 
 PI- and NNRTI-
containing HAART 
-- 1.00 -- -- -- -- -- 1.00 -- 
On HAART at 
baseline 
0.0274 0.78 0.62-0.97     
 Follow-up time < 
400 days 
-- -- -- 0.0007 2.59 1.50-4.48 -- -- -- 
 Follow-up time 
400-<750 days 
-- -- -- 0.0464 1.59 1.01-2.52 -- -- -- 
 Follow-up time ≥ 
750 days 
-- -- -- 0.5261 0.89 0.62-1.28 -- -- -- 
Endpoint HIV VL 
(per log10 copies/mL 
increase) 
<0.0001 1.27 1.23-1.31 <0.0001 1.27 1.23-1.32 <0.0001 1.28 1.24-1.32 
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Endpoint HIV 
therapy 
      
 
  
 PI-containing 
HAART 
0.8886 1.02 0.77-1.34 -- -- -- 0.3733 1.21 0.80-1.84 
 NNRTI-containing 
HAART 
0.1110 0.77 0.56-1.06 -- -- -- 0.0861 1.46 0.95-2.23 
 NRTI alone 
HAART 
0.7351 1.12 0.58-2.16 -- -- -- 0.8332 1.10 0.44-2.74 
 Not on HAART <0.0001 4.20 2.95-5.99 -- -- -- <0.0001 3.02 1.78-5.13 
 PI- and NNRTI-
containing HAART 
-- 1.00 -- -- -- -- -- 1.00 -- 
On HAART at 
endpoint 
<0.0001 0.23 0.17-0.30 <0.0001 0.37 0.24-0.55 -- -- -- 
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8.2 Hepatitis C exposure status 
 
 
8.2.1 Cox proportional hazards regression modeling risk of clinical AIDS 
Characteristic 
Model 3 (Adjusted) 
p-value HR CI 
HCV status  
 Chronic HCV 0.0962 1.49 0.93-2.39 
HCV-negative -- 1.00 -- 
Insurance (<500 days follow-up time)  
 Public 0.0044 5.50 1.70-17.74 
Uninsured 0.3632 2.86 0.30-27.50 
Unknown 0.0233 4.25 1.22-14.83 
Private -- 1.00 -- 
Insurance (≥ 500 days follow-up time)  
 Public 0.2079 1.61 0.77-3.37 
Uninsured 0.9774 0.00 0.00-. 
Unknown 0.0356 2.51 1.06-5.90 
Private -- 1.00 -- 
Endpoint HIV therapy  
 PI-containing HAART 0.3590 0.65 0.26-1.62 
NNRTI-containing HAART 0.0212 0.32 0.12-0.84 
NRTI alone HAART 0.9515 0.96 0.29-3.17 
Not on HAART 0.6612 0.80 0.29-2.20 
PI- and NNRTI-containing HAART -- 1.00 -- 
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8.2.2 Cox proportional hazards regression modeling risk of all-cause mortality 
 
Characteristic 
Model 3 (Adjusted) 
p-value HR CI 
HCV status  
 Chronic HCV 0.1580 1.60 0.83-3.05 
HCV-negative -- 1.00 -- 
Insurance  
 Public 0.3473 1.67 0.57-4.89 
Uninsured 0.9896 0.00 0.00-. 
Unknown <0.0001 22.31 7.58-65.66 
Private -- 1.00 -- 
Baseline age (per 10 year increase) <0.0001 1.75 1.33-2.29 
Year of HIV diagnosis (per 1 year increase) 0.0086 1.07 1.02-1.12 
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8.2.3 Cox proportional hazards regression modeling risk of virologic failure 
 
Characteristic 
Model 3 (Adjusted) 
p-value HR CI 
HCV status    
 Chronic HCV 0.0569 0.40 0.15-1.03 
HCV-negative 0.0300 0.37 0.15-0.91 
Resolved HCV -- 1.00 -- 
HIV risk group  
 IDU  0.1529 0.76 0.52-1.11 
MSM  0.0191 0.73 0.56-0.95 
Heterosexual -- 1.00 -- 
Insurance  
 Public 0.0832 1.34 0.96-1.86 
Uninsured 0.2057 0.47 0.15-1.52 
Unknown 0.0103 1.69 1.13-2.53 
Private -- 1.00 -- 
Baseline age (per 10 year increase) 0.0090 0.84 0.73-0.96 
Endpoint CD4 count (per 100 cells/L increase) <0.0001 0.84 0.80-0.88 
HIV therapy at endpoint  
 PI-containing HAART 0.3415 0.77 0.46-1.31 
NNRTI-containing HAART 0.0158 0.51 0.29-0.88 
NRTI alone HAART 0.6893 1.16 0.57-2.35 
Not on HAART 0.4256 1.27 0.71-2.26 
PI- and NNRTI-containing HAART -- 1.00 -- 
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8.2.4 Cox proportional hazards regression modeling risk of 25% CD4 cell decline 
Characteristic 
Model 3 (Adjusted) 
p-value HR CI 
HCV status  
 Chronic HCV 0.1627 2.74 0.67-11.27 
HCV-negative 0.3076 2.07 0.51-8.32 
Resolved HCV -- 1.00 -- 
Insurance  
 Public 0.0886 1.29 0.96-1.72 
Uninsured 0.3244 1.45 0.69-3.04 
Unknown 0.0025 1.75 1.22-2.52 
Private -- 1.00 -- 
Baseline age 0.0337 0.88 0.79-0.99 
HIV therapy at baseline  
 PI-containing HAART 0.7651 0.95 0.70-1.30 
NNRTI-containing HAART 0.0436 0.69 0.48-0.99 
NRTI alone HAART 0.9217 1.04 0.50-2.18 
Not on HAART 0.1693 1.24 0.91-1.69 
PI- and NNRTI-containing HAART -- 1.00 -- 
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8.2.5 Cox proportional hazards regression modeling risk of 10% CD4 cell decline 
 
Characteristic 
Model 1 (Crude) Model 2 (Adjusted) Model 3 (Adjusted) 
p-value HR CI p-value HR CI p-value HR CI 
HCV status    
 Chronic HCV 0.3285 1.41 0.71-2.80 0.4611 1.37 0.59-3.15 0.4068 1.42 0.62-3.27 
HCV-negative 0.9342 1.03 0.53-1.99 0.9672 1.02 0.45-2.28 0.9768 1.01 0.45-2.27 
Resolved HCV -- 1.00 -- -- 1.00 -- -- 1.00 -- 
Insurance    
 Public 0.8099 1.03 0.83-1.28 0.4729 1.09 0.87-1.37  
Uninsured 0.4848 0.79 0.42-1.52 0.9392 0.98 0.51-1.87 
Unknown 0.0518 1.301 1.00-1.72 0.0458 1.34 1.01-1.79 
Public -- 1.00 -- -- 1.00 -- 
On HAART at baseline 0.0009 0.73 0.61-0.90   
HIV therapy at baseline    
 PI-containing HAART 0.9146 1.03 0.66-1.60   
NNRTI-containing 
HAART 
0.9972 1.00 0.64-1.58 
NRTI alone HAART 0.6653 1.14 0.63-2.04 
Not on HAART 0.1446 1.39 0.89-2.17 
PI- and NNRTI-
containing HAART -- 1.00 -- 
Endpoint HIV RNA (per 
log10 copies/mL increase)  
<0.0001 1.19 1.16-1.22 
 
 
On HAART at endpoint <0.0001 0.45 0.37-0.56 <0.0001 0.45 0.36-0.55  
HIV therapy at endpoint    
 PI-containing HAART 0.0085 0.56 0.37-0.86  0.0042 0.53 0.34-0.82 
NNRTI-containing 
HAART 
0.0223 0.60 0.38-0.93 0.0141 0.57 0.37-0.89 
NRTI alone HAART 0.7101 1.11 0.64-1.93 0.8536 1.05 0.61-1.83 
Not on HAART 0.1821 1.36 0.87-2.13 0.2485 1.30 0.83-2.05 
PI- and NNRTI-
containing HAART -- 1.00 -- -- 1.00 -- 
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9 APPENDIX C: PROPORTIONAL HAZARDS MODEL DIAGNOSTICS: 
LOG-LOG SURVIVAL CURVES 
 
 
 
9.1 Hepatitis B exposure status 
9.1.1 Clinical AIDS 
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9.1.2 All-cause mortality 
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9.1.3 Virologic failure 
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9.1.4 10% decline in CD4 count 
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9.3 Hepatitis C exposure status 
 
9.3.1 Clinical AIDS 
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9.3.2 All-cause mortality 
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9.3.3 Virologic failure 
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9.3.4 25% decline in CD4 count 
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